---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description. Covers Product description and Place of product in therapy. 434 evidence topics quoted from 165 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027

> “Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027”
> “The company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is under review by the U.S. Food and Drug Administration”
> “(FDA), with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

> “A New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks is currently under review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

> “In July 2026, the U.S. Food and Drug Administration (FDA) accepted to review the Company’s New Drug Application (NDA) for deucrictibant IR for the on-demand treatment of HAE attacks, with the Prescription Drug User Fee Act (PDUFA) action date set for April 23, 2027.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “July 6, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 23, 2027.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-2"></a>

##### Launch: Anticipated in 2027

> “The increase in general and administrative expenses is primarily due to increases in commercial personnel, professional, and other expenses, supporting a potential launch of IR in 2027.”
> “We expect to recognize revenues from sales of deucrictibant IR in 2027, if it is approved for sale in the United States by the FDA.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-2.1.1-3"></a>

##### Investigational status and approval uncertainty

> “Clinical development timelines and associated costs may vary significantly and FDA approval of deucrictibant IR for the treatment of on-demand attacks in 2027 is uncertain.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

> “We do not have any drugs that have received regulatory approval and may never be able to develop marketable products.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-4"></a>

##### Content of the NDA

> “Pharvaris’ NDA details a comprehensive clinical development program for deucrictibant IR, including data from the treatment of over 1,300 HAE attacks.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-5"></a>

##### European Medicines Agency marketing authorization application

> “In July 2026, the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for deucrictibant IR and began its formal review of the MAA under the centralized procedure.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “The marketing authorization application (MAA) for deucrictibant IR is under formal review by the European Medicines Agency (EMA) under the centralized procedure.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-6"></a>

##### NDA submission timing, May 2026, superseded in July 2026

> “Submission of New Drug Application (NDA) of deucrictibant immediate release (IR) capsule for the on-demand treatment of HAE attacks remains on-track for 1H2026.”
> “Data from the pivotal, randomized, placebo-controlled Phase 3 study, RAPIDe-3, and the long-term extension study, RAPIDe-2, will serve as the basis for the NDA of deucrictibant IR, which is on-track for submission to the U.S. Food and Drug Administration (FDA) in the first half of 2026.”

Source: [Pharvaris Form 6-K, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526219372/phvs-ex99_1.htm)

<a id="topic-2.1.1-7"></a>

##### NDA submission timing, April 2026, superseded in July 2026

> “Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026”
> “Data from RAPIDe-3 and RAPIDe-2 will serve as the basis for the NDA of deucrictibant, which is on-track to be submitted in the first half of 2026.”

Source: [Pharvaris Form 6-K, fourth quarter and full year 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000012/phvs-ex99_1.htm)

> “Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-8"></a>

##### NDA submission timing, January 2026, superseded in July 2026

> “Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026”
> “The data from RAPIDe-3 and RAPIDe-2 will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.”

Source: [Pharvaris 2026 strategic priorities press release (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526009705/phvs-ex99_1.htm)

<a id="topic-2.1.1-9"></a>

##### NDA submission timing, December 2025, superseded in July 2026

> “The data from Pharvaris’ first pivotal Phase 3 study will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.”
> “Pharvaris remains on track to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-2.1.1-10"></a>

##### NDA submission timing, July 2025, superseded in July 2026

> “Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026”

Source: [Pharvaris RAPIDe-3 topline timing update press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm)

<a id="topic-2.1.1-11"></a>

##### RAPIDe-3 topline timing, January 2025, superseded in July 2025

> “Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026”

Source: [Pharvaris 2025 strategic priorities press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025004542/phvs-ex99_1.htm)

<a id="topic-2.1.1-12"></a>

##### Development history: duration of the development program

> “After 10 years of dedicated effort by the team at Pharvaris, this FDA acceptance of deucrictibant IR’s NDA represents a major milestone in our journey to develop a differentiated therapy with the potential to improve the standard of care for people living with HAE,”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.1-13"></a>

##### Development history: phase 1 studies and the RAPIDe-1 phase 2 trial

> “To date we have data from preclinical studies, Phase 1 clinical studies in healthy volunteers, and Phase 2 studies in people living with HAE of deucrictibant for both treatment and prophylaxis of HAE attacks, and a Phase 3 study in people living with HAE of deucrictibant for the treatment of HAE attacks.”
> “We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-14"></a>

##### Development history: end-of-phase 2 meeting with the FDA

> “An end-of-Phase 2 meeting with the agency occurred to align on key elements of RAPIDe-3 global Phase 3 study of deucrictibant immediate-release capsules for the on-demand treatment of HAE”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

<a id="topic-2.1.1-15"></a>

##### Development history: RAPIDe-3 initiation, enrollment, and topline results

> “Following the readout of RAPIDe-2, we initiated RAPIDe-3, a global, pivotal Phase 3, placebo-controlled study to evaluate deucrictibant IR capsule (20 mg) for the on-demand treatment of attacks in people 12 years and older with HAE, in March 2024 and reported topline data in December 2025.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “reached target enrollment in March 2025; the study continues to assess HAE attacks in enrolled participants.”

Source: [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)

> “Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025”

Source: [Pharvaris RAPIDe-3 topline timing update press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525157363/d17337dex991.htm)

> “Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal”
> “ZUG, Switzerland, December 3, 2025”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

> “RAPIDe-3 study results highlighting deucrictibant’s rapid and sustained efficacy in treating HAE attacks published in The Lancet.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-16"></a>

##### Development history: RAPIDe-2 open-label extension

> “In addition, we are also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “An open-label extension study of deucrictibant IR for the on-demand treatment of HAE attacks, RAPIDe-2 (NCT05396105), is ongoing.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

<a id="topic-2.1.1-17"></a>

##### Development history: CHAPTER-1, CHAPTER-3, and CHAPTER-4 prophylaxis trials of deucrictibant

> “We commenced CHAPTER-1 in November 2021 using twice-daily dosing of deucrictibant IR capsules as a proof-of-concept for once-daily deucrictibant XR tablets, and announced positive topline data in December 2023.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “CHAPTER-3 (NCT06669754) met the primary endpoint and all secondary efficacy endpoints with statistical significance.”
> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Filing of U.S. NDA of deucrictibant for the prophylaxis of AE-BK attacks anticipated 1H2027.”
> “The data from CHAPTER-3, CHAPTER-4 (NCT06679881), and part 1 of CREAATE will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-18"></a>

##### Development history: CREAATE in acquired angioedema due to C1 inhibitor deficiency

> “In October 2025, we initiated CREAATE, a global, pivotal Phase 3 study to assess the efficacy and safety of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks.”
> “In part 2, participants treat two attacks in a cross-over fashion, one attack with deucrictibant IR capsule (20 mg) and one with placebo, to evaluate deucrictibant IR as an on-demand treatment of AAE-C1INH attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Topline data from part 1 of CREAATE (NCT07266805) expected in 1Q2027.”
> “Enrollment in part 2 of CREAATE progressing as planned.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-19"></a>

##### FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024

> “the U.S. Food and Drug Administration (FDA) verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND) applications for the treatment of HAE.”

Source: [Pharvaris clinical hold press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022029851/phvs-ex991_6.htm)

> “FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

> “The agency requested that Pharvaris conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure”
> “In June 2023, FDA removed the clinical hold on on-demand trials”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

> “Findings were observed in the repeat-dose rat data package that were considered not to be related to bradykinin B2 receptor antagonism.”
> “Following review of data from a preplanned interim analysis of the study, the FDA lifted the clinical hold on the IND application for deucrictibant for the on-demand treatment of HAE in June 2023. In January 2024, the FDA lifted the clinical hold on the IND application for deucrictibant for the prophylactic treatment of HAE attacks following review of the full data set from the completed 26-week rodent toxicology study.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-20"></a>

##### FDA thorough QT study waivers

> “Following review of preclinical and clinical data, the U.S. Food and Drug Administration (FDA) has accepted Pharvaris’ TQT study waiver requests. These waivers apply to the prophylactic program (IND153097) for deucrictibant extended-release formulation and the on-demand program (IND155872) for deucrictibant immediate-release formulation.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-2.1.1-21"></a>

##### FDA orphan drug designation

| Field | Quoted record |
| --- | --- |
| Generic name | “deucrictibant” |
| Date designated | “03/18/2022” |
| Orphan designation | “Treatment of bradykinin-mediated angioedema (hereditary or acquired)” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Pharvaris GmbH” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=809521)

> “On March 18, 2022, the FDA granted orphan drug designation to PHA121 (deucrictibant), the active ingredient in our IR and XR product candidates for treatment of bradykinin-mediated angioedema.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.1-22"></a>

##### Orphan designations in the European Union and Switzerland

> “This medicine was designated as an orphan medicine for the treatment of bradykinin-mediated angioedema in the European Union on 25 March 2025.”

Source: [EMA orphan designation EU/3/25/3040 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040)

| Field | Quoted record |
| --- | --- |
| Active substance | “deucrictibant monohydrate” |
| Intended use | “Treatment of bradykinin-mediated angioedema” |
| EU designation number | “EU/3/25/3040” |
| Date of designation | “25/03/2025” |
| Sponsor | “Pharvaris Netherlands B.V.” |

Source: [EMA orphan designation EU/3/25/3040 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040)

> “Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.1-23"></a>

##### EU paediatric investigation plan, agreed October 2023 and modified January 2025

| Field | Quoted record |
| --- | --- |
| Decision | “P/0411/2023 of 25 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for deucrictibant” |
| Waiver | “the paediatric population from birth to less than 2 years of age” |
| Indication targeted by the plan | “Treatment of and prevention of hereditary angioedema (HAE) attacks in paediatric patients from 2 years to less than 18 years of age.” |
| Study in children under 12 years | “Open-label, sequential two-part study to assess pharmacokinetics, efficacy, and safety of deucrictibant (PHA-022121) for the treatment (Part 1) and prevention (Part 2) of attacks in paediatric patients from 2 years to less than 12 years and adolescents from 12 years to less than 18 years of age weighing less than 40 kg with hereditary angioedema” |
| Deferral | “Deferral for one or more measures contained in the paediatric investigation plan: Yes” |
| Date of completion | “Date of completion of the paediatric investigation plan: By January 2030” |

Source: [EMA paediatric investigation plan decision P/0411/2023 (2023)](https://www.ema.europa.eu/en/documents/pip-decision/p-0411-2023-ema-decision-25-october-2023-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-deucrictibant-emea-003090-pip02-22_en.pdf)

> “PM: decision on the application for modification of an agreed PIP”
> “28/01/2025”

Source: [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)

<a id="topic-2.1.1-24"></a>

##### FDA expedited program designations

No evidence found.

<a id="topic-2.1.1-25"></a>

##### Patent protection

> “As of December 31, 2025, we own five U.S. patents and 150 national/regional patents, including in Australia, China, India, Indonesia, Japan, Mexico, South Korea, France, Germany, Italy, Netherlands, Spain and United Kingdom, that expire on November 23, 2038 or later”
> “Two national/regional patents and 9 of our pending applications contain claims directed to the use of deucrictibant in on-demand treatment of HAE and in prophylaxis for HAE, and accordingly extend the patent applications to methods of use of the IR and XR product candidates.”
> “53 granted patents, including in China, France, Germany, Italy, Netherlands, Spain and United Kingdom, and 18 of our pending patent applications, including an U.S. application, contain claims directed to the formulation of our IR product candidate.”
> “In the future, if and when our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents we may obtain in the future covering deucrictibant, depending upon the length of the clinical trials for each product and other factors.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Pharvaris

> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.2.1-2"></a>

###### Ownership and license of the compound

> “On March 31, 2016, we entered into a license agreement”
> “we acquired a worldwide, exclusive license from BRAIN to use”
> “Certain rights associated with deucrictibant, IR and XR are subject to the BRAIN License.”
> “In addition, we will be required to pay low to medium single-digit tiered royalties on direct or indirect net sales of licensed products.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.1-3"></a>

###### Nonproprietary name, development codes, and therapeutic class

> “Our first molecule, deucrictibant (previously referred to as PHA-022121 or PHA121), is a novel, oral, small-molecule bradykinin B2 receptor antagonist under development for the prevention or treatment of attacks due to bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).”
> “Deucrictibant may address unmet medical needs of people living with AE-BK by both preventing attacks from occurring, using an extended-release (XR) tablet formulation of deucrictibant (previously referred to as PHVS719), and treating the manifestations of attacks, using an immediate-release (IR) capsule formulation of deucrictibant (previously referred to as PHVS416).”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

> “Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.2.1-4"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Immediate-release capsule, 20 mg: intended commercial dosage

> “RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg, which is the intended commercial dosage) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), reached target enrollment in March 2025”

Source: [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)

> “deucrictibant immediate-release (IR) capsule (20 mg)”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.2.2-2"></a>

###### Formulation design of the immediate-release capsule

> “The IR capsule formulation is designed to rapidly reach therapeutic exposure in order to mitigate HAE attacks symptoms rapidly and completely with a single oral dose.”

Source: [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-2.1.2.2-3"></a>

###### RAPIDe-3 study drug: one soft capsule per dose

> “Deucrictibant Soft Capsules for Oral Use”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “The study drug was packaged in aluminium–aluminium blisters.”
> “Each wallet contained one single capsule (either deucrictibant or placebo).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.2-4"></a>

###### RAPIDe-1 study drug: three capsules per dose

> “Capsules of deucrictibant and placebo were identical and each single dose consisted of a combination of three capsules of deucrictibant or placebo in a wallet.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.2-5"></a>

###### Extended-release tablet, 40 mg, for prophylaxis

> “Eighty-five participants were enrolled and randomized in a 2:1 ratio to receive deucrictibant XR (40 mg/day), the intended commercial formulation, or placebo, once daily for 24 weeks.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

<a id="topic-2.1.2.2-6"></a>

###### Pharmaceutical forms in the EU paediatric investigation plan

> “Age appropriate oral solid dosage form”
> “Capsule, soft”
> “Prolonged-release tablet”

Source: [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)

<a id="topic-2.1.2.2-7"></a>

###### Material safety data sheet

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO International Nonproprietary Name functional class

> “bradykinin receptor antagonist”

Source: [World Health Organization (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl126.pdf)

<a id="topic-2.1.2.4-2"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication named in the NDA accepted by the FDA

> “today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deucrictibant immediate-release (IR) capsule (20 mg) for the on-demand treatment (ODT) of Hereditary Angioedema (HAE) attacks.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

<a id="topic-2.1.2.5-2"></a>

###### Age range: adults and adolescents 12 years and older

> “orally administered deucrictibant IR for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.1.2.5-3"></a>

###### Indication named in the FDA orphan drug designation

> “Treatment of bradykinin-mediated angioedema (hereditary or acquired)”

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=809521)

<a id="topic-2.1.2.5-4"></a>

###### Investigational population in RAPIDe-3, including hereditary angioedema with normal C1 inhibitor

> “RAPIDe-3 (NCT06343779), a global, pivotal, placebo-controlled Phase 3 study of deucrictibant IR for the on-demand treatment of attacks in participants 12 years and older with HAE, including those with HAE with normal C1 inhibitor, met the primary and all 11 secondary efficacy endpoints with statistical significance.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”
> “Diagnosis of HAE-1/2/3.”
> “History of at least 2 HAE attacks in the last 3 months before screening.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “Adolescents (aged ≥12 to <18 years) and adults (aged ≥18 to ≤75 years) with hereditary angioedema, including those with normal C1 inhibitor associated with a documented genetic variant, at least two attacks within the last 3 months before screening, and experience with effectively using conventional on-demand therapies for hereditary angioedema attacks were eligible.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Competitive antagonism of the bradykinin B2 receptor

> “Excessive bradykinin generation, as in HAE, promotes vascular permeability by activating the bradykinin B2 receptor in vascular endothelium cells, leading to plasma extravasation and subcutaneous or submucosal tissue swelling typical of an angioedema attack.”
> “treatment with deucrictibant, a novel, orally-bioavailable, highly potent and selective bradykinin B2 receptor antagonist is intended to block activation of the bradykinin B2 receptor by bradykinin, and, therefore, prevent or halt the angioedema process.”
> “Deucrictibant is an orally bioavailable competitive antagonist of the bradykinin B2 receptor with high affinity and high antagonist potency.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Potency and selectivity in vitro, ex vivo, and in vivo

> “Deucrictibant has been observed to be a potent inhibitor in vitro as assessed using human recombinant bradykinin B2 receptors (150 pM); ex vivo as studied against endogenous bradykinin B2 receptors in a human umbilical vein model (350 pM); and in vivo in the human bradykinin-challenge model (170 pM).”
> “Deucrictibant demonstrated over 4000-fold selectivity for the bradykinin B2 receptor when compared to approximately 170 other molecular targets, including the bradykinin-B1-receptor.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.1-3"></a>

###### In vitro pharmacological profile of deucrictibant and its active metabolite

> “The present study describes the in vitro pharmacological characteristics of PHA-022121 and its active metabolite, PHA-022484 (M2-D).”
> “In mammalian cell lines, PHA-022121 and PHA-022484 show high affinity for the recombinant human bradykinin B2 receptor with Ki values of 0.47 and 0.70 nM, respectively, and potent antagonism of the human bradykinin B2 receptor with Kb values of 0.15 and 0.26 nM, respectively (calcium mobilization assay).”
> “potency at rat, mouse, rabbit and dog bradykinin B2 receptors is at least 100-fold lower than the potency at the human receptor for both compounds.”
> “It is about 20-fold more potent than icatibant at the human bradykinin B2 receptor as assessed using recombinant or endogenously expressed receptors.”

Source: [Lesage et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35086057/)

<a id="topic-2.1.2.6.1-4"></a>

###### Molecular design: deuteration at a metabolic soft spot and absence of partial agonism

> “Metabolic soft spot stabilized by introduction of a deuterium atom”
> “2.4-fold lower molecular weight than icatibant”
> “Pure antagonistic activity at bradykinin B2 receptor”
> “no partial agonistic activity as icatibant was found to exert at high”
> “concentrations, as reached locally at site of injection”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.1-5"></a>

###### Two oral formulations: immediate-release capsule for attacks and extended-release tablet for prophylaxis

> “Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment.”

Source: [Pharvaris CIIC Spring 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/evidence-supporting-combined-use-deucrictibant-ir-deucrictibant)

> “softgel capsule formulation”
> “rapid absorption in stomach and gut upon oral administration”
> “prolonged colonic absorption upon oral administration”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Bradykinin challenge in healthy volunteers: design

> “PHA-022121 (12 and 22 mg) was administered orally (p.o.) to 16 healthy volunteers.”
> “Bradykinin injections were administered to induce cardiovascular responses.”
> “PHA-022121-induced changes of these BK responses were evaluated with a nonlinear mixed-effect PK/PD model. The results were compared to published results obtained from icatibant (3).”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-2.1.2.6.2-2"></a>

###### Bradykinin challenge in healthy volunteers: composite EC50 and EC85

> “PK/PD analysis showed significant inhibition of bradykinin-induced cardiovascular changes with an average composite EC50 of 2.4 and EC85 of 13.8 ng/mL.”
> “Fifteen minutes after a 12-mg dose in fasting conditions, plasma levels reached 60.3 ng/mL, largely above these therapeutic thresholds.”
> “The in vivo PHA-022121 EC50 value of 2.4 ng/mL corresponds to a potency of 170 pM (free plasma concentration)”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

> “Deucrictibant ~4x higher potent vs.”
> “icatibant (published data1)”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-3"></a>

###### Bradykinin challenge in healthy volunteers: duration of effect compared with icatibant

> “The investigated single oral doses of PHA-022121 (12 and 22 mg) provide equivalent BK-antagonism for a longer time than a 30 mg s.c. icatibant injection.”
> “The table shows that using the same criteria the durations of effect for the investigated doses of PHA-022121 exceed that of 30 mg icatibant s.c. and are approximately twice as long for the higher dose (equivalent to two icatibant injections 6 h apart).”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

> “PK/PD analysis indicates that effective bradykinin inhibiting concentrations can be reached within 15 min and maintained for at least 12 h, which makes it well suited for development as a single oral dose treatment of acute HAE attacks.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="topic-2.1.2.6.2-4"></a>

###### Bradykinin challenge in non-human primates

> “In non-human primates, oral deucrictibant inhibited bradykinin effects with rapid achievement of maximal activity”
> “Deucrictibant / bradykinin challenge”
> “Maximal activity at 1 hour”
> “Icatibant / bradykinin challenge”
> “Maximal activity at 2 hours”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-5"></a>

###### EC85 as a surrogate threshold for onset and duration of clinical effect

> “For bradykinin B2 receptor antagonism (icatibant), concentrations predicted to be above EC85 were shown to correlate with therapeutic efficacy and its duration”
> “Achievement and persistence of plasma concentrations ≥EC85 are considered to be therapeutically relevant for deucrictibant as surrogate markers of its onset and duration of clinical effects, respectively”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.2-6"></a>

###### Bradykinin challenge as the basis for dose selection and its consistency with phase 2 results

> “The bradykinin challenge was validated as a surrogate assessment for dose selection in the original development program for icatibant, as reviewed by the FDA and the EMA. From the bradykinin challenge model, we were able to predict the efficacious dose range and the duration of effect of a single oral dose of deucrictibant; the topline data from our Phase 2 RAPIDe-1 trial treating HAE attacks were consistent with the predictions of the bradykinin challenge in both onset of symptom relief and duration of effect (use of rescue medication).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.2-7"></a>

###### Onset of clinical effect relative to therapeutic exposure in RAPIDe-3

> “The rapid achievement of end of progression in under 18 min is consistent with the pharmacokinetics of deucrictibant immediate-release capsule, exceeding the threshold concentration for therapeutic exposure (EC85) within 15 min, as previously shown in adults and confirmed in adolescents in this trial.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Single ascending doses of oral solution in healthy volunteers: absorption, dose proportionality, and half-life

> “PHA-022121 was very rapidly absorbed and reached peak plasma levels within 30 to 60 minutes after dosing in all subjects under fasted conditions. The systemic exposure was dose proportional with a mean t1/2 ranging from 3.5 to 5.6 h between doses.”
> “Plasma levels for PHA-022121 reached therapeutic efficacious threshold concentration”
> “within 15 min for all doses and were maintained for approximately 12 h with doses of 12 and 22 mg.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-2.1.2.6.3-2"></a>

###### Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters

| Parameter | 1 mg fasted | 2 mg fasted | 4.5 mg fasted | 12 mg fasted | 22 mg fasted | 22 mg after high-calorie, high-fat breakfast |
| --- | --- | --- | --- | --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |
| CL/F, L/h, mean (SD) | “42.3 (25.4)” | “33.8 (11.9)” | “37.6 (11.1)” | “40.9 (20.7)” | “31.5 (5.60)” | “25.3 (9.77)” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-2.1.2.6.3-3"></a>

###### Food effect after a single 22 mg dose of oral solution

> “Administration of the 22 mg dose with a HCHF breakfast led to a 32% lower Cmax, a 49% higher AUClast, and a delay of median tmax by approximately 2 h.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “After a 22 mg dose, mean Cmax of PHA-022121 was 32% lower after a high calorie high fat (HCHF) breakfast and 46% lower after a standard caloric meal (SCM), compared to fasting conditions. Mean AUCinf was 42% higher after a HCHF breakfast mainly caused by one outlier and comparable after SCM (+8%). Median tmax of PHA-022121 was delayed by 2.25 h after a HCHF breakfast and by 0.50 h after SCM. Absorption was still fast and plasma levels reached levels that were 4xEC85 within 15 min.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="topic-2.1.2.6.3-4"></a>

###### Company summary of phase 1 pharmacokinetics with and without food

> “In our Phase 1 clinical trials to-date, we have observed rapid exposure and predictable linear pharmacokinetics (PK) with and without food.”
> “Exposure exceeds the anticipated threshold therapeutic plasma level (EC85) in 30 minutes, with or without food”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.3-5"></a>

###### Population pharmacokinetic model from the bradykinin challenge study

> “PK was analyzed using a two-compartment body model with first-order oral absorption and a lag time.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-2.1.2.6.3-6"></a>

###### Immediate-release capsule 2 x 10 mg in healthy volunteers

> “Mean plasma levels >EC85 reached in 15 minutes after single dose of deucrictibant immediate-release capsule (2x10 mg)”
> “Mean plasma levels >EC85 maintained for ~12 hours after single dose of deucrictibant immediate-release capsule (2x10 mg)”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.3-7"></a>

###### Immediate-release capsule in adults with HAE in a non-attack state (RAPIDe-1 part 1)

> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1. After administration of a single dose of the immediate-release capsule formulation, mean plasma levels of deucrictibant reached the drug concentration estimated to provide 85% maximal response (EC85; above which clinical effects are anticipated based on icatibant studies)25 of 13·8 ng/mL within 15-30 min of drug administration and were maintained for 8 h or longer (appendix p 24).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.6.3-8"></a>

###### Immediate-release capsule 2 x 20 mg compared with the extended-release tablet 40 mg in healthy volunteers (PHA022121-C020)

> “Characterize the single-dose pharmacokinetics of deucrictibant XR tablet (40 mg) and deucrictibant IR capsule (2 x 20 mg) in healthy volunteers in a Phase 1, open-label, randomized, 2-period, crossover study (PHA022121-C020*).”
> “deucrictibant IR capsule (2 x 20 mg taken simultaneously) under fasting conditions.”
> “Deucrictibant IR resulted in a mean plasma concentration exceeding EC85 within 15-30 minutes.”
> “Mean t1/2 of deucrictibant was comparable for the XR tablet and IR soft capsules: 5.72 and 5.10 hours, respectively.”

Source: [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a)

| Parameter | Deucrictibant IR capsule 2 x 20 mg | Deucrictibant XR tablet 40 mg |
| --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “547 (193)” | “87.2 (25.5)” |
| tmax, hours, median (range) | “1.00 (0.50–1.50)” | “5.03 (3.98–24.00)” |
| AUCinf, ng⋅h/mL, mean (SD) | “1799 (745)” | “1547 (699)” |
| t1/2, hours, mean (SD) | “5.10 (1.28)” | “5.72 (1.70)” |
| CL/F, L/hours, mean (SD) | “26.5 (12.7)” | “31.5 (14.7)” |

Source: [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a)

<a id="topic-2.1.2.6.3-9"></a>

###### Half-life and peak concentration of the 20 mg immediate-release capsule compared with icatibant

> “Deucrictibant has a mean elimination half-life of approximately 5·1 h,34 compared with approximately 1·5 h for icatibant.35 Mean maximum plasma concentration is approximately 243 ng/mL by 0·5 h following a single 20 mg oral dose of deucrictibant immediate-release capsule25 and approximately 979 ng/mL by 0·75 h following a single 30 mg subcutaneous dose of icatibant.”
> “Mean plasma levels following a single 20 mg dose of deucrictibant immediate-release capsule achieved the EC85 of 13·8 ng/mL within 15–30 min of drug administration and were maintained for 8 h or longer,25 while the EC85 for icatibant has been estimated to be 54 ng/mL.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.6.3-10"></a>

###### Adolescents: single-capsule pharmacokinetics in a non-attack state (RAPIDe-3)

> “Before random allocation, adolescent participants received a single oral deucrictibant capsule in a non-attack state for pharmacokinetic assessment.”
> “Pharmacokinetic analyses were performed on samples from ten adolescent participants in non-attack state. Following a single capsule of deucrictibant, mean plasma levels reached the concentration estimated to provide 85% maximal response (EC85) of 13·8 ng/mL within 15 min and were maintained through to at least the last measured time point of 8 h.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.6.3-11"></a>

###### Multiple ascending doses of oral solution in healthy volunteers: accumulation, steady state, and half-life

> “PHA-022121 was well absorbed with median times to reach peak plasma levels within 1.00 to 1.75 h after dosing under fed conditions.”
> “Overall, Cmax and AUC0-12h on Day 1 and Day 10 were dose proportional over the investigated dose range of 12 to 50 mg BID PHA-022121 with a mean t1/2 ranging from 4.8 to 7.3 h after the Day 10 dose.”
> “Repeated dosing for 10 days resulted in about 1.0- to 1.6-fold accumulation in Cmax, Ctrough, and AUC for PHA-022121.”
> “At steady state, which was reached within 72 hours, plasma levels remained consistently above the therapeutic threshold (EC85) for all doses.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.6.3-12"></a>

###### Metabolism: CYP3A4 and an active metabolite

> “PHA-022121 is broken down by certain enzymes, among others by CYP3A4.”

Source: [Onderzoekmetmensen.nl NL-OMON49496](https://onderzoekmetmensen.nl/en/node/49496)

> “to assess steady-state PK of PHA-022121 and its active metabolite M2-D in the presence of a drug cocktail in healthy adult subjects.”

Source: [Onderzoekmetmensen.nl NL-OMON49587](https://www.onderzoekmetmensen.nl/en/node/49587)

<a id="topic-2.1.2.6.3-13"></a>

###### Mass balance study and Japanese bridging study

> “Absorption, metabolism, and excretion (mass balance)”
> “to characterize the absorption, metabolism, and excretion”
> “Japanese PK bridging”
> “Double-blind, randomized, single oral dose, two-period crossover comparing pharmacokinetics between Japanese and Caucasian volunteers”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information for deucrictibant

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Participants exposed across the clinical studies, data cutoff June 10, 2026

> “As of June 10, 2026, 743 unique participants are estimated to have been exposed to deucrictibant across 25 Pharvaris-sponsored clinical studies (based on number of participants treated with deucrictibant in open-label or completed studies and on randomization ratios for blinded trials ongoing at the time of data cutoff):”
> “339 were healthy participants, 16 had hepatic impairment, 24 had renal impairment, and approximately 312 were participants with HAE.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-3"></a>

###### Integrated cardiovascular adverse events across phase 1, phase 2, and phase 3 studies

> “There were no system organ class (SOC) cardiac disorder or SOC vascular disorder treatment-related treatment-emergent adverse events (TEAEs) across Phase 1 single-dose studies, RAPIDe-1, CHAPTER-1 RCT, RAPIDe-2 Part A, or RAPIDe-3.”
> “Of the 232 healthy participants receiving deucrictibant in Phase 1 multiple-dose studies, there were no SOC cardiac disorder treatment-related TEAEs, and 1 (0.4%) participant experienced an SOC vascular disorder TEAE of orthostatic hypotension considered related to treatment.”
> “Of 110 participants in the ongoing RAPIDe-2 Part B, there were no SOC vascular disorder treatment-related TEAEs, and 1 (0.9%) experienced an SOC cardiac disorder TEAE of tachycardia considered related to treatment.”
> “Overall, in these studies, no evidence of increased risk of CV events was observed.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-4"></a>

###### Concentration-QTc analysis of pooled phase 1 studies

> “A meta-analysis of pooled data from two single ascending dose (SAD) and one multiple ascending dose (MAD) Phase 1 studies.”
> “The highest mean maximum plasma concentration (Cmax) in the meta-analysis was 693 ng/mL, substantially higher than the concentration estimated to provide 85% maximal response (EC85: 13.8 ng/mL).”
> “The C-QTcF model estimated a slope of −0.00453 ms/(ng/mL) between deucrictibant plasma concentration and QTcF, which was statistically and clinically non-significant (P=0.1858 based on two-sided t-test).”
> “In the highest estimated clinical exposure scenario, the expected mean Cmax was approximately 840.6 ng/mL. The C-QTcF model dataset contained individual plasma concentrations up to 1550 ng/mL, nearly twice this value.”
> “The ΔΔQTcF in this scenario resulted in a slight negative value of −2.55 ms (upper 90% CI: +2.29 ms), below the 10 ms threshold for QTc prolongation set by regulatory agencies for a clinically meaningful change.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-5"></a>

###### Nonclinical cardiovascular safety and hERG channel assay

> “Deucrictibant had no evident effects on cardiac electrophysiology, hemodynamic parameters, cardiac morphology, and histopathology evaluation in acute and chronic nonclinical safety studies in non-human primates.”
> “A manual patch-clamp assay at physiologic temperature confirmed the absence of relevant inhibition of the hERG-mediated current at deucrictibant concentrations 162-fold above the highest estimated clinical exposure.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-6"></a>

###### Thorough QT study waivers accepted by the FDA

> “Following review of preclinical and clinical data, the U.S. Food and Drug Administration (FDA) has accepted Pharvaris’ TQT study waiver requests. These waivers apply to the prophylactic program (IND153097) for deucrictibant extended-release formulation and the on-demand program (IND155872) for deucrictibant immediate-release formulation.”

Source: [Pharvaris Form 6-K, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025070308/phvs-ex99_1.htm)

<a id="topic-2.1.2.7.1-7"></a>

###### Nonclinical toxicology, genotoxicity, and phototoxicity

> “The conducted nonclinical package for deucrictibant includes secondary pharmacodynamics, safety pharmacology, genotoxicity, reproductive and developmental studies and general toxicity studies up to six months in rats and up to nine months in non-human primates. Deucrictibant did not demonstrate any in vitro or in vivo genotoxicity nor in vitro phototoxic potential. No findings considered relevant to humans were observed in GLP (Good Laboratory Practices)-compliant general toxicity studies in rats up to 3-months duration and in cynomolgus monkeys up to 9-months duration at doses up to the maximum tolerated dose in each species.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

###### FDA clinical hold based on repeat-dose rat toxicology findings, August 2022

> “the U.S. Food and Drug Administration (FDA) verbally informed Pharvaris that, based on its review of nonclinical data, the agency is placing a clinical hold on the clinical trials of PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND) applications for the treatment of HAE.”

Source: [Pharvaris clinical hold press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022029851/phvs-ex991_6.htm)

> “Findings were observed in the repeat-dose rat data package that were considered not to be related to bradykinin B2 receptor antagonism. Based on review of these nonclinical findings, in 2022, the FDA put a clinical hold on trials of deucrictibant in the U.S.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The agency requested that Pharvaris conduct an additional long-term rodent toxicology study and update the Investigator’s Brochure”

Source: [Pharvaris corporate presentation, January 2024 (2024)](https://www.sec.gov/Archives/edgar/data/1830487/000095017024002680/phvs-ex99_2.htm)

> “FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.7.1-9"></a>

###### Clinical hold lifts: on-demand IND in June 2023 and prophylaxis IND in January 2024

> “Pharvaris aligned with the FDA to conduct and complete a 26-week rodent toxicology study to address the clinical holds. Following review of data from a preplanned interim analysis of the study, the FDA lifted the clinical hold on the IND application for deucrictibant for the on-demand treatment of HAE in June 2023. In January 2024, the FDA lifted the clinical hold on the IND application for deucrictibant for the prophylactic treatment of HAE attacks following review of the full data set from the completed 26-week rodent toxicology study.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.7.1-10"></a>

###### Strong CYP3A4 inhibitors and inducers excluded from the phase 3 on-demand trial

> “Use of concomitant medications with systemic absorption that are strong inhibitors of CYP3A4 or strong inducers of CYP3A4 within the last 30 days, or within 5 half-lives (whichever is longer) of the time of randomization.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.7.1-11"></a>

###### Immediate-release capsule in the phase 3 trial (RAPIDe-3): adverse events in the safety analysis set

> “Across the study, no treatment-related adverse events were assessed as severe or serious, and no adverse events led to treatment discontinuation.”
> “Six events in five participants in the deucrictibant group were reported as related to treatment as deemed by the investigators, all of which were observed once and resolved within 24 h spontaneously or with standard management (table 3).”
> “During the entire study, no treatment-emergent adverse events led to treatment discontinuation, or were associated with changes in clinical laboratory, vital signs, and electrocardiogram parameters.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.7.1-12"></a>

###### Immediate-release capsule in the phase 2 trial (RAPIDe-1): severity and seriousness of adverse events

> “No severe (grade 3), life-threatening (grade 4), or fatal (grade 5) treatment-emergent adverse events were reported. Additionally, no treatment-emergent adverse events were reported that were serious, led to discontinuation of treatment or from the study, or were associated with changes in laboratory or ECG parameters or vital signs (table 3).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.7.1-13"></a>

###### Phase 1 tolerability of single and multiple doses in healthy volunteers

> “Adverse events (AEs) were reported by 25% of the subjects in the combined group of all subjects treated with PHA-022121, identical to the 25% incidence with placebo. There was no dose related increase in the incidence of AEs.”
> “All AEs were mild or moderate and subsided rapidly and completely.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

> “PHA-022121 was well tolerated up to the highest dose of 50 mg BID. All reported treatment-emergent adverse events (TEAEs) were mild in intensity and resolved completely.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.7.1-14"></a>

###### Prophylaxis trial of the extended-release tablet (CHAPTER-3): safety and cardiovascular outcomes over 24 weeks

> “In CHAPTER-3, 85 participants received deucrictibant (n=55) or placebo (n=30) with a median (IQR) treatment duration of 24.0 (23.7–24.0) weeks.”
> “Deucrictibant was generally well tolerated, with no treatment-related serious TEAEs and no deaths.”
> “Treatment-related TEAEs were experienced by 11 (20%) participants receiving deucrictibant and 3 (10%) receiving placebo, and 1 participant in each group discontinued study treatment due to an adverse event.”
> “There were no SOC cardiac disorder or vascular disorder TEAEs that were deemed related to deucrictibant.”
> “There were no treatment-related clinically significant abnormalities in heart rate, systolic and diastolic blood pressure, or ECG findings.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-15"></a>

###### Prophylaxis trial with twice-daily immediate-release capsules (CHAPTER-1), randomized part: treatment-related adverse events

> “Treatment-related treatment-emergent adverse events were experienced by two (18%) patients receiving deucrictibant 20 mg, one (8%) patient receiving deucrictibant 40 mg, and one (9%) patient receiving the placebo; all were mild in severity (grade 1) and did not require dosing modification of the study drug. There were no serious adverse events or deaths in any treatment group.”

Source: [Aygören-Pürsün et al. (2026a)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2826%2900004-9/fulltext)

<a id="topic-2.1.2.7.1-16"></a>

###### Prophylaxis trial (CHAPTER-1) open-label extension: long-term cardiovascular outcomes

> “In the CHAPTER-1 OLE, participants received deucrictibant for a mean (standard deviation) duration of 22.2 (8.1) months, with a maximum exposure across the entire CHAPTER-1 study of 33.8 months.”
> “Of 30 participants receiving deucrictibant in the CHAPTER-1 OLE, no treatment-related SOC cardiac disorder or SOC vascular disorder TEAEs were reported.”
> “There were no clinically significant abnormalities in laboratory parameters or ECG findings.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.7.1-17"></a>

###### Combined use of the immediate-release capsule and extended-release tablet: estimated exposure and nonclinical safety margins

> “The combined use of deucrictibant extended-release (XR) tablet 40 mg and immediate-release (IR) capsule(s) 20 mg in the event of a bradykinin-mediated angioedema attack occurring during prophylactic treatment with XR tablet is supported by adequate safety margins, subject to approval of each formulation by regulatory authorities.”
> “The anticipated human Cmax (287 ng/mL) resulted in a margin of 8.8- to 19-fold the nonclinical Cmax at the NOAEL in different species (Table 2, Figure 2A).”
> “The margin for the estimated human Cmax of 342 ng/mL was between 7.4- and 16-fold the nonclinical Cmax at the NOAEL in different species (Table 2, Figure 2A).”
> “In both combined scenarios, the estimated systemic exposure remained below the highest exposure explored in humans following clinical administration of deucrictibant as an oral solution at 50 mg BID for 10 days (Table 4, Figure 2A and 2B), a dose that was not associated with adverse reactions.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Adolescents aged 12 to 17 years: eligibility and enrollment in the phase 3 trial

> “For adolescent participants aged ≥12 and”
> “18 years of age: body weight ≥40 kg.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “134 eligible participants (ten [7%] adolescents and 124 [93%] adults) were randomly allocated.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.8-2"></a>

###### Children younger than 12 years: EU paediatric investigation plan

> “Age appropriate oral solid dosage form”
> “Capsule, soft”
> “Prolonged-release tablet”
> “Treatment of hereditary angioedema”
> “EMA/PE/0000227462 : EMA decision of 28 January 2025 on the acceptance of a modification of an agreed paediatric investigation plan for deucrictibant monohydrate”

Source: [EMA paediatric investigation plan modification EMA/PE/0000227462 (2025)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000227462)

<a id="topic-2.1.2.8-3"></a>

###### Older adults: upper age limit and participants aged 65 years or older in the phase 3 trial

> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

| Age group | RAPIDe-3 enrolled participants (N = 134), n (%) |
| --- | --- |
| Aged 12 to younger than 18 years | “10 (7.5)” |
| Aged 18 to younger than 65 years | “116 (86.6)” |
| Aged 65 years or older | “8 (6.0)” |

Source: [Riedl et al. (2026a)](https://ir.pharvaris.com/static-files/39c3dc39-68f9-4cd9-b814-63bddfe7255b)

<a id="topic-2.1.2.8-4"></a>

###### Older adults: age limit of the phase 1 concentration-QTc population

> “Eligible participants: healthy male and female participants (of non-childbearing potential), between 18 and 65 years of age (inclusive) with a body mass index between 18.0 and 30.0 kg/m2 (inclusive).”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy and lactation: exclusion from the on-demand trials

> “As reproductive and developmental toxicity studies were not available for deucrictibant and potential effects of deucrictibant on the fetus were unknown, pregnant and breastfeeding women were not eligible. Women and male partners of women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Pregnant and breastfeeding women were not eligible. Women of childbearing potential were eligible if sexually abstinent or using medically acceptable contraception.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.8-6"></a>

###### Pregnancy and fertility: nonclinical reproductive studies

> “Deucrictibant has not demonstrated any adverse effects on embryo-fetal survival and development in the humanized bradykinin B2 receptor transgenic rat or in the rabbit. Furthermore, male and female fertility studies showed no adverse effects of deucrictibant on gonadal function, mating behavior, and reproductive performance.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.8-7"></a>

###### Hepatic impairment: dedicated pharmacokinetic study and exclusion from the on-demand trials

> “Hepatic impairment”
> “Open-label, single dose to assess the effect of hepatic impairment on pharmacokinetics”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Patients were excluded in cases of abnormal hepatic or renal function”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Abnormal hepatic function.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.8-8"></a>

###### Renal impairment: dedicated pharmacokinetic study and exclusion from the phase 3 trial

> “Renal impairment”
> “Open-label, single dose to assess the effect of renal impairment on pharmacokinetics”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Abnormal renal function (eGFR”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.8-9"></a>

###### Japanese, Chinese, and Caucasian participants: extended-release tablet multi-ethnicity study

> “XR multi-ethnicity study”
> “Open-label, multiple dose study to compare PK of extended-release formulation between healthy Japanese, Chinese, and Caucasian volunteers”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Deucrictibant

<a id="topic-2.1.2.9.1-1"></a>

###### Strong CYP3A4 inhibitor: itraconazole interaction study

> “An open-label, single-sequence crossover drug-drug interaction study to evaluate the effect of multiple oral doses of itraconazole on the pharmacokinetics of PHA-022121 in healthy subjects”
> “Itraconazole (a medicine against fungi and yeast) is a strong inhibitor of the enzyme CYP3A4, and may thus have an impact on how long PHA-022121 stays in the body.”
> “The primary PK parameters are Cmax, AUClast, and AUC* of the PHA-022121.”

Source: [Onderzoekmetmensen.nl NL-OMON49496](https://onderzoekmetmensen.nl/en/node/49496)

<a id="topic-2.1.2.9.1-2"></a>

###### Moderate CYP3A4 inhibitor: verapamil interaction study (PHA022121-C016)

> “Open-label, single-sequence, drug-drug interaction study to evaluate the effect of multiple oral doses of the moderate CYP3A4 inhibitor verapamil on the single dose PK deucrictibant”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.9.1-3"></a>

###### Gastric acid-reducing agent: rabeprazole interaction study with the extended-release tablet (PHA022121-C014)

> “Open-label, drug interaction study to investigate the effect of multiple doses of the gastric acid-reducing agent rabeprazole on the single dose pharmacokinetics of extended-release tablet.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

| Register field | Value |
| --- | --- |
| Title | “An open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of multiple doses of the gastric acid-reducing agent rabeprazole on the single dose pharmacokinetics of a 40 mg deucrictiban extended-release (XR) tablet.” |
| Protocol | “PHA022121-C014” |
| End of the trial | “12 Dec 2024” |
| Summary of the results | “deferred: adult category 1 trial (mostly phase I), results to be published from” |

Source: [CTIS.eu 2023-506305-18-01](https://ctis.eu/trial/2023-506305-18-01)

<a id="topic-2.1.2.9.1-4"></a>

###### CYP3A4 inhibitors and inducers excluded from the phase 2 trials

> “if they were receiving moderate or potent CYP3A4 inhibitors or inducers.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Use of concomitant medications that are strong CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir) or strong CYP3A4 inducers (e.g., carbamazepine and phenytoin).”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Deucrictibant on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### CYP1A2, CYP2C19, and CYP3A4 substrates: probe cocktail study

> “An open-label, single-sequence cross-over drug-drug interaction study to evaluate the effect of single and multiple oral doses of PHA-022121 on the pharmacokinetics of selective CYP1A2, CYP2C19, and CYP3A4 substrates in healthy subjects”
> “The primary objective of this study is to determine the potential inhibitory/inducing effects of multiple doses of PHA 022121 on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probe substrates of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19 and CYP3A4) in healthy adult subjects.”
> “drug cocktail consisting of 50 mg caffeine, 10 mg omeprazole, and 1 mg”

Source: [Onderzoekmetmensen.nl NL-OMON49587](https://www.onderzoekmetmensen.nl/en/node/49587)

<a id="topic-2.1.2.9.2-2"></a>

###### CYP3A4 activity after 10 days of twice-daily dosing: 4β-hydroxycholesterol marker

> “Plasma concentrations of 4β-hydroxycholesterol was used as a marker to investigate whether PHA-022121 has an induction or inhibition potential on CYP3A4 activity.”
> “After a dosing period of 10 days with any of the PHA-022121 doses, there were no indications for neither an increase nor a decrease in the CYP3A4 activity, based on plasma 4β hydroxycholesterol concentrations.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.9.2-3"></a>

###### P-gp and BCRP substrates: digoxin and rosuvastatin study with the extended-release tablet (PHA022121-C017)

> “Open-label, drug interaction study to investigate the effect of the extended-release tablet administered once daily on the”
> “pharmacokinetics of the P-gp substrate digoxin and the BCRP”
> “substrate rosuvastatin, administered as a drug cocktail”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

| Register field | Value |
| --- | --- |
| Title | “A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail” |
| Protocol | “PHA022121-C017” |
| End of the trial | “21 Oct 2024” |
| Summary of the results | “deferred: adult category 1 trial (mostly phase I), results to be published from” |

Source: [CTIS.eu 2024-514713-35-00](https://ctis.eu/trial/2024-514713-35-00)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Intended commercial dose: one 20 mg immediate-release capsule

> “RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg, which is the intended commercial dosage) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)”

Source: [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Phase 3 regimen: second capsule 4 hours or later for persisting or progressing non-laryngeal attacks

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-3"></a>

###### Phase 3 regimen: laryngeal attacks

> “For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-4"></a>

###### Phase 3 regimen: washout of at least 72 hours between treated attacks

> “Following attack treatment with study drug (or after the second dose of study drug or conventional rescue medication, if used), a washout period of at least 72 h before treatment of the next attack with study drug was required to avoid potential carry-over effects.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-5"></a>

###### Use of a second capsule in the phase 3 primary efficacy set of 88 participants with paired attacks

> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “83.0% of deucrictibant-treated attacks were treated with a single capsule of deucrictibant and 93.2% did not require conventional treatment as rescue medication.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

<a id="topic-2.1.2.10.1-6"></a>

###### Phase 2 dose range: 10, 20, and 30 mg as a single dose of three capsules

> “Capsules of deucrictibant and placebo were identical and each single dose consisted of a combination of three capsules of deucrictibant or placebo in a wallet.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “a statistically significant and clinical meaningful reduction of the patient-reported symptoms of HAE was observed for the attacks treated with all doses of deucrictibant (10, 20, 30 mg) compared to placebo-treated attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.10.1-7"></a>

###### Open-label extension regimen: 20 mg in adults and adolescents (RAPIDe-2 part B)

> “Part A: double-blind deucrictibant 10 mg, 20 mg, or 30 mg.”
> “Part B, which also included adolescents: open-label deucrictibant 20 mg.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.10.1-8"></a>

###### Combined use with the extended-release tablet during prophylaxis: modeled dosing scenarios

> “The evaluated scenarios (Table 1) included once daily deucrictibant XR tablet (40 mg, at steady state) combined with one deucrictibant IR capsule (20 mg), or two deucrictibant IR capsules taken 4 hours apart.”
> “Scenarios assumed that the first IR capsule was taken 6 hours (if only one capsule) or 2 hours (if two capsules) after the XR tablet, such that the peak plasma concentrations (Cmax) for the XR tablet and IR capsule(s) would be reached at the same time, providing a maximum peak of exposure in each scenario.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

> “The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s), in the event of a breakthrough attack while on prophylaxis, is supported by evidence of adequate safety margins.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral soft capsule

> “Deucrictibant Soft Capsules for Oral Use”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

<a id="topic-2.1.2.10.2-2"></a>

###### Self-administration after investigator-confirmed attack qualification in the phase 3 trial

> “Each attack was then assessed and qualified by the investigator during a telephone call or other live communication. Following investigator-confirmed qualification and before administration of the study drug, participants completed their pre-treatment assessments, including PGI-S and AMRA ratings, using the ePRO instruments on the electronic device. During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-3"></a>

###### Attacks eligible for treatment in the phase 3 trial

> “Qualifying attacks were defined as either non-laryngeal attacks, with at least one symptom item score of 20 or more on the angioedema symptom rating scale (AMRA) assessment, which measures skin swelling, skin pain, and abdominal pain, as described below, or non-severe laryngeal attacks without breathing difficulties or stridor.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-4"></a>

###### Timing of home treatment in the phase 2 trial

> “In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks within 3 h after at least one symptom (skin pain, skin swelling, or abdominal pain) reached a visual analog scale (VAS) individual score of at least 30 out of 100 and within 6 h from symptom onset.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.10.2-5"></a>

###### Packaging in the phase 3 trial: one capsule per blister wallet

> “The study drug was packaged in aluminium–aluminium blisters. Each blister was sealed into a wallet, labelled with a booklet label, and rendered tamper evident. Each wallet contained one single capsule (either deucrictibant or placebo).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-6"></a>

###### Capsule ingestion during laryngeal and abdominal attacks

> “No issues with capsule ingestion, such as difficulty swallowing, were reported, including for laryngeal attacks, and no reports of vomiting following study drug administration were reported in participants with abdominal symptoms.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.2-7"></a>

###### Administration with respect to food

> “No significant impact of food intake on achievement of therapeutic levels”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial preparation for a United States launch

> “Additionally, our team is preparing for our potential first commercial launch and is well on its way to building an experienced commercial team.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

> “In parallel to our recent regulatory successes, our ongoing pre-commercial activities are designed to support a timely, successful U.S. launch,”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “With the build out of our commercial infrastructure already underway, Pharvaris is poised for a successful launch of deucrictibant IR, if approved.”

Source: [Pharvaris NDA acceptance press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-announces-fda-acceptance-new-drug-application)

> “We intend to develop a fully integrated sales and marketing organization ahead of marketing approval for deucrictibant IR or deucrictibant XR.”
> “If any of our product candidates receive marketing approval, we intend to market, sell and distribute them using our own commercial infrastructure.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

###### Manufacturing, packaging, and distribution

> “We currently have two CDMOs for the production of deucrictibant active pharmaceutical ingredient (API).”
> “We also partner with a leading CDMO for the manufacturing of the on-demand treatment product, deucrictibant IR capsules.”
> “We partnered with a further Commercial Packaging Organization (CPO) with a global footprint for the packaging and labeling of commercial finished drug product.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### Expanded access program in the United States (NCT07759141)

> “Expanded Access Program (EAP) for deucrictibant IR for the on-demand treatment of HAE attacks opened in the U.S.”
> “The U.S. EAP for deucrictibant IR is available to people in U.S. living with HAE meeting eligibility requirements.”

Source: [Pharvaris Form 6-K, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526345702/phvs-ex99_1.htm)

> “An expanded access program (EAP) (NCT07759141) for deucrictibant IR for the on-demand treatment of HAE attacks is also available to people in U.S. meeting eligibility requirements.”

Source: [Pharvaris RAPIDe-3 Lancet publication press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/phase-3-study-results-highlighting-deucrictibants-rapid-and)

> “This is an expanded access program (EAP) designed to allow access to deucrictibant immediate-release (IR) capsule for eligible participants with hereditary angioedema (HAE) in the United States (US) and US territories who lack satisfactory alternative treatment options for on-demand treatment of HAE attacks, as determined by their treating physician.”
> “The program will continue beyond the commercial availability of deucrictibant IR, upon regulatory approval, for up to approximately 6 months to ensure continuity of treatment for participants for whom ongoing therapy is considered appropriate.”
> “Male or female, aged ≥12 to ≤75 years at the time of providing written informed consent/assent.”
> “Residence in the US or US territories.”

Source: [ClinicalTrials.gov NCT07759141](https://clinicaltrials.gov/study/NCT07759141)

<a id="topic-2.1.2.11-4"></a>

###### Continued investigational access through the RAPIDe-2 open-label extension

> “Part B is open-label treatment and includes participants rolling over from Part A, participants from Study PHA022121-C201 who did not participate in Part A, participants aged 12 years and older with HAE type I, type II, or HAE-nC1INH rolling over from Study PHA022121-C306, and deucrictibant treatment naïve adult participants with HAE-nC1INH who elect to participate in this extension study and meet the eligibility requirements.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-2.1.2.11-5"></a>

###### Specialty pharmacy or limited distribution arrangements

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### RAPIDe-3: concomitant long-term prophylaxis permitted

> “Participants using concomitant hereditary angioedema long-term prophylaxis were also eligible.”
> “stratified by age (≥12 to <18 years or ≥18 years) and concomitant long-term prophylaxis use at the time of screening (yes or no).”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “Participants on long-term prophylactic therapy with plasma-derived C1-INH (danazol, anti-fibrinolytics, berotralstat, or lanadelumab) must be on a stable dose and regimen and intend to remain on the same dose for 6 months before screening and the duration of the study.”
> “Use of attenuated androgens for short-term prophylaxis within 2 weeks before screening.”

Source: [ClinicalTrials.gov NCT06343779](https://clinicaltrials.gov/study/NCT06343779)

> “The patient population studied included adolescents and adults; participants on and not on long-term prophylaxis (LTP); people with HAE type 1, HAE type 2, and HAE with normal C1 inhibitor; and attacks studied included those of varying severities and across all body locations.”

Source: [Pharvaris RAPIDe-3 topline press release (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000119312525305951/d69798dex991.htm)

<a id="topic-2.1.2.12-2"></a>

###### RAPIDe-3: long-term prophylaxis agents used by participants who treated at least one attack

| Long-term prophylaxis | Deucrictibant (n=101) | Placebo (n=100) | Overall participants (n=113) |
| --- | --- | --- | --- |
| Any concomitant long-term prophylaxis | “20 (20%)” | “24 (24%)” | “26 (23%)” |
| Lanadelumab | “8 (8%)” | “10 (10%)” | “11 (10%)” |
| Berotralstat | “5 (5%)” | “7 (7%)” | “7 (6%)” |
| C1-esterase inhibitor | “4 (4%)” | “5 (5%)” | “5 (4%)” |
| Danazol | “3 (3%)” | “2 (2%)” | “3 (3%)” |

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.12-3"></a>

###### RAPIDe-3: second capsule and conventional rescue medication rules

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks. For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”
> “An intercurrent event was defined as the use of rescue medication or selected prohibited medication after an attack was treated with study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.12-4"></a>

###### RAPIDe-1: long-term prophylaxis excluded and rescue medication rules

> “Patients receiving long-term prophylactic therapy for hereditary angioedema at screening were not eligible.”
> “Attacks with any symptoms involving the internal head or neck, including laryngeal attacks, or presenting with vomiting, did not qualify for study drug treatment and patients were instructed to immediately treat with standard on-demand medication.”
> “At 4 h or more after study drug administration, conventional on-demand therapy as rescue medication was allowed in case of insufficient symptom relief.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.12-5"></a>

###### RAPIDe-2 Part B: concomitant long-term prophylaxis permitted

> “If a participant is receiving long-term prophylactic therapy with a medication indicated for HAE:, eg, plasma-derived C1INH, danazol at less than or equal to 200 mg/day, antifibrinolytics, berotralstat, or lanadelumab, they must be on a stable dose and regimen for at least 3 months before screening and intends to remain on the same dose for the duration of the study.”

Source: [ClinicalTrials.gov NCT05396105](https://clinicaltrials.gov/study/NCT05396105)

<a id="topic-2.1.2.12-6"></a>

###### Combined use of the immediate-release capsule during extended-release prophylaxis

> “The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s), in the event of a breakthrough attack while on prophylaxis, is supported by evidence of adequate safety margins.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

> “The combined use of deucrictibant extended-release (XR) tablet 40 mg and immediate-release (IR) capsule(s) 20 mg in the event of a bradykinin-mediated angioedema attack occurring during prophylactic treatment with XR tablet is supported by adequate safety margins, subject to approval of each formulation by regulatory authorities.”
> “The evaluated scenarios (Table 1) included once daily deucrictibant XR tablet (40 mg, at steady state) combined with one deucrictibant IR capsule (20 mg), or two deucrictibant IR capsules taken 4 hours apart.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

<a id="topic-2.1.2.12-7"></a>

###### CHAPTER-1: icatibant treatment of breakthrough attacks during deucrictibant prophylaxis

> “A recently published post-hoc analysis of the prophylaxis CHAPTER-1 study assessed the mean duration of breakthrough attacks, in both placebo and deucrictibant arms, that were treated with a single dose of icatibant, another bradykinin B2 receptor antagonist. The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treatment of attacks.”

Source: [Pharvaris CIIC Spring 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/evidence-supporting-combined-use-deucrictibant-ir-deucrictibant)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Deucrictibant on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Deucrictibant: route, dose, and time to onset of symptom relief in RAPIDe-3

> “Participants were randomly allocated in a 1:1 ratio to one of two double-blind crossover sequences to treat two attacks with a 20 mg oral deucrictibant immediate-release capsule or placebo as either deucrictibant–placebo or placebo–deucrictibant, stratified by age and use of long-term prophylaxis.”
> “Onset of symptom relief occurred significantly faster with deucrictibant than placebo, with median times of 1·28 h (95% CI 1·05 to 1·52) and more than 12 h (5·82 to >12), respectively (p<0·0001).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-2"></a>

###### Deucrictibant: redosing and rescue medication in RAPIDe-3

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”
> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-3"></a>

###### Sebetralstat: route, dose, redosing, and time to beginning of symptom relief in KONFIDENT

> “The recommended dosage of EKTERLY is one dose of 600 mg (two tablets) orally at the earliest recognition of an acute HAE attack.”
> “A second dose of 600 mg (two tablets) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur.”
> “The median time to beginning of symptom relief within 12 hours of first dose was 2.0 hours (95% CI: 1.5, 2.8) in patients administered EKTERLY 600 mg.”
> “Note: In the EKTERLY 600 mg group, 38% of patients administered a second dose within 12 hours.”
> “Less than 50% of placebo patients reached beginning of symptom relief within 12 hours; therefore, the median time could not be estimated.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Icatibant: route, dose, redosing, and time to symptom reduction in its placebo-controlled trial

> “The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur.”
> “No more than 3 doses may be administered in any 24 hour period.”
> “The median time to 50% reduction in symptoms for patients with cutaneous or abdominal attacks treated with FIRAZYR (n=43) compared to placebo (n=45) was 2.0 hours [95% CI 1.5, 3.0] versus 19.8 hours [95% CI 6.1, 26.3], respectively (p<0.001).”
> “Across the three trials, FIRAZYR had a median time to 50% reduction from baseline symptoms ranging from 2.0 to 2.3 hours.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Ecallantide: route, administration setting, redosing, and outcome measures in its two trials

> “The recommended dose of KALBITOR is 30 mg (3 mL), administered subcutaneously in three 10 mg (1 mL) injections.”
> “If an attack persists, an additional dose of 30 mg may be administered within a 24 hour period.”
> “Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.”
> “In both trials, the effects of KALBITOR were evaluated using the Mean Symptom Complex Severity (MSCS) score and the Treatment Outcome Score (TOS).”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

###### Plasma-derived C1 esterase inhibitor: route, dose, and time to onset of relief in its placebo-controlled trial

> “Administer BERINERT at a dose of 20 International Units (IU) per kg body weight by intravenous injection.”
> “Subjects treated with 20 IU/kg body weight of BERINERT experienced a significant reduction (p=0.0016;”
> “in time to onset of relief from symptoms of an HAE attack as compared to placebo (median of 48 minutes for BERINERT 20 IU/kg body weight, as compared to a median of >4 hours for placebo).”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Recombinant C1 esterase inhibitor: route, dose, redosing, and time to beginning of relief in its placebo-controlled trial

> “The recommended dose of RUCONEST is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.”
> “If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level.”
> “Time to Beginning of Relief of Symptoms, minutes RUCONEST 50 U/kg N=44 Placebo N=31 Median 90 152”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Cross-trial comparison with sebetralstat and icatibant as stated by the RAPIDe-3 investigators

> “In an independent trial of 600 mg oral sebetralstat, onset of symptom relief, measured using the same PGI-C-based endpoint definition, was met with a median time of 1·79 h to 2·0 h (6·72 h to >12 h for placebo).”
> “Variations in trial designs and instruments used across trials for on-demand treatment of hereditary angioedema attacks prevent direct outcome comparisons.”
> “In this trial, complete attack resolution (no symptoms) measured using PGI-S was reached within a median time of 11·95 h with deucrictibant (placebo >48 h).”
> “Using the same PGI-S-based definition of complete symptom resolution, attacks treated with 600 mg sebetralstat required a median time of 24 h or longer (placebo >24 h) to reach the same outcome.”
> “In another trial, the subcutaneously administered bradykinin B2 receptor antagonist, icatibant, attained almost complete resolution of attack manifestations (defined as all VAS item scores ≤10 for three consecutive timepoints) in a median time of 8·5 h (placebo 19·4 h).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-9"></a>

###### Redosing and rescue medication with deucrictibant and sebetralstat as stated by the RAPIDe-3 investigators

> “Treatment with deucrictibant resulted in relatively low use of second capsule (17%) and conventional on-demand therapy as rescue medication (7%) within 12 h, compared with 67% and 36% for placebo, respectively.”
> “In a phase 3 study of sebetralstat, 39·8% of attacks used a second dose of 600 mg sebetralstat (placebo 56·0%) and 8·6% used rescue medication within 12 h (placebo 25·0%).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-10"></a>

###### Pharmacokinetics and potency of deucrictibant and icatibant as stated by the RAPIDe-3 investigators

> “Although deucrictibant and icatibant have the same mechanism of action in targeting the bradykinin B2 receptor, they exhibit distinct pharmacokinetic profiles.”
> “Deucrictibant has a mean elimination half-life of approximately 5·1 h,”
> “compared with approximately 1·5 h for icatibant.”
> “Mean plasma levels following a single 20 mg dose of deucrictibant immediate-release capsule achieved the EC85 of 13·8 ng/mL within 15–30 min of drug administration and were maintained for 8 h or longer,”
> “while the EC85 for icatibant has been estimated to be 54 ng/mL.”
> “Lastly, in-vitro assays indicate that deucrictibant is approximately 20-fold more potent than icatibant at the human bradykinin B2 receptor (recombinant or endogenously expressed).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-11"></a>

###### Safety relative to icatibant as stated by the RAPIDe-3 investigators

> “Overall, these findings confirm the safety profile of orally administered deucrictibant observed to date and are consistent with the clinical experience of the subcutaneous bradykinin B2 receptor antagonist, icatibant, with the exception of injection-site reactions.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-12"></a>

###### Company statement: absence of head-to-head comparison with icatibant

> “However, we have not conducted a head-to-head comparison of icatibant or any other drug candidate to deucrictibant in a clinical trial.”
> “We have compared the published data for icatibant to data from our Phase 1, Phase 2 and Phase 3 randomized clinical trials (RAPIDe-1 and RAPIDe-3), and Phase 2/3 long-term extension study (RAPIDe-2) of deucrictibant IR.”
> “Accordingly, the value of comparisons to icatibant in this Annual Report may be limited because they are not derived from a head-to-head trial, and they are from trials that were conducted under different protocols at different sites and at different times.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.14-13"></a>

###### Company statement: anticipated differentiation of the immediate-release capsule

> “The availability of an immediate-release capsule formulation provides a good pharmacokinetic profile for on-demand treatment: rapid oral absorption independent of fed status resulting in almost immediate onset of action with longer expected duration of efficacy than subcutaneous injections of icatibant.”
> “Single dose resolution 83% of all attacks completely resolved with a single dose”
> “More potent inhibitor than icatibant - Lowest dosage of any oral AE-BK on-demand treatment”
> “Exposure exceeds the anticipated threshold therapeutic plasma level (EC85) in 30 minutes, with or without food”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.14-14"></a>

###### Company statement: anticipated position relative to the current standard of care

> “With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.”
> “the bradykinin B2 receptor antagonist icatibant (FIRAZYR, and available as a generic product”
> “which is currently the most widely used therapy); and the oral kallikrein inhibitor sebetralstat (EKTERLY).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Due to its mechanism of action, deucrictibant is expected to outcompete bradykinin at the B2 receptor, resulting in direct modulation of bradykinin signaling, as demonstrated by the rapid and sustained symptom relief and attack resolution findings from RAPIDe-3.”

Source: [Pharvaris AAAAI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/deucrictibant-data-supporting-potentially-differentiated-profile)

<a id="topic-2.1.2.14-15"></a>

###### Indirect comparison of sebetralstat with recombinant C1 esterase inhibitor funded by KalVista

> “Based on a systematic literature review and feasibility assessment, only the pivotal trial for intravenous rhC1INH (NCT01188564) reported necessary data for a comparable primary efficacy endpoint (time to beginning of symptom relief) to enable an ITC with oral sebetralstat.”
> “The fixed-effects model found no significant differences in time to beginning of symptom relief between sebetralstat 300 mg and rhC1INH 50 IU/kg (hazard ratio [95% credible interval], 0.96 [0.42–2.15] to 1.19 [0.58–2.45]).”
> “Third, the location of on-demand treatment administration differed, with the KONFIDENT trial being the first phase 3 trial to allow patients to treat at home; the impact of this difference cannot be assessed.”
> “The study was supported by KalVista Pharmaceuticals.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909897/)

<a id="topic-2.1.2.14-16"></a>

###### Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming

> “In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.”
> “All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].”
> “The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].”
> “In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).”
> “Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.”

Source: [Anderson et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13290826/)

<a id="topic-2.1.2.14-17"></a>

###### Methodological critique of the Pharming-funded indirect comparison

> “Unlike anchored comparisons, which preserve randomization through a common comparator, unanchored analyses require that all clinically relevant TEMs and PVs be identified, measured, and appropriately adjusted; the validity of unanchored comparisons depends critically on the assumption that no important differences remain between populations after adjustment [5].”
> “The unanchored comparison did not consider either attack severity or time to on-demand treatment, despite these variables being recognized as impacting treatment outcomes [8].”
> “This letter was funded by KalVista Pharmaceuticals.”

Source: [Hummel et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03836-5)

<a id="topic-2.1.2.14-18"></a>

###### Health technology assessment appraisal of the sebetralstat indirect comparison

> “The company explained that it is difficult to do reliable ITCs for on-demand treatments for hereditary angioedema because of the heterogeneity in trial designs and definitions of endpoints.”
> “The committee concluded that the results from the ITC were uncertain and did not compare sebetralstat with Berinert, Cinryze or icatibant.”
> “No direct evidence was available for sebetralstat compared with icatibant or C1-INHs”

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)

<a id="topic-2.1.2.14-19"></a>

###### Cross-trial comparison caveats: guideline statement

> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide (Table 4).”
> “Direct comparisons among these options are limited.”
> “Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.1.2.14-20"></a>

###### Cross-trial comparison caveats: infeasibility of a head-to-head trial

> “Lastly, it is recognized that the ideal comparison between therapies would be a randomized, double-blind, head-to-head clinical trial (double dummy design).”
> “However, in the context of HAE, there are multiple reasons making such an RCT infeasible, including challenges in aligning time to treatment for an oral versus an injectable treatment, and the ability to use a double-blind approach for evaluating oral versus injectable treatments, due to expected skin reactions with the latter.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909897/)

> “Because no head-to-head trials have evaluated on-demand therapies for hereditary angioedema (HAE), variability in study designs and outcome definitions across clinical trials limits direct interpretation of relative efficacy, including time to complete resolution (TTCR) and the need for redosing.”

Source: [Anderson et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13290826/)

<a id="topic-2.1.2.14-21"></a>

###### Oral therapies developed for prophylaxis and on-demand treatment

> “Over the past 6 years two oral therapies have been developed for HAE to include berotralstat for long term prophylaxis (LTP) and sebetralstat for on-demand therapy (ODT).”
> “Presently, deucrictibant, another oral HAE therapy, is under investigation and appears effective for LTP and ODT.”

Source: [Bui et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42635583/)

Additional sources: [Zuraw and Christiansen (2026)](https://pubmed.ncbi.nlm.nih.gov/42849490/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Inheritance pattern

> “an autosomal dominant pattern”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-2"></a>

###### Definition: recurrent bradykinin-mediated angioedema

> “Angioedema is a localized, self-limiting, asymmetric, and disfiguring non-inflammatory edema of the subcutaneous and submucosal tissues that arises because of increased vascular permeability.”
> “HAE comprises a group of genetic disorders characterized by recurrent episodes of angioedema, inherited across generations and typically mediated by bradykinin.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-3"></a>

###### Etiology: dysfunction or lack of C1 esterase inhibitor

> “Hereditary angioedema (HAE) is a rare disease caused by dysfunction or lack of the C1 esterase inhibitor (C1-INH) protein.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.1-4"></a>

###### Classification: HAE with C1-INH deficiency (types 1 and 2) and HAE with normal C1-INH

> “HAE (ORPHA:91378, OMIM: PS106100) is most commonly caused by a deficiency of C1 inhibitor (C1-INH), which can be confirmed through biochemical and genetic testing.”
> “It is subclassified into type 1 HAE (quantitative deficiency) and type 2 HAE (dysfunctional protein).”
> “Furthermore, in 2000, a new type of HAE was described in patients with normal C1-INH function, a form initially known as HAE type 3 but currently called HAE with normal C1-INH (HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-5"></a>

###### Genetic cause: SERPING1 and F12 variants

> “Variants (also called mutations) in the SERPING1 gene cause hereditary angioedema due to C1-INH deficiency.”
> “SERPING1 gene variants that cause hereditary angioedema due to C1-INH deficiency type I lead to reduced levels of C1-INH in the blood, while variants that cause type II result in the production of a C1-INH protein that functions abnormally.”
> “Variants in the F12 gene cause most cases of hereditary angioedema with normal C1-INH.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.1-6"></a>

###### Penetrance, transmission risk, and de novo variants

> “HAE-C1-INH is an autosomal dominant disorder characterized by high penetrance, with only about 5% of mutation carriers remaining asymptomatic over their lifetime.”
> “The risk of parent–child transmission is 50%, but up to 25% of cases result from de novo genetic mutations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.1-7"></a>

###### Distribution of HAE types: Swedish population-based cohort

> “Out of the 239 individuals, the majority had HAE type 1 (90.4%) while 9.6% where characterized as HAE type 2.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.1-8"></a>

###### Genetic causes of HAE with normal C1-INH

> “Abnormalities in proteins/genes, such as factor XII (encoded by the F12 gene), plasminogen (PLG), angiopoietin-1 (ANGPT1), kininogen 1 (KNG1), myoferlin (MYOF), and heparan sulfate-3-O-sulfotransferase 6 (HS3ST6), have been associated with these forms of HAE (collectively HAE-nC1-INH), and the involvement of bradykinin has not been confirmed in all cases.”
> “HAE of unknown origin (ie, with negative genetic test results) is referred to as HAE-UNK.”
> “HAE-nC1-INH forms also usually follow an autosomal dominant inheritance pattern, although autosomal recessive forms have been reported.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Hereditary angioedema

<a id="topic-2.2.1.2.1-1"></a>

###### Annual incidence of diagnosed HAE type 1 and 2: Finnish national register

> “In Finland, 103 new patients were diagnosed with HAE-1/2 within the 10-year study period.”
> “The mean incidence of HAE-1/2 was 0.16/100,000, showing an annual variability between 0.07 and 0.22/100,000 (4 to 12 new cases annually)”
> “In our study the incidence seemed quite stable, especially considering that HAE is a rare disease, and a few new patients (e.g. a new HAE family) have a big impact on the calculated annual incidence in a small country like Finland.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence of treated HAE: Swedish National Prescribed Drug Register, 2024

> “The total number of patients treated for HAE has increased from 188 to 245 patients between 2021 and 2024.”
> “This corresponds to a prevalence and incidence rate of 2.31/100,000 and 0.36/100,000 in 2024, respectively.”
> “The observed prevalence aligns with prior estimates, though the incidence, when measured as number of new patients treated for HAE, is higher than what has been observed elsewhere.”

Source: [Danielsson et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/current-use-of-hereditary-angioedema-hae-treatments-in-sweden-an-analysis-of-the-national-prescribed-drug-register)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence across ethnic groups

> “No significant differences in the incidence of C1-INH deficiency across ethnic groups have been confirmed.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Hereditary angioedema

<a id="topic-2.2.1.2.2-1"></a>

###### Epidemiology

> “Hereditary angioedema is estimated to affect 1 in 50,000 people worldwide.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence and incidence: systematic literature review

> “Diagnostic methodology varied greatly, with a minority of studies citing an established guideline.”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-3"></a>

###### Pooled diagnosed annual prevalence: combined HAE types and 95% confidence interval

> “1.70 per 100,000 (1.58–1.83; combined types).”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-4"></a>

###### Pooled diagnosed annual prevalence by HAE type and by region

> “Pooled diagnosed annual prevalence estimates (95% confidence interval) were 1.31 per 100,000 (0.83–2.08; type I HAE), 0.20 per 100,000 (0.14–0.29; type II HAE), 0.06 per 100,000 (0.01–0.40; HAE with normal C1-inhibitor [INH])”
> “Pooled estimates by region were 1.43 per 100,000 (0.99–2.08) and 1.64 per 100,000 (1.02–2.64) in North America and Europe, respectively, which were higher than individual estimates from the other regions.”

Source: [Craig et al. (2026b)](https://karger.com/iaa/article/doi/10.1159/000553023/953095/Prevalence-and-Incidence-of-Hereditary-Angioedema)

<a id="topic-2.2.1.2.2-5"></a>

###### United States prevalence of all HAE types: commercial claims database, 2018 to 2020

> “No US prevalence for all types of HAE has been estimated.”
> “For 2018, 2019, and 2020, the claims-based algorithm yielded overall annual unadjusted HAE prevalence estimates per 100,000 and number of people diagnosed with HAE of 2.67, 9559; 2.61, 9341; and 2.43, 8694, respectively.”
> “The corresponding estimates based on expert physician analysis were 2.13, 7602; 2.03, 7275; and 1.84, 6595, respectively.”
> “Our calculations (which exceed the frequently cited 2:100,000 prevalence for HAE with C1 inhibitor deficiency) afford a real-world projected prevalence encompassing all types of HAE.”

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/)

<a id="topic-2.2.1.2.2-6"></a>

###### Worldwide pooled prevalence: systematic review and meta-analysis of 24 studies

> “Twenty-four studies from 2000 to 2024 were included in the analysis, describing 11,245 cases of HAE.”
> “The pooled prevalence of HAE was 1.22 cases per 100,000 people (95% confidence interval [CI]: 0.91, 1.53), with lower prevalences reported in Asia and Africa compared to Europe and North America.”
> “HAE type 1 made up most of the cases, with a slight female predominance.”

Source: [Fisch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39827848/)

<a id="topic-2.2.1.2.2-7"></a>

###### Prevalence of diagnosed HAE type 1 and 2: Finnish national register

> “The prevalence of HAE-1/2 patients increased over the follow-up time from 0.8 to 2.6/100,000 persons, equalling 144 patients at the end of 2021.”
> “The prevalence of 2.6 per 100,000 at the end of 2021 in Finland is higher than the 1.5 per 100,000 that has been observed in the other Nordic countries including Sweden, Denmark, and Norway”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.2.2-8"></a>

###### Minimum prevalence of HAE types 1 and 2: United Kingdom survey of 37 centers

> “The survey identified 1152 patients with HAE-1/2 (58% female and 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency.”
> “Data were provided by 37 centers across the United Kingdom.”
> “This gives a minimum prevalence of 1:59,000 for HAE-1/2 and 1:734,000 for acquired C1 inhibitor deficiency in the United Kingdom.”

Source: [Yong et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37146882/)

<a id="topic-2.2.1.2.2-9"></a>

###### Minimal prevalence in the Asia Pacific region: survey of 12 countries and territories

> “Completed questionnaires were received from 14 representatives of 12 member countries and territories, representing 46% of the world population.”
> “Overall minimal prevalence of HAE in the AP region was 0.02/100,000 population, with significant heterogeneity across different centers.”

Source: [Li et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36584968/)

<a id="topic-2.2.1.2.2-10"></a>

###### Population prevalence of HAE with C1-INH deficiency: South Australia, 2021 to 2022

> “Case ascertainment was conducted over 18 months from January 2021 to July 2022, using a range of approaches with the aim of identifying all people with C1INH-HAE in South Australia.”
> “We identified 35 people with HAE in South Australia, yielding a population prevalence of 1 in 52,400, in line with average established international prevalence.”
> “There are relatively few systematic population prevalence studies, with reports from various countries of between 1 in 20,000 and 1 in 150,000.”

Source: [Troelnikov et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11239692/)

<a id="topic-2.2.1.2.2-11"></a>

###### Company statement: HAE prevalence worldwide, in the United States, and in the European Union

> “According to HAE International, as of October 2014, HAE affected from 1:30,000 to 1:80,000 individuals globally, or at least 7,000 patients in the U.S. and at least 15,000 patients in the EU.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.2.1.2.2-12"></a>

###### Company statement: prevalence by type of bradykinin-mediated angioedema

> “HAE-C1INH affects 1:50,000 individuals globally, HAE-nC1INH affects 1:250,000 individuals globally, and AAE-C1INH affects 1:500,000 individuals globally.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Age at symptom onset

> “Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.3-2"></a>

###### Long-term course: onset age, symptom-free years, and severity by sex

> “Clinical symptoms started at a mean age of 11.2 (SD 7.7) years.”
> “During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred.”
> “On average, women had a more severe course of the disease than men.”
> “Patients with early onset of clinical symptoms were affected more severely than those with late onset.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.3-3"></a>

###### Course of an attack and attack frequency without treatment

> “The episodes typically involve nonpruritic, nonpitting swelling that worsens over the first 24 hours and gradually subsides over the next 48 to 72 hours, usually lasting no more than 5–7 days.”
> “Untreated patients with HAE may experience attacks every 7–14 days on average, although some report attacks as frequently as every 3 days, while others may experience them rarely or never.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.3-4"></a>

###### Mortality from laryngeal attacks: German cohort of 728 patients

> “Of the 214 patients who had died, 70 asphyxiated during a laryngeal attack.”
> “Mortality by asphyxiation was higher in patients with undiagnosed HAE-C1-INH (63 cases) than in patients with diagnosed HAE-C1-INH (7 cases).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality from laryngeal attacks: Brazilian reference-center cohort of 433 patients

> “A total of 75 fatal events were evaluated.”
> “Only 10 of 75 patients were given the diagnosis of HAE before death, and the HAE diagnosis was made after death in 65 of 75 patients using verbal autopsy.”
> “The final cause of death after the investigation was asphyxiation owing to LE in 39 of 75 (52%) and deaths owing to other causes in 36 of 75 (48%).”
> “The life span of patients who died of LE was reduced by 20 years compared with those who died of other causes.”

Source: [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)

<a id="topic-2.2.1.3-6"></a>

###### Mortality from laryngeal edema: review of 23 real-world studies

> “The analyzed studies included 3292 patients and 411 deaths from asphyxia due to laryngeal edema.”
> “Death rates from laryngeal edema had an average of one death for every 20 patients.”
> “The percentage among deaths in general associated with laryngeal edema was evaluated in three studies (32.7%, 44.4%, and 56%).”

Source: [Minafra et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/34687444/)

<a id="topic-2.2.1.3-7"></a>

###### United States death certificates, 1979 to 2010

> “The age-adjusted death rate for hereditary angioedema decreased from 0.28 (95% confidence interval [CI] 0.25-0.32) to 0.06 (95% CI 0.05-0.08) per million persons per year.”
> “Lack of specific coding for acquired angioedema most likely explains the observed association between cancer and hereditary angioedema.”

Source: [Kim et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25280464/)

<a id="topic-2.2.1.3-8"></a>

###### Family deaths from HAE attacks: US patient registry

> “Morbidity surrogates including emergency department visits, hospitalizations, unnecessary abdominal surgeries, and intubations were strikingly high as was mortality with 36.9% of HAE-C1INH and 15.4% of HAE-nl-C1INH participants reporting family members who died from a HAE attack.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.3-9"></a>

###### All-cause mortality: Swedish population-based cohort

> “In the current study, there was no increased risk of death (OR 0.69; 95% CI 0.38–1.26) among HAE patients.”
> “Nonetheless, the mortality among HAE patients during the last decade seems to be low.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.3-10"></a>

###### Rising prevalence attributed to decreased mortality: Finnish national register

> “The rise in yearly prevalence is likely a combination of stable incidence and decreased mortality, e.g. due to more effective HAE treatment options”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.3-11"></a>

###### Factors associated with in-hospital mortality: US Nationwide Inpatient Sample, 2021

> “Older HA patients and those with autoimmune conditions, hypertension, or low income were at higher risk of mortality.”

Source: [Khalid and Hitch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12276015/)

<a id="topic-2.2.1.3-12"></a>

###### Risk of death from laryngeal edema without a diagnosis

> “In the absence of the HAE diagnosis, the risk of death with laryngeal edema is estimated at 20%–25%.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.3-13"></a>

###### Fatal laryngeal attacks: time to death and treatment received, Brazilian reference-center cohort

> “Time from onset of symptoms to seeking medical assistance was a median of 4 hours, and the time to death was a median of 8 hours.”
> “Three patients received fresh-frozen plasma and none received medications specific to HAE attacks.”
> “Throat pain or discomfort was the most common symptom, experienced by 71.8% of patients.”

Source: [Minafra et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35526778/)

<a id="topic-2.2.1.3-14"></a>

###### On-demand treatment and the risk of asphyxiation

> “All patients with confirmed HAE, even if asymptomatic, must have access to ODT, as the risk of a severe attack is unpredictable and persists throughout life.”
> “ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.3-15"></a>

###### Burden before and after on-demand therapies became available: US patient survey

> “Patients at a United States HAE Association summit meeting were asked to rate the burden of HAE currently and compare by recall with 2009 when these therapies were not available.”
> “Responses were obtained from 134 self-identified HAE subjects: 85 type I, 21 type II, and 28 with normal C1 inhibitor (C1INH).”
> “Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.”
> “Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.”

Source: [Christiansen et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25715243/)

<a id="topic-2.2.1.3-16"></a>

###### Company statement: attack frequency and course of untreated attacks

> “According to scientific publications, patients experience a median of 14 attacks per year, and half of patients experience a potentially life-threatening airway attack at least once in their lifetime.”
> “If left untreated, attacks can last multiple days and are commonly painful, leading to multiple sick days and even hospitalization.”
> “The number and severity of attacks vary highly between patients, and the most severely affected patients can experience attacks every few days.”
> “Swelling typically develops over 24 hours and resolves within five days without treatment.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.2.1.3-17"></a>

###### Company statement: airway attacks and risk of asphyxiation

> “Attacks often lead to discomfort, pain and nausea but can become life-threatening in the case of airway obstruction, with a 30% risk of asphyxiation if the attack remains untreated.”
> “Although rare, at least half of AE-BK patients have experienced a life-threatening airway swelling attack and airway attacks remain a major cause of mortality in AE_BK patients.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Pathophysiology

> “Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks”

Source: [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)

<a id="topic-2.2.1.4-2"></a>

###### Bradykinin generation: activation of prekallikrein to plasma kallikrein

> “In HAE-C1-INH, bradykinin is the primary mediator of swelling.”
> “This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.”
> “The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-3"></a>

###### Role of C1 inhibitor in regulating the kallikrein-kinin system

> “C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.”
> “HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.”
> “This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-4"></a>

###### Bradykinin and vascular permeability

> “When the body does not have enough normal C1-INH protein, it ends up with excessive amounts of a protein fragment (peptide) called bradykinin.”
> “Bradykinin promotes inflammation by increasing the amount of fluid that leaks through the walls of blood vessels into body tissues (vascular permeability).”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.4-5"></a>

###### Evidence for bradykinin as the mediator of attacks: plasma levels and the B2 receptor knockout model

> “In 1983, a pivotal study by Fields et al. implicated bradykinin as the likely primary mediator responsible for angioedema attacks.”
> “This hypothesis was further supported in 1999 by Nussberger et al, who analyzed plasma samples from individuals with HAE and reported elevated bradykinin levels in blood drawn from edematous sites compared to unaffected areas.”
> “Shortly thereafter, in 2002, a landmark experimental study using a double-knockout murine model deficient in both C1 inhibitor (C1-INH) and bradykinin B2 receptor (Bk2R) further confirmed the critical role of C1-INH deficiency and bradykinin in the pathogenesis of HAE.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-6"></a>

###### Kinin receptors: bradykinin B1 and B2 receptors

> “Bradykinin (BK)-related peptides, the kinins, are released from kininogens by kallikreins and exert various physiological and pathological effects via 2 related G protein-coupled receptors (GPCRs) termed the bradykinin B1 and B2 receptors”
> “While kinins and their receptors mediate compensatory and protective vasodilator effects under various pathological conditions, they are also mediators of inflammation, producing plasma extravasation and edema and pain”

Source: [Lesage et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7316994/)

<a id="topic-2.2.1.4-7"></a>

###### Bradykinin B2 receptor as the mediator of vascular permeability and swelling

> “which leads to the overproduction of bradykinin and activation of bradykinin B2 receptors.”
> “This increases vascular permeability and results in angioedema attacks.”
> “Bradykinin is rapidly metabolized by endogenous metalloproteases including angiotensin-converting enzyme (ACE).”
> “Increased vascular permeability and swelling induced by bradykinin are primarily mediated through the bradykinin B2 receptor.”
> “Bradykinin binds to and stimulates the bradykinin B2 receptor, thereby mediating vasodilatation and increased capillary permeability.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.4-8"></a>

###### Endothelial B2 receptor signaling: adherens junction disruption and resealing

> “Attacks are caused by overproduction of bradykinin, which binds to and activates vascular endothelial bradykinin B2 receptors, leading to disruption of the adherens junctions, resulting in increased vascular permeability and localised subcutaneous or submucosal swelling or both.”
> “The inhibition of signalling allows adherens junction resealing and progressive resolution of the accumulated interstitial fluid.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.1.4-9"></a>

###### Bradykinin production pathways and blockade at the receptor

> “thus leaving the bradykinin B2 receptor functional to activation from bradykinin produced from kallikrein–kinin independent pathways.”
> “Conversely, bradykinin B2 receptor antagonists can directly block the receptor activity caused by bradykinin, regardless of its production pathway.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.1.4-10"></a>

###### Kallikrein-kinin system targets of oral treatments

> “Currently approved and investigational oral treatments for HAE target components of the kallikrein‐kinin system, including plasma kallikrein (PKa), activated factor XII (FXIIa), or bradykinin B2 receptor (B2R; Figure 1).”
> “PKa inhibitors (e.g., berotralstat, sebetralstat, ATN249, VE‐4666, and VE‐4062) and FXIIa inhibitors prevent bradykinin generation by preventing cleavage of high molecular weight kininogen, whereas B2R antagonists (e.g., deucrictibant) block bradykinin binding.”

Source: [Valerieva et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11431061/)

<a id="topic-2.2.1.4-11"></a>

###### Mediators of swelling in HAE with normal C1-INH

> “Current evidence indicates that excessive bradykinin generation is still involved in most cases (HAE-FXII, HAE-PLG, HAE-KNG, HAE-HSST, and HAE-CPN).”
> “However, other mediators such as VEGF and angiopoietin have emerged as candidate contributors, potentially increasing vascular permeability either directly (HAE-MYOF, HAE-DAB2IP) or indirectly (HAE-ANGPT).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-12"></a>

###### Company statement: bradykinin B2 receptor activation in angioedema

> “Bradykinin is the principal mediator of the signs and symptoms that represent AE-BK attacks, acting as a potent and selective agonist of the bradykinin B2 receptor.”
> “Excessive bradykinin generation, as in HAE, promotes vascular permeability by activating the bradykinin B2 receptor in vascular endothelium cells, leading to plasma extravasation and subcutaneous or submucosal tissue swelling typical of an angioedema attack.”
> “Bradykinin B2 receptor inhibition is a clinically validated mechanism for the treatment of HAE, as demonstrated by icatibant, which is a peptide bradykinin B2 receptor antagonist approved in Europe in 2008 and in the United States in 2011 (as FIRAZYR).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic testing

> “Measurements of serum/plasma levels of C1–INH function, C1–INH protein, and C4 are used to diagnose HAE-1/2”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.5-2"></a>

###### Systematic literature review of HAE disease burden: diagnostic delay

> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.5-3"></a>

###### Guideline recommendation: initial C1-INH functional assay

> “We recommend that all patients for whom HAE is suspected undergo an initial assessment with a C1-INH functional assay, as long as it is performed by a specialized laboratory using an accurate, validated method.”
> “If the C1-INH functional assay is unavailable or unreliable, the diagnosis can still be confirmed through quantitative C1-INH measurement and/or genetic testing for SERPING1.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-4"></a>

###### Laboratory findings: C4, C1-INH antigen, and C1-INH function

> “C4 levels are low in 90%–95% of patients with HAE-C1-INH during asymptomatic periods and are almost always low during acute attacks.”
> “In HAE type 1, C1-INH antigen levels are reduced, whereas in HAE type 2, they are normal or elevated.”
> “In HAE-C1-INH, functional activity is typically less than 50% of normal levels.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-5"></a>

###### Guideline recommendations: genetic testing and cascade family testing

> “We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.”
> “We recommend cascade family testing for HAE when an index case is diagnosed, either through C1-INH testing or genetic testing, as appropriate based on age and diagnosis (HAE-C1-INH vs. HAE-nC1-INH).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-6"></a>

###### Diagnostic delay over time

> “Fortunately, diagnostic delay in HAE has declined considerably in the last decades, from an average of 21 years in the 1970s to around 7–10 years currently”
> “Under 40% of patients receive a diagnosis within 1 to 3 years after symptom onset.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-7"></a>

###### Diagnostic delay: US patient registry

> “Delay to diagnosis was shorter in HAE-C1INH (5 vs 11 years), but both had decreasing delays over time.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.5-8"></a>

###### Age at diagnosis and diagnoses preceding HAE: Finnish national register

> “Mean age at the time of diagnosis was 39 years, with 22.5% diagnosed at ≤18 years, and 13.6% before or at the age of 12.”
> “Of note, 37% had a diagnosis of angioedema before the first HAE diagnosis, 17% a diagnosis of oedema, whereas 6% had been diagnosed with urticaria, suggesting misdiagnosed HAE or unrelated urticaria.”

Source: [Sandberg et al. (2024)](https://medicaljournalssweden.se/actadv/article/download/24176/46018/110086)

<a id="topic-2.2.1.5-9"></a>

###### Laboratory findings in HAE with normal C1-INH and acquired C1-INH deficiency

> “Results for all 3 of these tests are normal in HAE-nC1-INH and in ACE inhibitor–induced angioedema and decreased in acquired C1-INH deficiency (ie, acquired angioedema [AAE-C1-INH]).”
> “C4, C1-INH antigenic levels, and functional activity are within normal ranges in HAE-nC1-INH and typically reduced in AAE-C1-INH.”
> “Of note, negative genetic test results should not be considered definitive for excluding HAE-C1-INH or HAE-nC1-INH.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-10"></a>

###### Clinical features suggesting HAE

> “Attacks not accompanied by urticaria, except in cases of HAE-CPN1”
> “No response to treatment of attacks with epinephrine, H1-antihistamines, or glucocorticoids”
> “Positive family history, especially if suggestive of autosomal dominant inheritance”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.5-11"></a>

###### Company statement: time from symptom onset to diagnosis

> “Symptoms typically first present in young children and may take 5-10 years (until early adolescence or young adulthood) to be diagnosed.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cutaneous swelling: hands, feet, and face

> “HAE is a very rare and potentially life-threatening genetic condition involving swelling of various parts of the body, hands, feet, or face.”

Source: [US Hereditary Angioedema Association](https://www.haea.org/)

<a id="topic-2.2.1.6-2"></a>

###### Gastrointestinal symptoms: intestinal attacks

> “severe abdominal pain, nausea, and vomiting.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-3"></a>

###### Airway symptoms: obstruction risk

> “can restrict breathing and lead to life-threatening obstruction of the airway.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-4"></a>

###### Distribution of attacks by site: edema episodes reported by 221 patients

> “Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.”
> “The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.6-5"></a>

###### Abdominal and laryngeal involvement: proportion of patients affected

> “Abdominal involvement occurs in 70%–90% of all individuals and is associated with high morbidity.”
> “Laryngeal involvement, although accounting for less than 1% of all attacks, poses a risk of death and occurs at least once in about half of patients.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-6"></a>

###### Airway symptoms: phases of fatal laryngeal attacks

> “Phase 1, the predyspnea phase, lasted on average for 3.7 ± 3.2 hours (range, 0-11 hours).”
> “Phase 2, the dyspnea phase, lasted on average for 41 ± 49 minutes (range, 2 minutes to 4 hours).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.6-7"></a>

###### Prodromal symptoms and erythema marginatum

> “Non-specific prodromal symptoms are common and can include anxiety, nausea, paresthesia, and fatigue.”
> “One third of patients with HAE, especially children, experience erythema marginatum (a nonpruritic form of flat, figurate erythema) as an initial manifestation, which may mimic the skin lesions of urticaria.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-8"></a>

###### Abdominal symptoms: presentation resembling an acute surgical abdomen

> “Abdominal attacks can cause severe abdominal pain, nausea, and vomiting and may lead to unnecessary abdominal surgery, as the clinical presentation can resemble an acute surgical abdomen.”
> “In some cases, intestinal angioedema may be accompanied by ascites and, very rarely, by hypovolemic shock.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-9"></a>

###### Laryngeal symptoms: frequency, age at first episode, and time to maximum swelling in 123 patients

> “Information on 123 patients with hereditary angioedema was obtained from medical histories and reports by the general practitioners, emergency physicians, and hospitals involved.”
> “Sixty-one patients (49.6%) experienced a total of 596 laryngeal edema episodes.”
> “The ratio of laryngeal edema episodes to skin swellings and abdominal pain attacks was approximately 1:70:54 in patients who had laryngeal edema.”
> “The mean (SD) age at the first laryngeal edema was 26.2 (15.3) years.”
> “The mean interval between onset and maximum development of laryngeal edema was 8.3 hours.”
> “In adults, the interval between onset of symptoms and acute risk of asphyxiation is usually long enough to allow for use of appropriate emergency procedures.”

Source: [Bork et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12767961/)

<a id="topic-2.2.1.6-10"></a>

###### Laryngeal symptoms: facial edema as a risk factor

> “Facial edema is considered a potential risk factor for laryngeal involvement.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-11"></a>

###### Laryngeal attacks during long-term prophylaxis: systematic review

> “Attacks at all anatomic locations, including laryngeal attacks, continued to occur in patients who received LTP, regardless of the LTP agent”
> “Of note, both interventional and observational studies reported that laryngeal attacks accounted for between 2%-7% of all attacks in patients who received LTP with pdC1INH, lanadelumab, danazol, or TA”

Source: [Longhurst et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11638394/)

<a id="topic-2.2.1.6-12"></a>

###### Prodromal symptoms: frequency, specificity, and sensitivity for predicting an attack

> “Prodromal symptoms, traditionally reported in up to 65%–70% of attacks, present an opportunity for early intervention but may lead to overuse of ODT.”
> “Recent studies indicate that although the specificity of prodromal symptoms for an attack exceeds 95%, their sensitivity for accurately predicting an attack varies from 18% to 64%, depending on the attack site.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-13"></a>

###### Prodromal symptoms: prospective study of 48 patients

> “In the present study, a cohort of 48 HAE patients prospectively reported four events of prodromes followed by attack, attacks not preceded by a prodrome and incidents with only a prodrome.”
> “We received reports on 119 prodromes and 192 attacks.”
> “The majority experienced a prodrome before at least one of their attacks, and 64% affirmed that they can predict an oncoming attack by having a prodrome.”
> “Mean duration of prodromes was significantly shorter than attacks, and prodromes overlapped the attack in 24.3% of cases.”
> “Sensitivity of the prodrome as a predictor of attack was 95% to 99%, and specificity 18% to 64%.”

Source: [Leibovich-Nassi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10092815/)

<a id="topic-2.2.1.6-14"></a>

###### Pain and swelling during attacks: European patient survey of 186 patients

> “The HAE Burden of Illness Study in Europe was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE from the patient perspective via a one-time survey, which included items on clinical characteristics and physical and emotional impacts.”
> “One hundred eighty-six patients participated; 59% reported having an attack at least once a month, 67% reported moderate-to-severe pain during their last attack, and 74% reported moderate-to-severe swelling.”
> “The most common sites of the last attack were the abdomen and extremities; 24% experienced an attack in more than one site.”

Source: [Caballero et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24268449/)

<a id="topic-2.2.1.6-15"></a>

###### Psychological symptoms during attacks: anxiety in the KONFIDENT trial

> “Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.”
> “Overall, 115 (44%) attacks were rated as inducing moderate‐to‐extreme anxiety.”
> “Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.”

Source: [Craig et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327167/)

<a id="topic-2.2.1.6-16"></a>

###### Attack site, severity, and duration with and without on-demand treatment: Milan cohort of 227 patients

> “From January 2009 to August 2014, data on attacks and treatments were collected from 227 patients from our centre in Milan.”
> “A total of 4244 attacks were reported; 50% were treated with approved therapies (pdC1-INH or icatibant), 15% were with tranexamic acid, and 35% were not treated.”
> “Attack locations were peripheral cutaneous (46%), abdominal (34%), multiple (12%), facial (5%) and laryngeal (3%).”
> “Attack severities were moderate (48%), mild (28%) and severe (24%).”
> “Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).”

Source: [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/)

<a id="topic-2.2.1.6-17"></a>

###### Attack site and duration with and without on-demand treatment: Milan angioedema centre, 2014

> “This is a prospective observational study conducted at Milan angioedema centre between 1 January and 31 December 2014.”
> “Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.”
> “Attacks were more often peripheral (47.6%), followed by abdominal attacks (39.4%), facial attacks (6.2%) and laryngeal attacks (4.8%).”
> “Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)”
> “In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates (HR 0.98, 95% CI 0.97 to 0.99), suggesting that each additional hour between onset of symptoms and treatment administration would increase the chance of a faster resolution by approximately 2%.”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

<a id="topic-2.2.1.6-18"></a>

###### Attack progression with delayed or no treatment: US patient survey

> “Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.”
> “Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).”
> “In the Untreated Cohort (n = 20), 50% of the respondents describing their last untreated attack as mild experienced progression to moderate or severe and 25% reported spread to another site including the larynx and face.”
> “Untreated attacks lasted a mean of 2.3 days.”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

<a id="topic-2.2.1.6-19"></a>

###### Attack severity mix at treatment in placebo-controlled trials of an oral on-demand treatment

> “Sebetralstat, an oral plasma kallikrein inhibitor, was evaluated in 2 randomized, placebo-controlled clinical trials, which instructed early treatment of attacks with no minimum severity requirement.”
> “377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.”
> “Baseline severity was rated as "Mild" (46.2%), "Moderate" (40.6%), or "Severe"/"Very Severe" (12.7%).”
> “At the time of attack onset, 156 attacks (41.4%) were mucosal; of these, 115 (30.5%) were abdominal-only attacks, and 8 (2.1%) were laryngeal attacks.”
> “For sebetralstat 300 mg, sebetralstat 600 mg, and placebo, earlier-treated attacks (43.5%, 55.6%, and 48.0%, respectively) were more likely to be mild compared with later-treated attacks (29.6%, 33.3%, and 31.3%, respectively)”

Source: [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)

<a id="topic-2.2.1.6-20"></a>

###### Presentation of HAE with normal C1-INH

> “The clinical manifestations of HAE-nC1-INH are similar to those of HAE-C1-INH, and the 2 are largely indistinguishable based on signs and symptoms alone.”
> “However, in certain HAE-nC1-INH subtypes, angioedema attacks tend to have a later onset and may be accompanied by local hematomas.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-21"></a>

###### Company statement: symptoms, attack sites, triggers, and prodromes

> “HAE is a rare and potentially life-threatening genetic condition with symptoms that include episodes of debilitating and often painful swelling in the hands, feet, face (lips and tongue), gastrointestinal tract, urogenital region, or airways.”
> “Attacks are unpredictable in frequency, location, timing, and severity, and can be caused by multiple types of triggers.”
> “Attacks can occur spontaneously although they often are associated with anxiety, stress, minor trauma, surgery, or illnesses.”
> “Commonly, patients are alerted to an impending attack by prodromal symptoms which include rash, fatigue, and muscle aches.”
> “The severity of attacks is unpredictable and not related to their underlying frequency.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Consequences of abdominal attacks

> “abdominal attacks may lead to unnecessary surgeries or opiate dependence.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.7-2"></a>

###### Cardiovascular, thromboembolic, and autoimmune comorbidity: Swedish population-based cohort

> “Increased risk of cardiovascular disease (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.32–2.54), including arterial (OR 6.74; 95% CI 1.89–24.06) and venous thromboembolic disease (OR 4.20; 95% CI 2.42–7.23) as well as hypertension (OR 1.64; 95% CI 1.12–2.39) was seen in HAE.”
> “Furthermore, the risk of autoimmune disease was increased (OR 1.65; 95% CI 1.15–2.35) being particularly pronounced for systemic lupus erythematosus (OR 71.87; 95% CI 8.80–586.7).”
> “In contrast, the risk of cancer was not increased.”
> “A two-fold higher prevalence of allergy, asthma, and atopic dermatitis was found (OR 2.19; 95% CI 1.60–2.99).”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-3"></a>

###### Comorbidity associated with attenuated androgen prophylaxis

> “Side effects of attenuated androgens can contribute to comorbidities in HAE since long-term use of danazol is associated with increases in atherogenic indices.”

Source: [Sundler Björkman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8967273/)

<a id="topic-2.2.1.7-4"></a>

###### Composite venous thromboembolism: reanalysis of the Swedish cohort

> “Our analysis revealed that individuals with HAE had a significantly increased risk of composite VTE compared to controls (odds ratio 3.57, 95% confidence interval 2.16-5.81, Figure 1A).”
> “In contrast, individuals with HAE did not have a significantly increased risk of composite ATE (odds ratio 1.3, 95% confidence interval 0.81-2.09, Figure 2B).”
> “C1INH is a potent inhibitor of plasma kallikrein, which spans the kallikrein kinin pathway and intrinsic coagulation pathway, and the intrinsic coagulation pathway components activated factor XII and activated factor XI”

Source: [Grover et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12541594/)

<a id="topic-2.2.1.7-5"></a>

###### Comorbidity compared with the general US population: US patient registry

> “Females with HAE-C1INH had a significant increase in the prevalence of depression, sleep disorders, kidney disease, anemia, and hepatitis.”
> “Cardiovascular comorbidities were significantly reduced in the HAE-C1INH group.”

Source: [Christiansen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37619776/)

<a id="topic-2.2.1.7-6"></a>

###### Consequences of delayed diagnosis

> “Delays in HAE diagnosis can lead to serious consequences, including reduced quality of life (QoL), loss of productivity and income, depression, unnecessary medical interventions, increased healthcare costs, and an imminent risk of death.”
> “Unnecessary abdominal surgeries, such as appendectomies, along with exploratory diagnostic procedures such as colonoscopy, also are frequent.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.7-7"></a>

###### Presumptive post-traumatic stress disorder: US HAE Association survey

> “Participants ≥ 18 with HAE-C1INH were recruited from the US HAE Association: Cohort 1, self-referred; Cohort 2, randomized from the HAEA membership.”
> “The prevalence of presumptive PTSD based on the PLC-C outcomes was between 20 and 25% in HAE-C1INH participants (n = 77).”
> “Diagnosis was correlated with high rates of depression and reduced SF-36 mental domain performance.”

Source: [Christiansen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488251/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Hereditary angioedema

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Burden of disease in adults: multinational survey

> “In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.”

Source: [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-2"></a>

###### Multinational adult survey: treatment exposure and quality-of-life outcomes

| Measure | Reported result |
| --- | --- |
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |

Source: [Watt et al. (2026b)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-3"></a>

###### Health-related quality of life, depression, and work productivity: US patient survey

> “A total of 457 HAE patients responded to the survey (response rate, ∼19%).”
> “Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).”
> “HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.”
> “Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.”
> “Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.”

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)

<a id="topic-2.2.1.8.1-4"></a>

###### Anxiety and depression: health technology assessment background

> “Studies have shown that almost three-quarters of HAE patients noted that the disease had a significant impact on their quality of life, including anxiety (15% of patients) and depression (almost 40% of patients) related to their ability to carry out daily activities, fear of attacks, and concerns about transmission of the condition to their children.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.1-5"></a>

###### Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey

> “The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.”
> “In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.1-6"></a>

###### Burden despite current therapies: US adult survey

> “A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.”
> “Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.”
> “Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.”
> “Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).”
> “The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.”

Source: [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)

<a id="topic-2.2.1.8.1-7"></a>

###### Preferences for long-term prophylaxis and willingness to switch: US adult survey

> “A total of 150 individuals completed the survey.”
> “Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.”
> “Route of administration and convenience were more than twice as important as dosing frequency.”
> “Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).”
> “Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.”

Source: [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)

<a id="topic-2.2.1.8.1-8"></a>

###### Health-related quality of life during the last treated attack by time to on-demand treatment: US patient survey

> “Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.”
> “A total of 94 respondents were included in the Treated Cohort, and 20 were included in the Untreated Cohort.”
> “In the Treated Cohort, the mean (SD) EQ-5D-5L index score was 0.849 (0.2) “Today” and 0.568 (0.3) “During the last treated attack” (Fig. 1A), with the latter score indicative of substantial impairment in HRQoL.”
> “The mean (SD) index score was 0.667 (0.3) in patients who treated <1 h of attack onset and 0.504 (0.3) in those who treated 5 to < 8 h of attack onset (Fig. 1B).”
> “In terms of administration route, reductions in HRQoL and work productivity and increases in activity impairment were generally more pronounced among IV OD users than among SC OD users (mean EQ-5D-5L index score “During the last treated attack”: 0.480 vs 0.615).”
> “Consistent with this, IV OD users took longer to administer treatment following attack onset than SC OD users (mean: 5.8 vs 2.8 h).”
> “Funding for Outcomes Insights was provided by KalVista Pharmaceuticals (Cambridge, MA, USA).”

Source: [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)

<a id="topic-2.2.1.8.1-9"></a>

###### Work productivity and activity impairment after a treated attack: US patient survey

> “Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey.”
> “In the Treated Cohort, the mean value for attack-related activity impairment was 38% (Fig. 4).”
> “In the 7 days following attack onset, the average rates of absenteeism (work missed due to HAE), presenteeism (impairment while working due to HAE), and overall work impairment were 15%, 35%, and 39%, respectively.”
> “For respondents with “Mild,” “Moderate,” and “Severe” attacks, the mean level of absenteeism was 5%, 16%, and 35%; the mean level of presenteeism was 29%, 32%, and 68%; and mean overall work impairment was 32%, 36%, and 75%, respectively.”

Source: [O'Connor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12320545/)

<a id="topic-2.2.1.8.1-10"></a>

###### Treatment-related anxiety and delay of on-demand treatment: US patient survey

> “Patients with HAE (type I or II) aged 12 years or older with more than or equal to 1 treated (Treated Cohort) or untreated (Untreated Cohort) attack in the past 3 months were recruited by the US HAE Association.”
> “In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.”
> “Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.”
> “Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).”
> “Untreated attacks lasted a mean of 2.3 days.”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

<a id="topic-2.2.1.8.1-11"></a>

###### Attack-related anxiety in a randomized on-demand treatment trial: KONFIDENT

> “Participants in the randomised, double‐blind, phase 3 KONFIDENT trial (NCT05259917) treated attacks with sebetralstat 300 mg, 600 mg or placebo as early as possible after onset.”
> “The full analysis set included 264 attacks.”
> “Overall, 115 (44%) of the attacks were rated as inducing moderate‐to‐extreme anxiety (i.e., GA‐NRS ≥ 4) at treatment administration (Table 1 and Table S1).”
> “Female sex, shorter time since HAE diagnosis and greater attack severity were associated with greater anxiety at treatment administration.”
> “This study was sponsored by KalVista Pharmaceuticals.”

Source: [Craig et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327167/)

<a id="topic-2.2.1.8.1-12"></a>

###### Burden of injectable on-demand treatment: US and UK patient and caregiver interviews

> “The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.”
> “Participants reported a dislike of needles, pain associated with injection of the medicine, and the need to go to a hospital or medical center as treatment-related reasons for delaying or opting not to treat an attack.”
> “The majority of participants (80%) reported not treating every attack; all participants described delaying treatment intentionally or unintentionally at least once.”
> “All participants expressed interest in an oral on-demand treatment for reasons including portability, pain-free administration, and ability to treat attacks earlier.”
> “The study was supported by KalVista Pharmaceuticals.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.1.8.1-13"></a>

###### Carrying, delaying, and not treating attacks with on-demand treatment: US patient survey

> “People living with HAE were recruited by the US Hereditary Angioedema Association (HAEA) to complete a 20-minute online survey between September 6, and October 19, 2022.”
> “Respondents included 107 people with HAE, 80% female, 98% adults (≥ 18 years).”
> “Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home.”
> “The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).”
> “Overall, 86% of respondents reported delaying on-demand treatment, despite recognizing the initial onset of an HAE attack and despite 97% of patients agreeing that it is important to recover quickly from an HAE attack.”
> “On average, one of every five (20%) HAE attacks are untreated (24% amongst on-demand only patients; 15% amongst prophylaxis patients).”
> “This work was sponsored by KalVista Pharmaceuticals.”

Source: [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/)

<a id="topic-2.2.1.8.1-14"></a>

###### Administration-site adverse drug reactions with parenteral on-demand treatments: FDA Adverse Event Reporting System

> “We searched the FAERS database from October 1, 2009, to March 31, 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH).”
> “The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).”
> “Conclusion: Real-world data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks.”
> “It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.”

Source: [Tachdjian et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993116/)

<a id="topic-2.2.1.8.1-15"></a>

###### Utility weights during and between attacks: European patient survey mapped to EQ-5D

> “Survey items that overlapped conceptually with the EuroQol 5-Dimensions (EQ-5D) domains (pain/discomfort, mobility, self-care, usual activities, and anxiety/depression) were manually crosswalked to the corresponding UK population-based EQ-5D utility weights.”
> “Overall, a total of 111 HAE-BOIS-Europe participants completed all selected survey items and thus allowed for computation of EQ-5D-based utilities.”
> “The mean utilities for an HAE attack and between attacks were 0.44 and 0.72, respectively.”
> “Utilities for an acute attack were dependent on the severity of pain of the last attack (0.61 for no pain or mild pain, 0.47 for moderate pain, and 0.08 for severe pain).”

Source: [Aygören-Pürsün et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5019462/)

<a id="topic-2.2.1.8.1-16"></a>

###### Time trade-off utilities by attack location: general public valuation in England

> “Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.”
> “TTO analysis was based on vignette valuation completed by 100 members of the general public.”
> “The TTO values were as follows: attack-free, 0.783 (standard deviation [SD] 0.316); hand: 0.582 (SD 0.380); facial: 0.483 (SD 0.448); abdominal: 0.345 (SD 0.458); and laryngeal: 0.128 (SD 0.529).”
> “This study was funded by BioCryst Pharmaceuticals, Inc.”

Source: [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="topic-2.2.1.8.1-17"></a>

###### Utility weights with and without attack symptoms drawn from the literature for an economic model

> “Utility values were drawn from the literature”
> “citing a utility of 0.51 when experiencing attack symptoms and 0.83 without symptoms.”
> “Nonattack baseline utility and attack utility were implemented for effectiveness calculations; time to attack resolution was considered as well.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-2.2.1.8.1-18"></a>

###### EQ-5D-5L utility and its decrement during an attack: Dutch patient survey

> “Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.”
> “The response rate was 78% (69 of 88).”
> “The mean quality of life in the entire sample was 30.99 as expressed by the AE-QoL and 0.873 as expressed by the EQ-5D-5L utility value.”
> “Utilities dropped by 0.320 points during an angioedema attack.”

Source: [Fijen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36990433/)

<a id="topic-2.2.1.8.1-19"></a>

###### Patient-defined attack severity and EQ-5D-5L by attack location: US qualitative study for economic evaluation

> “Semi-structured qualitative interviews were conducted with US adults with HAE, purposively sampled with quotas for attack severity and attack locations.”
> “A total of 25 adults with HAE took part in the interviews.”
> “The results indicate that HRQoL is only slightly impaired by a mild attack compared to in-between attacks, however a severe attack has a considerable impact on HRQoL.”
> “The lowest utility value in the TTO study was 0.128 for a laryngeal attack, which is higher than the lowest values reported in this study (0.03, throat attack and 0.06 abdominal attack).”
> “This study was funded by Ionis Pharmaceuticals.”

Source: [Gallop et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2740956)

<a id="topic-2.2.1.8.1-20"></a>

###### Physician-reported attainment of treatment goals: international physician survey

> “Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE.”
> “Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey.”
> “Burden of disease remains a challenge among patients, as reported by their physicians.”
> “This study was funded by CSL Behring.”

Source: [Buttgereit et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12306030/)

<a id="topic-2.2.1.8.1-21"></a>

###### Attacks, on-demand treatment, anxiety, and depression: multinational patient survey

> “We conducted a noninterventional, cross-sectional, web-based survey of patients with a self-reported diagnosis of HAE type 1/2 in Australia, Austria, Canada, France, Germany, Spain, Switzerland, and the United Kingdom to gain a comprehensive real-world understanding of the characteristics of HAE and its burden from the perspective of the patient.”
> “A total of 242 patients (67.4% female; mean [range] age 43.8 [18–92] years) completed the survey.”
> “Patients reported a mean (SD) of 12.5 (14.1) attacks in the past 6 months.”
> “The most recent attack occurred within the past month in 79.7% of patients; most were of moderate severity, 6.6% affected the larynx, 21.9% lasted ≥ 3 days, and 76.4% were treated with on-demand medication.”
> “Moderate to severe anxiety and depression were reported in 38.0% and 17.4% of patients, respectively, as measured using the HADS.”

Source: [Mendivil et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7893968/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims

> “A total of 328 patients were included in this analysis.”
> “Most patients (67%) had ≥1 post-index on-demand therapy claim.”
> “During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.”
> “Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).”
> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.1.8.2-3"></a>

###### Healthcare costs with lanadelumab compared with berotralstat: US claims

> “Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.”
> “Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.”
> “On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).”
> “all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.”

Source: [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)

<a id="topic-2.2.1.8.2-4"></a>

###### Treatment costs over time with lanadelumab: US claims

> “Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.”
> “Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).”

Source: [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)

<a id="topic-2.2.1.8.2-5"></a>

###### Direct and indirect costs of on-demand treatment alone: US patient survey

> “Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.”
> “Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.”
> “The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.2-6"></a>

###### Annual per-patient costs by attack severity before current prophylactic agents: US patient survey

> “Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.”
> “Hospital costs account for 67% of direct medical costs.”
> “Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.”

Source: [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)

<a id="topic-2.2.1.8.2-7"></a>

###### Resource use after insurance delays or denials of prophylaxis

> “A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.”
> “Twenty-five percent of respondents reported more urgent care or emergency department visits.”

Source: [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)

<a id="topic-2.2.1.8.2-8"></a>

###### On-demand drug costs per member before and after starting long-term prophylaxis: US commercial claims

> “This was a retrospective analysis of medical and pharmacy claims from a commercial database of 17 million lives across the United States.”
> “Among 61 members initiated on LTP for HAE, 52.5% (n=32) started LTP without prior ODT while 47.5% (n=29) previously received ODT.”
> “Overall, ODT spend in this subgroup declined by $1.37M, averaging a $47,358 reduction per member.”
> “After starting LTP, the average ODT utilization per member decreased from 13.6 to 9.7, a 29% reduction.”
> “Despite a more than 5-fold increase in medication costs with the initiation of LTP, over one-third of members continued to require ODT without reduction.”

Source: [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web)

| Population | Allowed cost per member, pre-LTP | Allowed cost per member, post-LTP | Change in allowed cost per member | Percent change |
| --- | --- | --- | --- | --- |
| On-demand therapy experienced cohort (N = 29) | “$108,748” | “$61,390” | “-$47,358” | “-43.6%” |

Source: [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web)

<a id="topic-2.2.1.8.2-9"></a>

###### Cost per attack treated on demand: Italian prospective cohort

> “To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.”
> “Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.”
> “Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.”
> “Only 78.9% of attacks were treated in contrast to current guidelines.”
> “The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).”
> “Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

<a id="topic-2.2.1.8.2-10"></a>

###### Modeled cost per attack of on-demand treatments: US commercial payer decision model

> “To estimate the cost-effectiveness of on-demand treatment for HAE attacks, a decision-tree model from the U.S. commercial payer perspective was developed using TreeAge Pro 2018 R1 release”
> “All costs are dated to 2019, either directly or by inflation using the medical-care inflation subset of the Consumer Price Index for All Urban Consumers.”
> “The base case model outputs show costs and calculated effectiveness per attack at $12,905 and 0.806 for rhC1-INH, $14,806 and 0.765 for icatibant, $14,668 and 0.769 for pdC1-INH, and $21,068 and 0.792 for ecallantide, respectively.”

Source: [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/)

<a id="topic-2.2.1.8.2-11"></a>

###### Emergency department and hospital use among users of intravenous C1 inhibitor: US claims

> “The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).”
> “This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.”
> “Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.”
> “There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.”
> “Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).”
> “This study was funded by CSL Behring.”

Source: [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)

<a id="topic-2.2.1.8.2-12"></a>

###### Emergency department visits with hereditary angioedema: Nationwide Emergency Department Sample, 2006 to 2007

> “We evaluated epidemiology, resource use, and discharge destinations of HAE (International Classification of Diseases, Version 9, clinical modification [ICD-9-CM] code 277.6) ED visits within the Nationwide Emergency Department Sample, part of Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, in 2006 and 2007.”
> “In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).”
> “Two thousand fifty-nine (40.9%) resulted in a hospitalization.”
> “Mean HAE ED visits costs were $1479 (95% confidence interval, $1028-1929).”

Source: [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)

<a id="topic-2.2.1.8.2-13"></a>

###### Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007

> “We examined hospitalizations and ED utilization for HAE and AE in two large nationally representative databases.”
> “We also used AHRQ-HCUP's 2007 Nationwide Emergency Department Sample (NEDS) to study annual rates of ED visits and subsequent hospitalizations with these conditions.”
> “There were 1691 hospitalizations with HAE and 22,572 with AE (4.25 HAE and 57.08 AE cases/100,000 hospitalizations).”
> “In aggregate, HAE and AE PD hospitalizations accrued 35,000 hospital days and hospital costs of $63 million.”
> “There were 2282 ED visits with HAE and 112,105 ED visits with AE (1.87 HAE and 91.64 AE cases/100,000 ED visits).”
> “Forty-five percent of HAE patients and 18.3% of AE patients required hospitalization.”

Source: [Zilberberg et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20964950/)

<a id="topic-2.2.1.8.2-14"></a>

###### Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims

> “To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.”
> “This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).”
> “The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).”
> “When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.”
> “Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients”
> “Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study”

Source: [Christiansen et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12123198/)

<a id="topic-2.2.1.8.2-15"></a>

###### Medical care, activity loss, and missed work or school: European patient survey

> “The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.”
> “Overall, 164 patients had an attack in the past 6 months and were included in the analysis.”
> “The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).”
> “Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.”
> “The last attack prevented patients from their normal activities an average of 4–12 hours.”
> “Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.”
> “The study was funded by ViroPharma SPRL-BVBA.”

Source: [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/)

<a id="topic-2.2.1.8.2-16"></a>

###### Societal costs: Dutch patient survey

> “Adult patients with HAE under treatment at the Dutch national center of reference completed a cross-sectional survey in 2021.”
> “The response rate was 78% (69 of 88).”
> “On average, total costs per year incurred €22,764, predominantly existing of HAE-medication costs.”
> “Total costs showed substantial variation between patients.”

Source: [Fijen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36990433/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Hereditary angioedema on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Income loss from work missed because of attacks

> “missed work because of acute attacks resulted in an income loss of $3402 annually”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="topic-2.2.1.8.3-2"></a>

###### Caregiver productivity costs: US patient and caregiver survey

> “For those respondents who indicated that they were either patients or caregivers or solely caregivers, the fact that they would no longer have to take time off work or could participate in the labor force, or be more productive while at work, accounted for $7630 (14.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver time off work

> “Caregivers, often parents of children with HAE, may also need to take time off work to care for an HAE patient.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver time, missed work, and children's missed school: multinational caregiver survey

> “Using web-based surveys (July 2022‒February 2023), this international study (Argentina, Brazil, Colombia, Croatia, Denmark, Germany, Hungary, Ireland, Norway, Poland, Portugal, Romania, and Sweden) assessed the humanistic and psychosocial burden of caregivers (≥ 18 years old) of pediatric (< 18 years) and adult (≥ 18 years) patients with diagnosed HAE.”
> “In total, 120 caregivers completed the surveys: 54 caregivers of pediatric patients (CoPs; mean age 40.6 years; 79.6% female) and 66 caregivers of adult patients (CoAs; mean age 42.7 years; 48.5% female).”
> “In the 4 weeks before completing the survey, caregivers of pediatric patients reported being absent from work for 2.6 ± 5.8 days (mean ± SD; median, 1.0 day), while the patients in their care missed 3.9 ± 6.2 days of school (mean ± SD; median, 2.0 days) over the same period.”
> “Caregivers reported providing care for 23.5 ± 11.8 (mean ± SD) days per month.”
> “Caregivers of pediatric patients reported that their caregiving responsibilities limited their ability to plan their own lives in different ways, notably, to work full time (33.3%), to advance in their professional careers (25.9%), to pursue their personal interests or hobbies (25.9%), their freedom to travel or go on holiday (24.1%), and to relocate to another city or country (9.3%).”
> “In the 4 weeks before the survey, caregivers (n = 33) reported missing 0.94 ± 1.39 (mean ± SD) days of work”
> “During the patient’s most recent HAE attack, help provided by the caregivers primarily included providing emotional support (72.7%), spending time with the patient (68.2%), help with administering HAE medication (51.5%), and help with household chores (48.5%).”
> “This study was sponsored by Takeda Development Center Americas, Inc.”

Source: [Watt et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12895942/)

<a id="topic-2.2.1.8.3-5"></a>

###### Caregiver absenteeism by attack frequency: European patient survey

> “The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.”
> “Patient and caregiver absenteeism increased with attack severity and frequency.”
> “Specifically, the average numbers of missed days for patients were 2.2, 6.0, and 11.6 among patients with attacks less than once a month, at least once a month but less than once a week, and at least once a week, respectively (p = 0.128), and they reported that their caregivers missed 3.3, 3.6, and 10.1 days, respectively (p = 0.088).”

Source: [Aygören-Pürsün et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4105891/)

<a id="topic-2.2.1.8.3-6"></a>

###### Caregiver assistance with injectable on-demand treatment: US and UK interviews

> “Interview participants included 25 individuals residing in either the UK (n = 8) or US (n = 17) (Table 1).”
> “Eight patients (57%) self-administered icatibant, while six (43%) required a parent or caregiver to administer, including two of the 10 adult patients (20%) and all adolescents (n = 2).”
> “The three adolescents using C1INH had their injectable on-demand treatment administered in a health care setting.”
> “Some patients and caregivers described disruptions to leisure activities (n = 15) and having to leave work or school (n = 11), and these negative impacts were reported more frequently for adolescents.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.1.8.3-7"></a>

###### Caregiver health state utility during an attack: general public time trade-off valuation in England

> “Members of the general public in England rated vignettes in TTO interviews, which included a visual analogue scale (VAS) component.”
> “Qualitative interviews were undertaken to inform vignette development for the TTO study, including vignettes for abdominal, facial, hand and laryngeal attack health states, and an attack-free and caregiver state.”
> “The caregiver rating was 0.762 (SD 0.303).”

Source: [Lo et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8864034/)

<a id="topic-2.2.1.8.3-8"></a>

###### Caregiver tasks and burden: US caregiver survey

> “In the United States, we conducted an online survey of adults caring for an individual with HAE to better understand their experiences with the disease and identify psychosocial impacts of providing care for a patient with HAE.”
> “Thirty caregivers provided responses to the survey.”
> “Most caregivers were family members of the care recipient and many had HAE themselves.”
> “Caregivers reported participating in a number of medical-related tasks and experiencing some burdens as a result of caring for a person with HAE.”

Source: [Craig et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33980328/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic testing: cost and limited routine necessity

> “genetic testing can be costly, time-consuming, and rarely necessary.”

Source: [Henao et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859422/)

<a id="topic-2.2.1.8.4-2"></a>

###### Medicare payment rates for complement antigen and functional assays

> “2026,86160,,20260101,N,00012.00,Complement antigen”
> “2026,86161,,20260101,N,00012.00,Complement/function activity”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-3"></a>

###### Functional C1 inhibitor assay as the single initial test and expected effect on diagnostic costs

> “This approach involves performing only the C1-INH functional assay whenever this test is available and reliable, rather than following the traditional recommendation of conducting all 3 tests (C1-INH levels, C1-INH functional assay, and C4 level), potentially reducing diagnostic costs (Fig. 5).”
> “The C1-INH antigenic assay is widely available, simple to perform, and generally accessible.”
> “Functional activity testing of C1-INH and genetic testing are both rarely available in low- and middle-income countries, and genetic testing is often expensive in high-income countries.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.8.4-4"></a>

###### Genetic testing for hereditary angioedema with normal C1 inhibitor and cascade family testing

> “We recommend genetic testing for HAE-nC1-INH in patients for whom there is high clinical suspicion of HAE and who have normal C1-INH functional assay results.”
> “Cascade screening refers to the process of sequentially testing close blood relatives, beginning with first-degree relatives and extending to siblings, parents, and children when a family member is found to be affected.”
> “This approach helps reduce costs, improves management of currently asymptomatic but affected individuals, and alleviates anxiety for unaffected family members.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.8.4-5"></a>

###### Cost of sequential biochemical and genetic testing and sample transport

> “Firstly, the use of a series of multiple tests from the initial C4 and C1-INH levels, followed by C1-INH function, and in equivocal cases or suspected HAE-nC1INH, genetic tests, is considerably costly.”
> “In regions lacking local laboratory capacity, samples must be shipped to external reference centres, incurring further costs and diagnostic delays [37].”
> “C1-INH protein is labile in vitro; unless testing is performed within hours, samples require on-site centrifugation and storage at − 20 °C, necessitating an expensive cold chain for transport [38, 39].”

Source: [Leung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630838/)

<a id="topic-2.2.1.8.4-6"></a>

###### Effect of cascade family screening on hereditary angioedema-related costs: prospective screening program

> “Prospective data on clinical, psychological, and HAE-related outcomes were collected at baseline and 1-year follow-up.”
> “Potential HAE relatives were screened through the CFS approach.”
> “Of 179 relatives, 53% were contactable, 67% of whom consented to screening.”
> “Twenty-nine patients (46%) were newly given the diagnosis of HAE; half were symptomatic at baseline (52%).”
> “By extrapolation, CFS led to a reduction of at least HK $1,200 (US $153) in HAE-related costs per patient per year.”
> “Screening using a greater than suggested C4 cutoff of 22.9 mg/dL yielded superior sensitivity (100%) and specificity (77%).”

Source: [Wong et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35964924/)

<a id="topic-2.2.1.8.4-7"></a>

###### Diagnostic delay and its association with direct and indirect costs

> “In total, 65 articles that met the search inclusion criteria reported 10,310 patients with HAE, of whom 5861 were female patients.”
> “The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years.”
> “The major components accounting for the increase in economic costs were hospitalization, treatments, unnecessary surgeries, doctors’ visits, specialist services, and nurse costs.”
> “However, there is considerable evidence indicating that delayed diagnosis of HAE is associated with decreased physical function, increased risk of mortality, negative psychological impact, and higher direct and indirect costs.”

Source: [Guan et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03265-z)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 C1 Esterase Inhibitor Concentrates

<a id="topic-2.2.2.1.1-1"></a>

###### Plasma-derived C1 inhibitor: indication, dose, and self-administration

> “BERINERT is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.”
> “The safety and efficacy of BERINERT for prophylactic therapy have not been established.”
> “Administer BERINERT at a dose of 20 International Units (IU) per kg body weight by intravenous injection. Doses lower than 20 IU/kg body weight should not be administered.”
> “Inject at a rate of approximately 4 mL per minute.”
> “For self-administration, provide the patient with instructions and training for intravenous injection outside of a clinic setting so patients may self-administer BERINERT upon recognition of symptoms of an HAE attack”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### Plasma-derived C1 inhibitor: laryngeal attacks, thromboembolism, and infectious risk

> “Given the potential for airway obstruction during acute laryngeal HAE attacks, patients self-administering BERINERT should be advised to immediately seek medical attention in an appropriate healthcare facility after treatment with BERINERT.”
> “Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including BERINERT, following administration in patients with HAE.”
> “Because BERINERT is made from human blood, it may carry a risk of transmitting infectious agents”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### Plasma-derived C1 inhibitor 20 IU/kg versus placebo: randomized clinical trial in the label

> “The RCT assessed the efficacy and safety of BERINERT in 124 adult and pediatric subjects with C1 esterase inhibitor deficiency who were experiencing an acute moderate to severe attack of abdominal or facial HAE.”
> “Subjects were randomized to receive a single 10 IU/kg body weight dose of BERINERT (39 subjects), a single 20 IU/kg dose of BERINERT (43 subjects), or a single dose of placebo (42 subjects)”
> “in time to onset of relief from symptoms of an HAE attack as compared to placebo (median of 48 minutes for BERINERT 20 IU/kg body weight, as compared to a median of >4 hours for placebo).”
> “No subjects treated with BERINERT at 20 IU/kg body weight reported worsening of symptoms at 4 hours after administration of study medication compared to baseline.”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### Plasma-derived C1 inhibitor 10 or 20 U/kg versus placebo: published randomized trial in 125 participants

> “This was a randomized, double-blind, placebo-controlled study in 125 patients with type I or II hereditary angioedema.”
> “Median time to onset of relief was significantly shorter with C1 esterase inhibitor concentrate at a dose of 20 U/kg than with placebo (0.5 vs 1.5 hours; P = .0025), whereas with 10 U/kg, the time to onset of relief was only slightly shorter than with placebo (1.2 vs 1.5 hours; P = .2731).”
> “Compared with placebo, the reduction in time to onset of relief was greatest for severe attacks (0.5 vs 13.5 hours).”

Source: [Craig et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19767078/)

<a id="topic-2.2.2.1.1-5"></a>

###### Plasma-derived C1 inhibitor for laryngeal attacks: open-label extension in the label

> “BERINERT was evaluated in a prospective, open-label, uncontrolled, multicenter extension study conducted at 15 centers in the US and Canada”
> “During the extension study, 51 subjects experienced 747 abdominal attacks, 21 subjects experienced 51 facial HAE attacks, 30 subjects experienced 235 peripheral HAE attacks, and 16 subjects experienced 48 laryngeal HAE attacks.”
> “An analysis of laryngeal HAE attacks showed that the median time to initial onset of symptom relief and median time to complete resolution in the per-attack analysis were 0.25 hours and 8.4 hours, respectively”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.2.2.1.1-6"></a>

###### Recombinant human C1 inhibitor: indication, dose, redosing limit, and contraindication

> “RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).”
> “Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.”
> “The recommended dose of RUCONEST is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.”
> “If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level. Do not exceed 4200 U per dose. No more than two doses should be administered within a 24-hour period.”
> “RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products.”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Recombinant human C1 inhibitor 50 U/kg versus placebo: Study 1 in the label

> “Seventy-five (75) adults and adolescent patients were randomized (3:2) to receive RUCONEST 50 U/kg (N = 44) or placebo (N = 31).”
> “In the RCT phase, the median time to beginning of relief of symptoms was statistically significantly shorter in patients treated with RUCONEST 50 U/kg compared with patients treated with placebo as assessed by the TEQ”
> “Among patients who achieved relief within 4 hours, there were 4 (27%) patients in the placebo group who had a relapse of their symptoms within 24 hours as compared with 1 (3%) in the RUCONEST group.”
> “Life-threatening laryngeal attacks were excluded from the randomized-controlled phase of Study 1”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

> “Seventy-five patients experiencing peripheral, abdominal, facial, and/or oropharyngeal laryngeal attacks were randomized (3:2) to rhC1INH (n = 44) or placebo (saline; n = 31).”
> “Median (95% confidence interval) time to beginning of symptom relief at the primary attack location was 90 minutes (61-150) in rhC1INH-treated patients vs 152 minutes (93, not estimable) in placebo-treated patients (P = .031) based on the TEQ”
> “Overall, rhC1INH was safe and well tolerated; no thromboembolic events, anaphylaxis, or neutralizing antibodies were observed.”

Source: [Riedl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24468257/)

<a id="topic-2.2.2.1.1-8"></a>

###### Recombinant human C1 inhibitor 50 or 100 U/kg versus saline: pooled analysis of two randomized trials

> “Two similar independent, randomized, saline controlled, double-blind studies were conducted to evaluate the efficacy and safety of recombinant human C1-inhibitor (rhC1INH) as a treatment of acute angioedema attacks in patients with HAE.”
> “rhC1INH at 100 (n = 29) and 50 (n = 12) U/kg body weight resulted in a significant reduction for both the primary endpoint time to the beginning of relief of symptoms compared with saline (n = 29): median, 66 (95% CI, 61-122) minutes, 122 (72-136) minutes, and 495 (245-520) minutes, P < .001 and P = .013, respectively”
> “Therapeutic failure occurred in 59% (17/29) of the saline group compared with 0% (0/12) of the 50 U/kg group and 10% (3/29) of the 100 U/kg group.”

Source: [Zuraw et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20920772/)

<a id="topic-2.2.2.1.1-9"></a>

###### Intravenous C1 inhibitor as a first-line on-demand treatment: guideline recommendations

> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide”
> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”
> “It is commercially available in 2 plasma-derived concentrates and 1 recombinant human product for intravenous administration.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that attacks are treated with either intravenous C1 inhibitor, ecallantide, or icatibant.”
> “For on-demand treatment, only the intravenous application of C1–INH is effective.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Effective therapies include ecallantide, icatibant, intravenous C1INH (plasma-derived or recombinant), and sebetralstat.”
> “It is administered intravenously either by healthcare professionals or by patients or caregivers who have been trained in its administration”
> “pdC1INH continues to play an important role in the treatment of attacks in patients with HAE due to C1INH deficiency”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.1-10"></a>

###### Dose rounding, half-life, and rabbit allergy: guideline statements

> “When pdC-1INH is used, it should be administered at a dose of 20 IU/kg, rounded to the nearest 500 IU (as vials contain 500 IU) to minimize product waste.”
> “rC1-INH is produced through genetic engineering, and because it is secreted in the milk of transgenic rabbits, it is contraindicated in patients with a known allergy to rabbits.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “The mean plasma half-life of pdC1-INH is longer than 30 h.”
> “It appears that differential glycosylation of Ruconest relative to the human protein decreases the plasma half-life to approximately 3 h.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.1-11"></a>

###### Plasma-derived C1 inhibitor in pregnancy and in children: guideline recommendations

> “Plasma-derived C1-INH is considered safe and effective for on-demand treatment of HAE attacks during pregnancy, whereas all other drugs are off-label alternatives.”
> “For pregnant patients with HAE, we recommend first-line ODT with IV pdC1-INH.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “In neonates and infants with hereditary angioedema due to C1 inhibitor deficiency between birth and 2 years, we recommend the use of intravenous plasma‐derived C1 inhibitor concentrate as first‐line therapy for acute treatment of angioedema attacks.”
> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Bradykinin B2 Receptor Antagonists

<a id="topic-2.2.2.1.2-1"></a>

###### Icatibant: receptor antagonism

> “a specific and selective competitive antagonist of the bradykinin B2 receptor”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.2-2"></a>

###### Icatibant: FDA-approved indication

> “FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.”
> “Safety and effectiveness in pediatric patients below the age of 18 years have not been established.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

###### Icatibant: dosing and maximum number of doses

> “The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur.”
> “No more than 3 doses may be administered in any 24 hour period.”
> “FIRAZYR injection is supplied in a prefilled syringe delivering 30 mg icatibant.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

###### Icatibant: self-administration

> “Patients may self-administer FIRAZYR upon recognition of symptoms of an HAE attack after training under the guidance of a healthcare professional”
> “Self-administration of FIRAZYR by 56 patients was assessed in an open label trial.”
> “Patients who administered FIRAZYR during an acute attack of HAE had a median time to 50% reduction from the pretreatment composite 3-itemVAS score of 2.6 hours.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

###### Icatibant: injection-site reactions

> “The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials.”
> “Injection site reactions are reported in most patients after administration of FIRAZYR.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

> “It generally has an adequate safety and tolerability profile, although mild injection site reactions may occur in up to 97% of cases.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-6"></a>

###### Icatibant: laryngeal attacks and interaction with ACE inhibitors

> “Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with FIRAZYR.”
> “FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-7"></a>

###### FAST-3: results as described in the FDA label

> “Trial 1 was a randomized, placebo-controlled, double-blind, parallel-group study of 98 adult patients with a median age of 36 years.”
> “The median time to 50% reduction in symptoms for patients with cutaneous or abdominal attacks treated with FIRAZYR (n=43) compared to placebo (n=45) was 2.0 hours [95% CI 1.5, 3.0] versus 19.8 hours [95% CI 6.1, 26.3], respectively (p<0.001).”
> “In Trial 1, the median times to almost complete symptom relief were 8.0 versus 36.0 hours for FIRAZYR and placebo, respectively.”
> “In terms of rescue medication use, 3/43 (7%) patients treated with FIRAZYR used additional rescue medication in comparison to 18/45 (40%) patients treated with placebo.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### FAST-3: published primary and key secondary endpoints

> “Cutaneous or abdominal attacks: icatibant significantly reduced median times (vs placebo) to 50% or more reduction in symptom severity (2.0 vs 19.8 hours; P < .001, primary endpoint), onset of primary symptom relief (1.5 vs 18.5 hours; P < .001, key secondary endpoint), or almost complete symptom relief (8.0 vs 36.0 hours; P = .012) and provided a shorter time to initial symptom relief (0.8 vs 3.5 hours; P < .001).”
> “All icatibant-treated subjects experienced injection site reactions, but none reported clinically relevant changes in safety parameters or serious AEs.”

Source: [Lumry et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22123383/)

<a id="topic-2.2.2.1.2-9"></a>

###### FAST-1 and FAST-2: icatibant compared with placebo and with tranexamic acid

> “In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days.”
> “In FAST-1, the primary end point, the median time to clinically significant relief of the index symptom, was 2.5 hours in the icatibant group versus 4.6 hours in the placebo group (P = 0.14) (Table 2 and Fig. 1A).”
> “In FAST-2, the median time to clinically significant relief of the index symptom was 2.0 hours with icatibant versus 12.0 hours with tranexamic acid (P<0.001) (Table 2 and Fig. 1B).”
> “The median time to almost complete relief of symptoms was 8.5 hours with icatibant versus 19.4 hours with placebo (P = 0.08) in FAST-1 (Table 2 and Fig. 2A) and 10.0 hours with icatibant versus 51.0 hours with tranexamic acid (P<0.001) in FAST-2 (Table 2 and Fig. 2B).”

Source: [Cicardi et al. (2010a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4662377/)

<a id="topic-2.2.2.1.2-10"></a>

###### Icatibant: treatment of recurrent attacks in open-label extensions

> “A total of 225 patients were treated with 1,076 doses of 30 mg FIRAZYR for 987 attacks of acute HAE in these trials.”
> “The majority (93%) of these attacks of HAE were treated with a single dose of FIRAZYR.”
> “A total of 60 patients with laryngeal attacks were treated with FIRAZYR in the controlled trials.”
> “Efficacy results were similar to those observed for non-laryngeal (cutaneous and abdominal) sites of attack.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.2.2.1.2-11"></a>

###### Generic icatibant: SAJAZIR indication and dosing

> “SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.”
> “The recommended dose of SAJAZIR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “SAJAZIR is supplied in a prefilled syringe delivering 30 mg icatibant.”

Source: [Cycle SAJAZIR prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c)

<a id="topic-2.2.2.1.2-12"></a>

###### Generic icatibant: number of approved generic products

> “Seven generic forms of icatibant have been approved in the U.S.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “The recent approval of several generics for icatibant have decreased cost and hopefully will allow broader access.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-13"></a>

###### Icatibant: timing of treatment and attack duration in the Icatibant Outcome Survey

> “The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant.”
> “Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).”
> “Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.”
> “The proportion of attacks treated within 1 hour after attack onset was twice as high for self-administrators as for those who received HCP-administered icatibant (44% attacks versus 22% attacks, respectively; p = 0.001) (Figure 4).”

Source: [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)

<a id="topic-2.2.2.1.2-14"></a>

###### Icatibant: guideline recommendation and redosing compared with C1 esterase inhibitor

> “Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.”
> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.2-15"></a>

###### Deucrictibant: oral bradykinin B2 receptor antagonist in development

> “Deucrictibant is the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of hereditary angioedema attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Plasma Kallikrein Inhibitors for On-demand Treatment

<a id="topic-2.2.2.1.3-1"></a>

###### Sebetralstat: oral on-demand treatment

> “EKTERLY is a plasma kallikrein inhibitor that is used for the treatment of acute attacks of hereditary angioedema (HAE)”
> “an oral tablet.”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.3-2"></a>

###### Sebetralstat: FDA approval date

> “Approval date: July 03, 2025”

Source: [FDA Drug Trials Snapshot EKTERLY](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-ekterly)

<a id="topic-2.2.2.1.3-3"></a>

###### Sebetralstat: FDA-approved indication

> “EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Sebetralstat: dosing and maximum daily dose

> “The recommended dosage of EKTERLY is one dose of 600 mg (two tablets) orally at the earliest recognition of an acute HAE attack.”
> “A second dose of 600 mg (two tablets) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur.”
> “Maximum recommended dosage is 1,200 mg (four tablets) in any 24-hour period.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### Sebetralstat: dose modification for CYP3A4 inhibitors and inducers and hepatic impairment

> “Avoid use with strong CYP3A4 inhibitors.”
> “In patients taking moderate CYP3A4 inhibitors, take one dose of 300 mg.”
> “Avoid use with moderate or strong CYP3A4 inducers.”
> “Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C).”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### Sebetralstat: adverse reactions in KONFIDENT

> “The most common adverse reaction (incidence ≥2%) is headache.”
> “Adverse Reaction EKTERLY 600 mg (N = 93) Placebo (N = 83)a n (%) n (%) Headache 3 (3.2) 1 (1.2)”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### KONFIDENT: design and results as described in the FDA label

> “KONFIDENT employed a 3-way, complete crossover design comparing EKTERLY 600 mg and EKTERLY 300 mg to placebo.”
> “Severe laryngeal attacks were not treated in KONFIDENT.”
> “Although evaluated in KONFIDENT, EKTERLY 300 mg is not a recommended dose for treatment of acute HAE attacks.”
> “A total of 71 out of 93 (76%) patients administered EKTERLY 600 mg and 41 out of 84 (49%) patients administered placebo achieved”
> “The median time to beginning of symptom relief within 12 hours of first dose was 2.0 hours (95% CI: 1.5, 2.8) in patients administered EKTERLY 600 mg.”
> “A total of 46 out of 93 (49%) patients administered EKTERLY 600 mg and 23 out of 84 (27%) patients administered placebo achieved attack resolution within 24 hours.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

###### KONFIDENT: published primary and key secondary endpoints

> “A total of 136 participants were assigned to one of six trial sequences, with 110 treating 264 attacks.”
> “The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.”
> “The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.”
> “(Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; EudraCT number, 2021-001226-21.).”

Source: [Riedl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819658/)

<a id="topic-2.2.2.1.3-9"></a>

###### Sebetralstat: pooled analysis of the phase 2 and phase 3 trials

> “377 attacks were treated: 87 with sebetralstat 300 mg; 151 with sebetralstat 600 mg; 139 with placebo.”
> “Median (interquartile range) time to treatment was 32.5 min (8.0–94.0).”
> “Median time to beginning of symptom relief was 1.6 h (0.8–7.0) and 1.8 h (1.0–4.3) with sebetralstat 300 mg and 600 mg, respectively, and 8.3 h (1.5 to >12) with placebo.”

Source: [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)

<a id="topic-2.2.2.1.3-10"></a>

###### KONFIDENT-S: interim long-term safety and effectiveness

> “This analysis evaluated long-term safety and effectiveness of sebetralstat in KONFIDENT-S (NCT05505916), an ongoing, 2-year, open-label extension study.”
> “At data cutoff (January 31, 2024), 84 participants (mean age: 35.9 years; 14.3% <18 years; 64.3% female) treated 640 attacks with sebetralstat (84% of total attacks); the median (interquartile range [IQR]) number of attacks per participant was 5 (2-8).”
> “The median (IQR) time from attack onset to treatment was 9 (1-69) minutes.”
> “Treatment-related TEAEs occurred in 8 participants (9.5%); none were serious.”
> “The median time to beginning of symptom relief (allowing for missing data entries between consecutive time points) was 1.68 (0.79-3.89) hours, to reduction in severity 6.57 (1.61 to >12) hours, and to complete attack resolution 21.02 (7.22 to >24) hours.”

Source: [Farkas et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40886933/)

<a id="topic-2.2.2.1.3-11"></a>

###### KONFIDENT-S: breakthrough attacks in participants receiving long-term prophylaxis

> “The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).”
> “As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).”
> “Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.1.3-12"></a>

###### KONFIDENT-S: laryngeal and abdominal attacks

> “This prespecified interim analysis evaluated the safety and effectiveness of sebetralstat in laryngeal and abdominal attacks in the ongoing, 2‐year, open‐label extension KONFIDENT‐S study (NCT05505916).”
> “At data cutoff (Sep 14, 2024), 32 laryngeal (16 participants) and 533 abdominal only attacks (102 participants) were treated with sebetralstat.”
> “Median (IQR) time to treatment: 11.5 min (1.0–34.0) and 20.0 min (1.0–61.0) for laryngeal and abdominal attacks, respectively; time to beginning of symptom relief: 1.29 h (0.76–3.02) and 1.27 h (0.76–3.54); reduction in attack severity: 4.25 h (1.22 to > 12) and 3.52 h (1.26 to > 12); complete attack resolution: 12.69 h (5.11 to > 24) and 15.17 h (4.46 to > 24).”
> “Conventional on‐demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks.”

Source: [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12626162/)

<a id="topic-2.2.2.1.3-13"></a>

###### Sebetralstat: guideline statement

> “Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study.”
> “The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.3-14"></a>

###### Ecallantide: boxed warning for anaphylaxis

> “Anaphylaxis has been reported after administration of KALBITOR.”
> “Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.”
> “Healthcare professionals should be aware of the similarity of symptoms between hypersensitivity reactions and hereditary angioedema and patients should be monitored closely.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-15"></a>

###### Ecallantide: FDA-approved indication and dosing

> “KALBITOR® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.”
> “The recommended dose of KALBITOR is 30 mg (3 mL), administered subcutaneously in three 10 mg (1 mL) injections.”
> “If an attack persists, an additional dose of 30 mg may be administered within a 24 hour period.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-16"></a>

###### Ecallantide: incidence of anaphylaxis in clinical studies

> “In 255 HAE patients treated with intravenous or subcutaneous KALBITOR in clinical studies, 10 patients (4%) experienced anaphylaxis.”
> “For the subgroup of 187 patients treated with subcutaneous KALBITOR, 5 patients (3%) experienced anaphylaxis.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-17"></a>

###### EDEMA4 and EDEMA3: design and results as described in the FDA label

> “The safety and efficacy of KALBITOR to treat acute attacks of hereditary angioedema in adolescents and adults were evaluated in 2 randomized, double-blind, placebo-controlled trials (EDEMA4 and EDEMA3) in 168 patients with HAE.”
> “EDEMA4 was a randomized, double-blind, placebo-controlled trial in which 96 patients were randomized 1:1 to receive KALBITOR 30 mg subcutaneous or placebo for acute attacks of HAE.”
> “The primary endpoint was the change from baseline in MSCS score at 4 hours, and the TOS at 4 hours was a key secondary endpoint.”
> “More patients in the placebo group (24/48, 50%) required medical intervention to treat unresolved symptoms within 24 hours compared to the KALBITOR-treated group (16/48, 33%).”
> “In EDEMA3, the primary endpoint was the TOS at 4 hours, and the key secondary efficacy endpoint was the change from baseline in MSCS at 4 hours.”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.2.2.1.3-18"></a>

###### Ecallantide compared with placebo: treatment outcome score at 4 hours in the trial funded by Dyax

> “The median treatment outcome score at 4 hours was 50.0 in the ecallantide group and 0.0 in the placebo group (interquartile range [IQR], 0.0 to 100.0 in both groups; P=0.004).”
> “The estimated time to significant improvement was 165 minutes with ecallantide versus more than 240 minutes with placebo (P=0.14).”
> “(Funded by Dyax; ClinicalTrials.gov number, NCT00262080.)”

Source: [Cicardi et al. (2010b)](https://pubmed.ncbi.nlm.nih.gov/20818887/)

<a id="topic-2.2.2.1.3-19"></a>

###### Ecallantide compared with placebo: change in mean symptom complex severity score at 4 hours

> “Mean (SD) change from baseline in mean symptom complex severity score 4 hours after dosing was significantly greater with ecallantide use (-0.8 [0.6]) compared with placebo use (-0.4 [0.8]) (P = .01 comparing distributions).”
> “The benefit of ecallantide was apparent within 2 hours after dosing and was maintained through 24 hours after dosing.”

Source: [Levy et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20568386/)

<a id="topic-2.2.2.1.3-20"></a>

###### Ecallantide: guideline position as a second-line option

> “However, concerns about a 3%-4% risk of potentially serious hypersensitivity reactions, including anaphylaxis, led the manufacturer to withdraw its application in Europe.”
> “Despite this, it remains approved by the US Food and Drug Administration (FDA) for administration exclusively by healthcare providers in the United States.”
> “We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Long-term Prophylaxis

<a id="topic-2.2.2.1.4-1"></a>

###### First-line long-term prophylaxis options: guideline recommendations

> “We recommend SC pdC1-INH, lanadelumab, berotralstat, garadacimab, or donidalorsen as first-line options for LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Berotralstat, donidalorsen, garadacimab, lanadelumab, or pdC1INH could be used as first-line therapy for long-term prophylaxis in patients with HAE due to C1INH deficiency.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.4-2"></a>

###### Subcutaneous plasma-derived C1 inhibitor: indication and dosing

> “HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.”
> “Administer 60 International Units per kg body weight twice weekly (every 3 or 4 days).”

Source: [CSL Behring (2022)](https://labeling.cslbehring.com/PI/US/HAEGARDA/EN/HAEGARDA-Prescribing-Information.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Intravenous plasma-derived C1 inhibitor: indication and dosing

> “CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).”
> “1,000 IU Intravenous every 3 or 4 days”
> “Doses up to 2,000 IU (not exceeding 80 IU/kg) every 3 or 4 days may be considered based on individual patient response.”

Source: [FDA (2022)](https://www.fda.gov/media/75907/download)

<a id="topic-2.2.2.1.4-4"></a>

###### Lanadelumab: indication and dosing interval

> “TAKHZYRO is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and older.”
> “The recommended starting dosage in adult and pediatric patients 12 years of age and older is 300 mg administered subcutaneously every 2 weeks (q2wks).”
> “A dosing interval of 300 mg every 4 weeks (q4wks) is also effective and may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months.”

Source: [FDA TAKHZYRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761090s020lbl.pdf)

<a id="topic-2.2.2.1.4-5"></a>

###### Berotralstat: oral prophylaxis and dosing

> “ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.”
> “The recommended dosage of ORLADEYO for adults and pediatric patients 12 years of age and older is 150 mg taken orally once daily with food”
> “ORLADEYO should not be used for treatment of acute HAE attacks.”

Source: [FDA ORLADEYO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/214094s006lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### Garadacimab: mechanism, population, and dosing

> “Garadacimab-gxii is an inhibitor of activated FXII”
> “an initial loading dose of 400 mg”
> “200 mg administered subcutaneously every month.”
> “ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.”
> “ANDEMBRY is intended for self-administration or administration by a caregiver.”

Source: [FDA ANDEMBRY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761367s000lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

###### Donidalorsen: indication, mechanism, and dosing

> “DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.”
> “The recommended dosage of DAWNZERA is 80 mg administered subcutaneously every 4 weeks.”
> “A dosage of 80 mg administered subcutaneously every 8 weeks may be considered.”
> “Donidalorsen lowers PKK concentration, preventing excessive bradykinin production in patients with HAE.”

Source: [FDA DAWNZERA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf)

<a id="topic-2.2.2.1.4-8"></a>

###### Lanadelumab and berotralstat: guideline summary of efficacy

> “Lanadelumab, a fully human monoclonal antibody directed against plasma kallikrein, reduces the risk of attacks in the context of LTP, with a low risk of adverse events and a positive impact on QoL.”
> “Reported attack rates with this drug are less than 0.3 per month with biweekly dosing, and over 95% of treatment-emergent adverse events are non-serious.”
> “Berotralstat, an oral plasma kallikrein inhibitor, demonstrated efficacy in a pivotal trial, achieving a ∼50% reduction in attack rate.”
> “Patients should be aware of delayed onset of action.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.4-9"></a>

###### Attenuated androgens: second-line prophylaxis

> “We recommend the use of androgens only as second-line long-term prophylaxis.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We suggest IV C1-INH, attenuated androgens (at the lowest effective dose, preferably not exceeding 200 mg per day), or antifibrinolytics as second-line options for LTP in patients for whom first-line therapies are not available, not feasible, or not tolerated.”
> “Attenuated androgens are strongly associated with virilization in women, dyslipidemia, and hepatotoxicity, with an increased risk of hepatic neoplasms.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.4-10"></a>

###### Deucrictibant extended-release tablet for prophylaxis: CHAPTER-3 phase 3 results (investigational)

> “CHAPTER-3 (NCT06669754) met the primary endpoint and all secondary efficacy endpoints with statistical significance.”
> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.1.4-11"></a>

###### Attacks during prophylaxis and continued access to on-demand treatment: guideline statements

> “Attacks can still occur even in patients under LTP, and on-demand medication must remain available to them.”
> “We recommend that patients have access to ODT, even while receiving LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Although the aim of LTP is to reduce the number and severity of attacks, it does not completely eliminate the risk of attacks.”
> “All patients must have a plan for on-demand treatment of attacks and have at least two doses of acute treatments available even while on LTP therapy.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “We recommend supplying all pediatric patients with hereditary angioedema with acute treatment for at least two angioedema attacks even if they are on long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.4-12"></a>

###### Attacks and on-demand treatment use during prophylaxis: systematic review of 45 studies

> “Forty-five primary studies met the inclusion criteria.”
> “In phase 3 trials, attack-free rates were 40% for subcutaneous pdC1INH 60 IU/kg twice weekly at 16 weeks, and 44% for lanadelumab 300 mg every second week at 6 months (77% during steady-state [days 70–182]); there was no difference in attack-free rate for berotralstat 150 mg versus placebo at 24 weeks.”
> “Laryngeal attacks accounted for 2%-7% of all attacks in observational and interventional studies, regardless of the LTP agent received.”
> “On-demand therapy was used in 49%-94% of attacks occurring in the presence of LTP.”

Source: [Longhurst et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11638394/)

<a id="topic-2.2.2.1.4-13"></a>

###### Persistence, switching, and on-demand use after starting prophylaxis: US claims

> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”
> “Even with use of LTP, on-demand treatment utilization remained present for over two-thirds of patients.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.2.1.4-14"></a>

###### On-demand prescriptions after starting subcutaneous prophylaxis: US claims

> “Study population included 196 patients (C1-INH-SC: N=65; lanadelumab: N=131); mean age was 39 years and 69% were female.”
> “Mean annualized number of ODT prescriptions was 3.8 (3.6–4.1) per patient”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.2.1.4-15"></a>

###### On-demand rescue medication during intravenous C1 inhibitor prophylaxis: US claims

> “There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.”

Source: [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)

<a id="topic-2.2.2.1.4-16"></a>

###### On-demand dispensing during lanadelumab or berotralstat prophylaxis: Swedish national register

> “Among patients with ≥12 months on modern LTP (n=69) who had at least one ODT dispensation event during their most recent 12 months of treatment (n=46/59 for lanadelumab; n=8/9 for berotralstat), the mean number of ODT packages dispensed”
> “in addition to emergency stock ODT”
> “was 4.3 per patient on lanadelumab and 6.5 per patient on berotralstat.”
> “Overall, 22% (n=15/69) of patients receiving modern LTP did not dispense ODT medication during their most recent 12-months of treatment.”

Source: [Meisgen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13461400/)

<a id="topic-2.2.2.1.4-17"></a>

###### Breakthrough attack rate during prophylaxis: KONFIDENT-S interim analysis

> “As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month).”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Fresh Frozen Plasma and Other Measures

<a id="topic-2.2.2.1.5-1"></a>

###### Solvent detergent-treated plasma and fresh frozen plasma: third-line on-demand treatment

> “If IV C1-INH, icatibant, sebetralstat or ecallantide is unavailable, solvent detergent-treated plasma (SDP) or FFP may be considered, provided that a safe and reliable supply of these blood products can be ensured.”
> “We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Where these first-line therapies are not available, attacks should be treated with solvent detergent-treated plasma (SDP). If SDP is not available, attacks should be treated with fresh frozen plasma (FFP), where safe supply is available.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.1.5-2"></a>

###### Fresh frozen plasma: US guideline fallback and risk of worsening

> “treat HAE attacks if none of the FDA-approved on-demand medications are available.”
> “The efficacy of FFP has not been studied in randomized trials, and there are anecdotal reports of HAE symptoms precipitously worsening after FFP administration”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Frozen plasma: International/Canadian guideline recommendation and access delays

> “Frozen plasma could be used for acute treatment of attacks if other recommended therapies are not available.”
> “Additionally, FP contains substrates that may promote bradykinin generation, potentially worsening angioedema attacks.”
> “Both FP and SDP are only available for in-hospital use, and there can be significant delays”
> “Therefore, FP use should be limited to life-threatening or severely painful attacks when no other HAE-specific therapies are accessible.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-4"></a>

###### Fresh frozen or solvent detergent plasma in children: pediatric guideline

> “We suggest, when none of the first‐line treatment options are available, using fresh frozen or solvent detergent plasma for acute treatment of angioedema attacks involving the upper airway, gastrointestinal tract, neck, or face in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency.”
> “These agents are associated with a risk of anaphylactic reaction and transmission of blood‐borne infections”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.1.5-5"></a>

###### Antifibrinolytics and attenuated androgens: not recommended for acute attacks

> “Using antifibrinolytics (such as tranexamic acid) or attenuated androgens (such as danazol) for ODT is discouraged because of a lack of benefit.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We advise against the use of antifibrinolytics (eg, tranexamic acid) or androgens (eg, danazol) for on-demand treatment of HAE attacks”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Attenuated androgens and tranexamic acid should not be used for the acute treatment of attacks.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-6"></a>

###### Antihistamines, corticosteroids, and epinephrine: ineffective for bradykinin-mediated attacks

> “Antihistamines, corticosteroids, and epinephrine are ineffective for BK-AE and should not be used, as their use may delay the administration of specific treatments for BK-AE.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “specifically avoid therapies that lack supporting evidence, such as antihistamines, corticosteroids, or epinephrine, which treat mast cell–mediated but not bradykinin-mediated angioedema.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.1.5-7"></a>

###### Supportive care when effective on-demand treatment is not available

> “IV fluids, antiemetics, narcotic pain medication, or intubation”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.1.5-8"></a>

###### Upper airway involvement and airway management: guideline recommendations

> “We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.”
> “We recommend that airway interventions (intubation, cricothyroidotomy, or tracheotomy) be promptly considered during the initial evaluation of patients presenting with signs of upper airway involvement.”
> “If intubation is indicated but proves difficult or impossible, an emergency cricothyrotomy or tracheotomy should be performed without delay.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that intubation or surgical airway intervention is considered early in progressive upper airway edema.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We recommend that upper airway, facial, and neck edema should always be treated. In case of upper airway edema, pediatric patients with hereditary angioedema should also have an emergency referral to a hospital where airway management is available.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Limitations of Current Therapies

<a id="topic-2.2.2.1.6-1"></a>

###### Summary: injectable administration, treatment delay, and untreated attacks

The approved on-demand C1 inhibitors are given intravenously (plasma-derived C1 inhibitor at 20 IU/kg by intravenous injection; recombinant C1 inhibitor at 50 U/kg as a slow intravenous injection), icatibant is given as a 30 mg subcutaneous injection, and ecallantide as three 10 mg subcutaneous injections; sebetralstat is taken orally. The sponsor states that most on-demand therapies are administered by injection and that this burden causes people to delay or forgo treatment of their attacks. In interviews with 25 US and UK patients and caregivers, participants cited fear of needles, portability, and complexity of administration as reasons for delaying or forgoing injectable on-demand treatment; 80% reported not treating every attack, and some adult and all adolescent patients reported needing assistance with administration.

In a survey of 107 respondents, 57% did not treat all attacks, only 14% treated attacks immediately, and the mean time to treatment was 2.4 h; respondents who waited 1 h or longer cited the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and the treatment being too painful (32.8%), and 32.7% of respondents experienced the return of an attack after initial treatment. Another report of 107 US survey respondents found that 63.6% did not carry on-demand treatment at all times when away from home, 86% reported delaying on-demand treatment, and an average of 20% of attacks were untreated (24% among on-demand-only patients and 15% among prophylaxis patients). In a further US survey, of the 67% of the treated cohort (n = 94) who reported treating early, only 26% administered on-demand treatment in less than 1 hour, 79% reported treatment-related anxiety that correlated with treatment delay, and untreated attacks lasted a mean of 2.3 days. In a survey funded by KalVista Pharmaceuticals, the mean delay from attack onset to on-demand treatment was 2.9 h (SD 2.7), 10% treated within 1 h, 13% sought hospital or emergency services for administration during the last treated attack, 51% required caregiver support, and adolescents and users of intravenous on-demand treatment were more likely to delay treatment because of administration-related barriers. Patients using long-term prophylaxis reported treating a mean of 84.8% of their attacks, compared with 75.6% for patients using on-demand treatment only. In the Icatibant Outcome Survey, 44% of attacks in self-administrators and 22% in patients receiving icatibant from a health care professional were treated within 1 hour of onset, and attack duration was 6.1 hours in patients treated within 1 hour of onset and 16.8 hours in those treated at 1 hour or later.

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf); [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf); [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf); [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf); [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/); [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/); [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/); [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/); [Cancian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12590309/); [Lumry et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39586588/); [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)

<a id="topic-2.2.2.1.6-2"></a>

###### Summary: adverse reactions, administration by health care professionals, and restrictions of use

Injection site reactions occurred in 97% of patients receiving icatibant in clinical trials. In FDA Adverse Event Reporting System data for the parenteral on-demand therapies, the highest reported rates of administration-site reactions were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year), and access-site complications or malfunctions were reported only for recombinant C1 inhibitor (9.5 per year); these rates are not exposure adjusted. Serious arterial and venous thromboembolic events have been reported with plasma-derived C1 esterase inhibitor products, and plasma-derived C1 inhibitor may carry a risk of transmitting infectious agents. Recombinant C1 inhibitor is contraindicated in patients with allergy to rabbits or rabbit-derived products, and its effectiveness was not established in laryngeal attacks. Anaphylaxis occurred in 10 of 255 participants (4%) treated with ecallantide in clinical studies, and ecallantide is administered only by a health care professional; a guideline suggests it only as a second-line option. Icatibant is indicated for adults 18 years of age and older. Patients who self-administer plasma-derived C1 inhibitor or icatibant for a laryngeal attack are advised to seek medical attention in a health care facility. Plasma products used when HAE-specific treatment is unavailable are available only for in-hospital use, with delays of sometimes up to 24 h in obtaining them.

Users of intravenous C1 inhibitor had higher crude rates of hospitalization (20% vs 6%) and emergency department visits (57% vs 43%) than patients not using an HAE medication requiring intravenous access, and 18 (5.4%) had a central venous access device. Severe laryngeal attacks were not treated in the sebetralstat trial KONFIDENT, and a guideline states that long-term data from extension studies and real-world evidence for sebetralstat are still lacking.

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf); [Tachdjian et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993116/); [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf); [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf); [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/); [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.2.2.1.6-3"></a>

###### Summary: repeat dosing and rescue medication

Repeat treatment during a single attack is approved for icatibant (up to 3 doses within 24 hours at intervals of at least 6 hours) and for ecallantide and recombinant C1 inhibitor (up to 2 doses within 24 hours); sebetralstat allows a second 600 mg dose at least 3 hours after the first, up to 1,200 mg in any 24-hour period. A guideline states that icatibant more frequently requires a second dose than C1 inhibitor. In Trial 1 of the icatibant label, 3 of 43 participants (7%) treated with icatibant used additional rescue medication, compared with 18 of 45 (40%) with placebo, and in a further analysis in the label, 93% of 987 attacks were treated with a single dose. In the sebetralstat label, 38% of participants in the 600 mg group administered a second dose within 12 hours. Recombinant C1 inhibitor was given as rescue medication to 5 of 44 participants (11%) randomized to it and 13 of 31 (42%) randomized to placebo, and 5 of 170 attacks (3%) in the open-label phase received a second dose. In EDEMA4, 16 of 48 participants (33%) treated with ecallantide and 24 of 48 (50%) given placebo required medical intervention for unresolved symptoms within 24 hours. In the KONFIDENT-S extension, conventional on-demand treatment was administered within 12 h for 3 (9.4%) laryngeal and 43 (8.1%) abdominal attacks treated with sebetralstat.

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf); [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf); [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf); [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf); [Bernstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12626162/)

<a id="topic-2.2.2.1.6-4"></a>

###### Summary: attacks and on-demand treatment use during long-term prophylaxis

Guidelines state that long-term prophylaxis does not completely eliminate the risk of attacks and recommend that patients receiving it keep access to on-demand treatment, with at least two doses available. A review of 45 primary studies reported attack-free rates in phase 3 trials of 40% for subcutaneous plasma-derived C1 inhibitor at 16 weeks and 44% for lanadelumab every second week at 6 months, with no difference in attack-free rate for berotralstat versus placebo at 24 weeks; laryngeal attacks accounted for 2% to 7% of attacks, and on-demand therapy was used in 49% to 94% of attacks occurring during prophylaxis. In one claims analysis, on-demand treatment use remained present for over two-thirds of patients after starting prophylaxis, and 55% had refill gaps, discontinued, or switched prophylaxis within a year. Among 196 patients on subcutaneous prophylaxis in another analysis, the mean annualized number of on-demand prescriptions was 3.8 per patient, and in a third, on-demand rescue medication was used during 53% (163/306) of episodes of intravenous C1 inhibitor prophylaxis. In another cohort, patients with at least 12 months on lanadelumab or berotralstat who had an on-demand dispensation were dispensed a mean of 4.3 and 6.5 packages, respectively, in their most recent 12 months, and 22% (15/69) dispensed none. In the KONFIDENT-S extension, 35 participants receiving prophylaxis experienced a mean of 1.7 attacks per month (SD 1.5). A guideline states that only about 50% of patients currently receive long-term prophylaxis, even in high-income countries, and that the higher costs of newer drugs limit their availability.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Longhurst et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11638394/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/); [Meisgen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13461400/); [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.1.6-5"></a>

###### Parenteral administration and treatment delay: sponsor statement

> “Most on-demand therapies are administered by injection, the burden of which causes people to delay or forego treatment of their attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.2.2.1.6-6"></a>

###### Burden of injectable on-demand treatment: patient and caregiver interviews

> “The 25 study participants from the US and UK (17 patients; 8 caregivers), who completed the interview, highlighted emotional and logistical reasons for delaying or forgoing injectable on-demand treatment, including fear of needles, portability, and complexity of administration.”
> “Although indicated for self-administration, some adult and all adolescent patients reported needing assistance with administration of their injectable on-demand treatment.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.2.1.6-7"></a>

###### Untreated attacks, delayed treatment, and attack recurrence: US survey of 107 participants

> “A total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female).”
> “The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately.”
> “Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment.”
> “The most important reasons cited by those who waited 1 h or longer to initiate on-demand treatment were the attack not being considered severe enough to treat (86.9%), not having on-demand treatment with them (59%), and their on-demand treatment being too painful (32.8%).”
> “Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence.”
> “This work was sponsored by KalVista Pharmaceuticals, Inc.”

Source: [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/)

<a id="topic-2.2.2.1.6-8"></a>

###### Share of attacks treated by prophylaxis status: US survey

> “Patients using LTP reported treating a mean ± standard deviation 84.8% ± 23.8% of their HAE attacks compared with a mean ± standard deviation 75.6% ± 27.5% for patients with on-demand only treatment.”

Source: [Lumry et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39586588/)

<a id="topic-2.2.2.1.6-9"></a>

###### Time to treatment, treatment-related anxiety, and untreated attacks: US survey

> “In the Treated Cohort (n = 94), of the 67% who reported treating their attack early, only 26% administered OD in less than 1 hour.”
> “Furthermore, 79% (n = 74) reported treatment-related anxiety, which correlated with treatment delay.”
> “In the Untreated Cohort (n = 20), 50% of the respondents describing their last untreated attack as mild experienced progression to moderate or severe and 25% reported spread to another site including the larynx and face.”
> “Untreated attacks lasted a mean of 2.3 days.”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

<a id="topic-2.2.2.1.6-10"></a>

###### Treatment delays, emergency care, and administration barriers: Italian survey

> “For the respondents' last treated attack, 13% sought hospital/emergency services for OD administration, and 51% required caregiver support.”
> “Respondents reported a mean (SD) delay of 2.9 (2.7) h from attack onset to OD, with 10% treating < 1 h, 24% treating 1 to < 2 h, 51% treating 2 to < 5 h, and 16% treating ≥ 5 h from onset.”
> “Of note, adolescents and those receiving intravenously administered OD were more likely to delay treatment because of administration‐related barriers than adults and those receiving subcutaneously administered OD.”
> “Funding: This study was funded by KalVista Pharmaceuticals.”

Source: [Cancian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12590309/)

<a id="topic-2.2.2.1.6-11"></a>

###### Administration-site reactions with parenteral on-demand treatments: FDA adverse event reports

> “The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site swelling (6.7 per year).”
> “RhC1-INH was the only drug for which access-site complications and/or malfunctions were reported (9.5 per year).”
> “It should be noted that ADR rates are not exposure adjusted and are based on spontaneous reporting.”

Source: [Tachdjian et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37993116/)

<a id="topic-2.2.2.1.6-12"></a>

###### Venous access devices, hospitalization, and emergency department visits with intravenous C1 inhibitor: US claims

> “Users of C1-INH(IV) (n = 336; 64.5%) had higher crude rates of hospitalization (20% vs 6%) and ED visits (57% vs 43%) compared with patients not using an HAE medication requiring IV access (Table 4).”
> “Eighteen patients (5.4%) had a central venous access device (CVAD); of these, 5 (27.7%) required hospitalization and 14 (77.7%) had an ED visit.”

Source: [Riedl et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6186115/)

<a id="topic-2.2.2.1.6-13"></a>

###### Emergency department visits for hereditary angioedema: US national sample, 2006 to 2007

> “In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD).”
> “Two thousand fifty-nine (40.9%) resulted in a hospitalization.”

Source: [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)

<a id="topic-2.2.2.1.6-14"></a>

###### Repeat dosing limits and second-dose frequency with existing on-demand agents

> “Repeat treatment during a single attack has been approved for icatibant (maximum of 3 doses within a 24-hour period at intervals of at least 6 hours) as well as ecallantide and rhC1INH (both with maximum of 2 doses within a 24-hour period).”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

> “Both icatibant and C1-INH effectively reduce attack duration, with icatibant offering faster and more convenient self-administration but more frequently requiring a second dose.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “In terms of rescue medication use, 3/43 (7%) patients treated with FIRAZYR used additional rescue medication in comparison to 18/45 (40%) patients treated with placebo.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

> “Note: In the EKTERLY 600 mg group, 38% of patients administered a second dose within 12 hours.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

> “The proportion of patients who received RUCONEST as rescue medication was greater in patients randomized to placebo (13 of 31 patients; 42%) than in patients randomized to RUCONEST (5 of 44 patients; 11%).”
> “In the OLE phase of Study 1, 5/170 (3%) attacks received a second dose of RUCONEST 50 U/kg.”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

<a id="topic-2.2.2.1.6-15"></a>

###### Ecallantide administration restriction and limited long-term data for sebetralstat: guideline statements

> “Due to the risk of hypersensitivity reactions, ecallantide must be administered only under the supervision of healthcare personnel.”
> “Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.1.6-16"></a>

###### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.2.1.6-17"></a>

###### Uptake of prophylaxis and cost as a barrier to access

> “Nevertheless, even with recent advances, LTP is still not the standard of care, even in high-income countries, with only about 50% of patients currently receiving it.”
> “Despite their greater effectiveness, newer drugs are associated with higher costs that clearly limit their availability, particularly in low- and middle-income countries.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: guideline recommendations for on-demand treatment

The guideline by Vázquez et al. recognizes four types of on-demand treatment as effective (intravenous C1-INH, icatibant, sebetralstat, and ecallantide), recommends intravenous C1-INH, icatibant, or sebetralstat as first-line, suggests ecallantide as a second-line option only when first-line therapies are not available or feasible, and recommends solvent detergent-treated plasma or fresh frozen plasma as third-line; it states that direct comparisons among these options are limited, and recommends intravenous plasma-derived C1-INH as first-line for pregnant patients. The guideline by Betschel et al. lists ecallantide, icatibant, intravenous C1INH, and sebetralstat as effective therapies, discussed “without implying any hierarchy of preference”, and states that access to another effective acute treatment is crucial given variation in patient response. A pediatric guideline recommends icatibant, intravenous plasma-derived C1-INH, or recombinant C1-INH as first-line acute treatment for children aged 2 to 12 years, and ecallantide, icatibant, either intravenous C1-INH, or sebetralstat for adolescents aged 12 years or older.

The guidelines recommend that all attacks be considered for on-demand treatment and treated as early as possible, that every patient have medication for at least 2 attacks, kept at home, and that patients carry on-demand medication at all times; the US HAEA Medical Advisory Board recommends that all patients with HAE due to C1-INH deficiency have access to at least two standard doses. Upper airway swelling calls for on-demand treatment as early as possible and emergency care, and all patients with laryngeal edema are to be assessed in the emergency department even after self-therapy. The Vázquez et al. guideline states that the only oral on-demand treatment available is sebetralstat and that long-term data for it are still lacking. Deucrictibant appears in none of the guidelines' lists of recommended agents; the Vázquez et al. guideline states that preliminary results have demonstrated its efficacy for treating attacks, and the pediatric guideline notes that RAPIDe-3 is evaluating it in adolescent and adult patients.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/); [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.2-2"></a>

###### Summary: anticipated use of an oral on-demand option and care setting

Deucrictibant is described as the first and only orally administered bradykinin B2 receptor antagonist investigated for on-demand treatment of HAE attacks. In RAPIDe-3, participants self-administered the study drug during or immediately after a qualification call with the investigator, and in Part 2 of RAPIDe-1 participants self-administered it at home. Adolescents with laryngeal attacks of any severity and adults with severe laryngeal attacks were instructed to take their conventional on-demand therapy instead of the study drug and to seek medical care urgently. One publication notes that the recommendation to treat all attacks as early as possible shaped the design of recent trials, including those of sebetralstat and deucrictibant.

The trial investigators state that an efficacious oral on-demand option with a favourable safety profile “could address key unmet needs”, and that further studies of patient preferences, including number of pills administered per dose, are warranted. A guideline states that HAE is well suited to self-treatment, especially by oral administration, and that injectable therapies can pose barriers such as needle phobia, poor venous access, or impaired dexterity; ecallantide must be administered under the supervision of health care personnel. The sponsor intends to file for approval of and commercialize deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks through its own commercial infrastructure, states that an oral on-demand treatment could decrease the burden of therapy through easier administration, portability, and discretion, and states its belief that deucrictibant could become standard of care for on-demand treatment. The sponsor is also preparing an NDA for the extended-release tablet for prophylaxis, which reduced the mean monthly attack rate by 83% in CHAPTER-3, with submission planned for 1H2027; these data concern the extended-release tablet.

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext); [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [Cohn et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39724968/); [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8); [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-3"></a>

###### Summary: patient and physician preference

In a study in which Pharvaris participated in the interpretation of the data, 225 physicians completed patient record forms for 1131 patients and 279 patients completed a questionnaire; 84% of patients in the patient-reported group indicated that, given the choice, they would prefer to take their on-demand treatment by mouth. The top physician-reported unmet needs of on-demand treatment were a different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%]); patients most often reported not liking injections and experiencing pain, bruising, or burning with injections (42/227 [19%] each), followed by not liking to inject medications in public places (38/227 [17%]). In interviews with 25 US and UK patients and caregivers, in a study supported by KalVista Pharmaceuticals, all participants expressed interest in an oral on-demand treatment, and 8 indicated that they would treat attacks earlier with one; more than half regarded the need to swallow a tablet as a potential disadvantage during a throat or facial attack, and some were concerned about how quickly an oral tablet would begin to work.

Source: [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2); [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.2.2-4"></a>

###### Summary: payer criteria and quantity limits

Published payer policies refer to generic icatibant in their criteria for on-demand treatment, including sebetralstat (Ekterly). Cigna requires prior authorization, with coverage for patients aged 12 to under 18 years, patients who have previously treated an attack with Ekterly, or patients who have tried generic icatibant; its quantity limits allow treatment of 4 attacks per 28 days at the maximum Ekterly dose, with an override for an additional 4 attacks each month and a one-time override of 16 additional tablets. Univera Healthcare requires documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant for Ekterly requests in patients 18 years of age and older, lists a quantity limit of 4 tablets per 30 days, authorizes one acute HAE medication at one time, and does not approve requests for quantities in excess of its limits. A Regence policy requires documentation that generic icatibant and either Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, or four to six attacks per month when its criteria are met (including, for HAE types I and II, evaluation for prophylactic therapy), and states that “Generic icatibant is the lowest cost of all available options.”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf); [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)

<a id="topic-2.2.2.2-5"></a>

###### First-line on-demand treatment options: WAO guideline

> “We recommend that first-line ODT for HAE attacks include either IV C1-INH, icatibant or sebetralstat.”
> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide”
> “Direct comparisons among these options are limited.”
> “We suggest considering ecallantide as a second-line option for ODT for HAE attacks only when first-line therapies are not available or feasible.”
> “We recommend SDP/FFP as third-line treatment, with SDP preferred over FFP if available due to a lower risk of viral transmission.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-6"></a>

###### Oral on-demand treatment in the WAO guideline

> “The only oral ODT available is sebetralstat and the dose is 2 300 mg tablets.”
> “Sebetralstat, an oral plasma kallikrein inhibitor, was recently approved by the United States Food and Drug Administration (FDA) as an ODT for HAE, based on the findings of the KONFIDENT study”
> “long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-7"></a>

###### Effective acute therapies: International/Canadian guideline

> “Effective therapies should be used for the acute treatment of attacks of angioedema to reduce duration and severity of attacks. Effective therapies include ecallantide, icatibant, intravenous C1INH (plasma-derived or recombinant), and sebetralstat.”
> “The following therapies are discussed in alphabetical order, without implying any hierarchy of preference.”
> “Given the variation in patient response to acute therapies [53], it is crucial that healthcare professionals have access to another effective acute treatment, if necessary, to optimize patient outcomes.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-8"></a>

###### Treatment of every attack as early as possible: guideline recommendations

> “We recommend that ODT be considered for all HAE attacks, which is mandatory when upper airway involvement is detected, and should be instituted as early as possible.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that all attacks are considered for on-demand treatment.”
> “We recommend that attacks are treated as early as possible.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Attacks should be treated early to reduce morbidity.”
> “Attacks should be treated early to reduce mortality.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-9"></a>

###### On-demand medication at home for at least two attacks: guideline recommendations

> “We recommend that every patient, even if asymptomatic, must have ODT available at home because the risk of a serious attack is unpredictable and persists throughout their lifetime.”
> “HAE attacks can follow an unpredictable clinical course, rebound is possible, and multiple attacks can appear in quick succession. Therefore, patients should always have enough medication available to treat at least 2 acute attacks at home.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend that all patients have sufficient medication for on-demand treatment of at least two attacks and carry on-demand medication at all times.”
> “In patients with frequent attacks, the time it takes to obtain more on-demand medication should be taken into consideration in the provision of treatment, so that they never run out of on-demand medication.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “All patients should have access to at least two doses of acute therapy, and their ability to administer these therapies should be routinely assessed.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “Based on the US HAEA Medical Advisory Board recommendations, all patients with HAE due to C1-Inhibitor deficiency should have access to at least two (2) standard doses of a medication proven effective in treating HAE attacks.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.2-10"></a>

###### Pediatric guideline: first-line acute treatment by age

> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 2 and 12 years, we recommend the use of icatibant, intravenous plasma‐derived C1 inhibitor concentrate, or intravenous recombinant human C1 inhibitor as first‐line therapy for acute treatment of angioedema attacks.”
> “In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of ecallantide, icatibant, intravenous plasma‐derived C1 inhibitor concentrate, intravenous recombinant human C1 inhibitor, or sebetralstat as first‐line therapy for acute treatment of angioedema attacks.”
> “We recommend acute treatment of angioedema attacks in pediatric patients with hereditary angioedema as early as possible.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.2-11"></a>

###### Upper airway attacks: emergency care setting

> “We recommend that in the case of upper airway swelling, ODT should be given as early as possible, and patients should seek emergency care.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “All attacks of angioedema involving the upper airway are medical emergencies and must be treated immediately.”
> “It is also recommended that all patients with laryngeal edema, even following self-therapy, be assessed in the emergency department, in case the angioedema does not respond to therapy and expertise in airway management is required”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-12"></a>

###### Phase 3 trial instructions for laryngeal attacks

> “Adolescent participants with laryngeal attacks, regardless of severity, and adult participants with severe laryngeal attacks (those with symptoms of breathing difficulties or stridor) were instructed to immediately take their conventional on-demand therapy instead of the study drug and to seek medical care urgently.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.2-13"></a>

###### Care setting: self-administration at home in deucrictibant trials

> “During the qualification call with the investigator or immediately following, patients then self-administered the study drug.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.2.2.2-14"></a>

###### Care setting: agents requiring administration by health care personnel

> “Due to the risk of hypersensitivity reactions, ecallantide must be administered only under the supervision of healthcare personnel.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Both FP and SDP are only available for in-hospital use, and there can be significant delays”
> “sometimes up to 24 h”
> “in obtaining these products”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-15"></a>

###### Oral administration and self-treatment: International/Canadian guideline

> “Several characteristics of HAE make it particularly well-suited for self-treatment via SC, IV, and especially oral administration.”
> “However, injectable therapies can pose barriers to some patients due to factors such as needle phobia, poor venous access, or impaired dexterity, which can make SC/IV self-administration difficult.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.2-16"></a>

###### Evolution of on-demand treatment guidelines and trial design

> “In 2013, the US Hereditary Angioedema Association guidelines recommended that all attacks, irrespective of location or severity, be considered for treatment as early as possible after onset to minimize morbidity and mortality.”
> “This approach remains the cornerstone of current treatment guidelines and has shaped the design of recent clinical trials, such as those for the investigational agents, oral plasma kallikrein inhibitor sebetralstat and oral bradykinin B2 receptor antagonist deucrictibant.”

Source: [Cohn et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39724968/)

<a id="topic-2.2.2.2-17"></a>

###### Deucrictibant in guideline and review discussion

> “Two distinct formulations are being investigated: immediate-release capsule (previously referred to as PHVS416) and extended-release tablet (previously referred to as PHVS719).”
> “Preliminary study results on the use of deucrictibant for the treatment of HAE attacks have demonstrated its efficacy.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “RAPIDe‐3 is evaluating an oral BDKRB2 antagonist (deucrictibant) in adolescent and adult patients”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “Published and ongoing clinical studies demonstrate favorable safety, tolerability, and efficacy profiles for both LTP and ODT, offering a convenient oral alternative that may reduce treatment burden and improve patient quality of life.”

Source: [Bui et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42635583/)

<a id="topic-2.2.2.2-18"></a>

###### Trial investigators' statement on the role of an oral on-demand option

> “An oral therapy option for on-demand treatment of hereditary angioedema attacks that is efficacious, with a favourable safety profile, could address key unmet needs in the management of bradykinin-mediated angioedema, including improving symptom control as guidelines recommend.”
> “Further studies are warranted to explore patient preferences and effects on clinical outcomes of different oral on-demand therapies, including number of pills administered per dose.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.2-19"></a>

###### Company statements on intended positioning

> “Most on-demand therapies are administered by injection, the burden of which causes people to delay or forego treatment of their attacks. An oral on-demand treatment could decrease the burden of therapy by improving convenience through easier administration, portability, and discretion.”
> “With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.”
> “According to our analysis, oral therapy remains the highest unmet need for both on-demand and prophylactic use in AE-BK.”
> “We intend to file for approval and commercialize deucrictibant IR capsules as a fast-acting, orally available, potent inhibitor and selective on-demand treatment for HAE attacks.”
> “If any of our product candidates receive marketing approval, we intend to market, sell and distribute them using our own commercial infrastructure.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “If approved, deucrictibant could potentially address unmet needs across both on-demand and long-term prophylaxis of bradykinin-mediated angioedema attacks”
> “our team is preparing for our potential first commercial launch and is well on its way to building an experienced commercial team.”
> “By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema.”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-20"></a>

###### Company statement: deucrictibant XR prophylaxis development

> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-21"></a>

###### Patient and physician survey: preference for oral on-demand treatment, Pharvaris-supported analysis

> “Participating physicians (n = 225) completed PRFs for 1131 patients (age range: 3–82 years); 279 patients completed the questionnaire.”
> “The top three physician-reported unmet needs of ODT included different route of administration (320/817 [39%]), discomfort upon administration (112/817 [14%]), and injection site reactions (111/817 [14%])”
> “The patient-reported top three unmet needs of ODT were not liking injections, experiencing pain/bruising/burning with injections (42/227 [19%] each), and not liking to inject medications in public places (38/227 [17%])”
> “In the patient-reported group, 84% of patients indicated that, given the choice, they would prefer to take their ODT by mouth.”
> “Pharvaris participated in the interpretation of the data and the review and approval of this manuscript”

Source: [Anderson et al. (2026b)](https://link.springer.com/article/10.1007/s12325-026-03790-2)

<a id="topic-2.2.2.2-22"></a>

###### Qualitative interviews: perceptions of an oral on-demand treatment

> “All participants expressed interest in an oral on-demand treatment when asked directly, with some suggesting this spontaneously during interviews while discussing the difficulties with their current injectable treatments. Participants indicated that if they had oral on-demand treatment available, they would treat attacks earlier (n = 8).”
> “More than half of participants believed the need to swallow a tablet was a potential disadvantage if they were having a throat or facial attack.”
> “Some participants expressed concerns about the speed at which an oral tablet would begin to work, as a pill needs to dissolve to enter the blood stream, unlike injectable medications.”

Source: [Yong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12715920/)

<a id="topic-2.2.2.2-23"></a>

###### Case series: reasons for switching to an oral on-demand treatment

> “Reasons for switching were administration-related treatment barriers (8/12 [66.7%]), improved lifestyle compatibility(6/12 [50.0%]), and enhanced treatment autonomy (5/12 [41.7%]).”

Source: [Lochbaum et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43025858/)

<a id="topic-2.2.2.2-24"></a>

###### Payer step therapy and quantity limits for oral on-demand treatment: Regence

> “Clinical documentation (such as chart notes) confirming that treatment with the following has been ineffective, not tolerated, or contraindicated: 1. Generic icatibant. AND 2. At least one of the following (a or b): a. Berinert (plasma-derived C1-INH) OR b. Ruconest (recombinant C1-INH)”
> “Initial quantities: Acute treatments for HAE may be authorized in a quantity sufficient for the treatment of three attacks per month.”
> “Higher quantities: Acute treatments for HAE may be authorized in a quantity sufficient for the treatment of four to six attacks per month when all criteria (1 through 3) below are met:”
> “For HAE types I and II only: Documentation that the patient is being evaluated for initiation of prophylactic HAE-specific therapy.”
> “Generic icatibant is the lowest cost of all available options.”

Source: [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf)

<a id="topic-2.2.2.2-25"></a>

###### Payer quantity limits for oral on-demand treatment: Cigna drug quantity management

> “The quantity limits outlined below provide for the patient to treat 4 attacks (at the maximum Ekterly dose) per 28 days, with an override provided to treat an additional 4 attacks (at the maximum Ekterly dose) each month.”
> “If the patient requires additional doses of Ekterly to treat a subsequent attack of hereditary angioedema (HAE), approve a one-time override for 16 additional tablets at retail or home delivery.”

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf)

<a id="topic-2.2.2.2-26"></a>

###### Payer preferred product criteria for oral on-demand treatment: Cigna prior authorization

> “Prior Authorization is required for benefit coverage of Ekterly.”
> “Patient meets one of the following (1, 2, or 3): 1. Patient is ≥ 12 years of age and ˂ 18 years of age. 2. Patient has previously treated an acute HAE attack with Ekterly. 3. Patient has tried generic icatibant”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf)

<a id="topic-2.2.2.2-27"></a>

###### Payer step therapy and quantity limits for on-demand treatments: Univera Healthcare

> “For patients 18 years of age and older, requests for Ekterly will require documentation of therapeutic failure, severe intolerance, OR a contraindication to generic icatibant.”
> “Quantity limit of 4 tablets per 30 days.”
> “Quantity limit of #3 (3ml each) pre-filled syringes – 9ml/30 days.”
> “Quantity limit of 10 vials per 30 days on Rx benefit”
> “Individuals will only be authorized for one acute HAE medication at one time.”
> “Due to lack of evidence for more frequent administration, requests for quantities in excess of the established limits will not be approved.”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

Additional sources: [Zuraw and Christiansen (2026)](https://pubmed.ncbi.nlm.nih.gov/42849490/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### RAPIDe-3 subgroups: participants with at least one study drug-treated attack

> “Sensitivity and subgroup analyses employed an expanded analysis set including all participants who treated at least one attack with study drug”
> “Of the 113 participants who treated at least one attack, 26 (23%) were receiving long-term prophylaxis at enrolment and during the study.”
> “Outcomes were consistent across subgroups defined by age, hereditary angioedema types, whether concomitant long-term prophylaxis was used or not, and attack location and severity”
> “Results were consistent across clinically relevant subgroups defined according to age, geographical location, hereditary angioedema type, concomitant long-term prophylaxis, and attack severities and locations (including non-severe laryngeal).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-2"></a>

###### RAPIDe-3 subgroups: hereditary angioedema with normal C1 inhibitor

> “In the two participants with hereditary angioedema with normal C1 inhibitor who each had one deucrictibant-treated attack, the time to onset of symptom relief was 1·53 h and 0·84 h, respectively.”
> “Results in the two participants with hereditary angioedema with normal C1 inhibitor with a variant in the plasminogen gene who each had one deucrictibant-treated attack demonstrated a promising response to deucrictibant treatment, but the small dataset and absence of placebo control prevent further speculation on these findings.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-3"></a>

###### RAPIDe-3 limitations bearing on subgroup interpretation

> “Limitations of this trial include the lack of attack stratification according to location and severity due to the rarity of the disease and the unpredictable nature of attack characteristics. Therefore, a larger proportion of severe attacks was observed in the placebo group. Additionally, only two unpaired attacks for participants with hereditary angioedema with normal C1 inhibitor were recorded. Lastly, severe laryngeal attacks were not included, which is consistent with other placebo-controlled studies of on-demand hereditary angioedema therapies.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.3-4"></a>

###### RAPIDe-3 regional subgroups: North America and Europe/Rest of World, all participants with treated attacks

> “subgroup analysis included all participants with treated attacks”
> “In this subgroup analysis, orally administered deucrictibant IR capsule provided faster onset of symptom relief, reduction in attack severity, and complete resolution in both the NA and EU/RoW subgroups compared with placebo.”
> “Data were consistent across geographical locations and with the overall study population.”
> “Deucrictibant IR showed consistent efficacy in treating HAE attacks, regardless of HAE subtypes, age group, LTP use, and attack severity and locations”

Source: [Riedl et al. (2026b)](https://ir.pharvaris.com/static-files/2e62f03b-fbb8-4376-9151-f74c41dd8c0f)

<a id="topic-2.2.2.3-5"></a>

###### RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution

| Outcome and region | Deucrictibant IR | Placebo |
| --- | --- | --- |
| Onset of symptom relief, North America | “1.20 hours (95% CI: 0.84, 1.84)” | “6.55 hours (95% CI: 1.88, >12)” |
| Onset of symptom relief, Europe/Rest of World | “1.28 hours (95% CI: 1.04, 1.41)” | “>12 hours (95% CI: 5.74, >12)” |
| Reduction in attack severity, North America | “2.43 hours (95% CI: 1.03, 5.12)” | “>12 hours (95% CI: 2.65, >12)” |
| Reduction in attack severity, Europe/Rest of World | “2.53 hours (95% CI: 1.70, 2.98)” | “>12 hours (95% CI: 12.10, >12)” |
| Complete symptom resolution, North America | “11.61 hours (95% CI: 2.94, 26.14)” | “>48 hours (95% CI: 17.21, >48)” |
| Complete symptom resolution, Europe/Rest of World | “12.04 hours (95% CI: 8.64, 21.79)” | “>48 hours (95% CI: >48, >48)” |

Source: [Riedl et al. (2026b)](https://ir.pharvaris.com/static-files/2e62f03b-fbb8-4376-9151-f74c41dd8c0f)

<a id="topic-2.2.2.3-6"></a>

###### RAPIDe-1 attack location: cutaneous and abdominal attacks

> “For attacks with cutaneous or abdominal manifestations, or both, shorter times to symptom relief and resolution were consistently observed with deucrictibant compared with placebo (appendix pp 13–14).”
> “A higher proportion of attacks primarily occurring in the abdominal area were treated with deucrictibant 10 mg than with other doses or placebo (appendix p 11).”
> “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity.”
> “Attacks presenting with vomiting or affecting the internal head or neck, including laryngeal attacks, before treatment were excluded from qualification and reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.2.2.3-7"></a>

###### Sebetralstat pooled phase 2 and 3 trials: subgroups by location, severity, age, sex, region, and regimen

> “In the subgroup analysis, results favoring sebetralstat versus placebo were generally consistent when analyzed by pooled primary HAE attack location (mucosal, abdominal only, or subcutaneous), baseline attack severity, age, sex, geographic region, and treatment regimen (Fig. 3). Of note, HAE attacks with a baseline severity of “Severe” or “Very Severe” more strongly favored sebetralstat over placebo in terms of time to beginning of symptom relief compared with attacks with a baseline severity of “Mild” or “Moderate”, although results should be interpreted with caution due to the wide confidence intervals.”
> “For HAE attacks rated “Severe” or “Very Severe” at baseline, conventional medication was used for 2 of 14 attacks (14.3%) treated with sebetralstat 300 mg, 3 of 20 attacks (15.0%) treated with sebetralstat 600 mg, and 6 of 14 attacks (42.9%) treated with placebo.”
> “Subgroup analyses are exploratory in nature and not adjusted for multiplicity.”

Source: [Aygören-Pürsün et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273462/)

<a id="topic-2.2.2.3-8"></a>

###### Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age

> “In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively”
> “Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively”
> “In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively”
> “Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.3-9"></a>

###### Icatibant: time to treatment, attack location, and severity in the Icatibant Outcome Survey

> “Attack duration was significantly shorter in patients treated <1 hour of attack onset compared with those treated ≥1 hour (6.1 hours versus 16.8 hours [p<0.001]).”
> “Self-administrators were more likely to treat early and experience shorter attacks than those treated by a healthcare professional.”
> “Both abdominal and cutaneous attacks were found to be of shorter total duration when treated early. Additionally, early treatment resulted in significant reductions in attack duration regardless of attack severity (Tables 4 and 5).”

Source: [Maurer et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3563637/)

<a id="topic-2.2.2.3-10"></a>

###### Ecallantide: response by time to treatment in the EDEMA trials

> “Change from baseline in MSCS score and TOS at 4 hours revealed significantly better response to ecallantide versus placebo for patients treated >2-4 (n = 46; p = 0.002; p = 0.003) or >4-6 (n = 47; p = 0.044; p = 0.043) hours after symptom onset. Fewer patients were treated within 2 hours of symptom onset; for these patients (n = 10; p = 0.752; p = 0.422) treatment did not achieve statistical significance.”

Source: [Banta et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21781409/)

<a id="topic-2.2.2.3-11"></a>

###### Icatibant and plasma-derived C1 inhibitor: attack site and time to treatment in a prospective cohort

> “Attack severity and attack site were not found to be associated with different remission rates, with the only exception for laryngeal attacks (HR 1.44, 95% CI 1.07 to 1.95).”
> “In addition, shorter time to treatment was associated with a small (2%) but significant positive effect on remission rates”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### US HAEA Medical Advisory Board guidelines: on-demand medication access

> “Effective treatment of HAE requires that all patients have rapid access to effective on-demand medications.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.4-2"></a>

###### On-demand treatment during long-term prophylaxis: guideline recommendations

> “We recommend that patients have access to ODT, even while receiving LTP.”
> “We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend supplying all pediatric patients with hereditary angioedema with acute treatment for at least two angioedema attacks even if they are on long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-3"></a>

###### Self-administration and home therapy

> “Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.”
> “We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-4"></a>

###### Monitoring of disease control with validated instruments

> “We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-5"></a>

###### Specialist care and referral centers

> “We recommend that HAE patients be managed by physicians with expertise in the condition, with the support of a referral center.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-6"></a>

###### Individualized action plans: guideline recommendations

> “We recommend that all patients have an action plan.”
> “It should include an effective emergency (on-demand) treatment plan, with clear instructions on how to best use medications to treat HAE attacks. Patients should carry on-demand medication and an HAE identification card with instructions on how to manage an HAE attack. Patients on long-term prophylaxis also require an action plan and available therapy for on-demand use.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “We recommend creating an action plan for acute treatment of angioedema attacks in pediatric patients with hereditary angioedema, considering availability of medications and patient/caregiver preferences.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “Moreover, identification cards detailing the condition and therapy are essential for proper management of the disease.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-7"></a>

###### HAE management plan elements: US HAEA

> “Recent guidelines from the US HAEA Medical Advisory Board call for an HAE Management Plan for every HAE patient.”
> “The patient should know exactly where their medication is kept, how to use it, and who to contact if assistance is required for treatment. Acute treatment medications should be reliably and efficiently accessible to avoid treatment delays.”
> “The US HAEA Medical Advisory Board suggests all patients keep a record of their attacks, noting which medications were used, their response to treatment, and any possible medication side effects.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

> “Because of the rarity of the condition, HAE-specific medications are not readily available in most hospitals and medical facilities, so must be prescribed for individual patients.”
> “Patients should be familiar with refill processes to efficiently replace HAE medications after doses are used.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

<a id="topic-2.2.2.4-8"></a>

###### Home therapy training: guideline recommendations

> “We recommend that all patients who are provided with on-demand treatment licensed for self-administration should be taught to self-administer.”
> “Home therapy decreases the severity and duration of HAE attacks, reduces morbidity and disability, and can improve quality of life and productivity. In addition, the cost of care is reduced considerably using home and self-therapy.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “All patients with HAE should be trained on self-administration of HAE-specific therapies if they are suitable candidates. If patients cannot self-administer therapy, provisions should be made to ensure timely access to all appropriate therapies.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “We recommend home treatment of angioedema attacks to ensure early treatment in pediatric patients with hereditary angioedema.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.4-9"></a>

###### Education programs and call centers

> “Educational programs focused on the self-administration of on-demand medications, along with national call centers that provide support to patients during acute attacks, have a significant impact on outcomes. Evidence shows that these initiatives can reduce the need for emergency department visits and hospitalizations.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.4-10"></a>

###### Comprehensive care and HAE treatment centers

> “We recommend that HAE-specific comprehensive, integrated care is available for all patients.”
> “We recommend that patients are treated by a specialist with specific expertise in managing HAE.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Comprehensive care for all patients with HAE should be provided to optimize treatment and outcomes.”
> “In addition, the ACARE program launched by global HAE patient groups specifies 32 requirements on topics such as infrastructure, management, research, education, and advocacy that must be fulfilled to demonstrate excellence in the management of angioedema”
> “After its implementation in emergency departments, the time to first medication decreased (from 1.3 h to 0.9 h), the diagnosis of airway swelling declined (from 29 to 4%), HAE diagnoses increased (from 10 to 30%), and the use of C1INH more than doubled (from 29 to 61%)”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.4-11"></a>

###### Carrying on-demand treatment away from home: patient survey

> “Most patients (63.6%) reported that they did not carry on-demand treatment at all times when away from home. The most common reason for not carrying on-demand treatment when away from home was ‘prefer to treat at home’ (72.1%).”

Source: [Betschel et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11271048/)

<a id="topic-2.2.2.4-12"></a>

###### Payer involvement of HAE specialists: International/Canadian guideline

> “Payers must consider the opinion of the HAE specialist when evaluating reimbursement for treatment of patients with HAE, including HAE nC1INH.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

<a id="topic-2.2.2.4-13"></a>

###### Payer prescriber requirements for on-demand treatments

> “The medication is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.”

Source: [Cigna Ekterly prior authorization policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0756_coveragepositioncriteria_hereditary_angioedema_ekterly.pdf)

> “Medication must be prescribed by an allergist, immunologist, hematologist, or dermatologist”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

> “Must be prescribed by or under the direction of a HAE specialist. A HAE specialist is defined as an allergist/immunologist who demonstrates clinical expertise in HAE through research, publication, referrals/consults.”

Source: [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf)

<a id="topic-2.2.2.4-14"></a>

###### Payer benefit channel: pharmacy and medical benefit coverage of on-demand treatments

> “Ekterly is an oral medication and will therefore be covered under the pharmacy benefit”
> “Berinert will be reviewed under the medical benefit when administered by a health care professional. If the member transitions to self-administration, then Berinert can be authorized under the pharmacy benefit.”
> “Firazyr, Sajazir, and icatibant can be self-administered upon recognition of an HAE attack after training under the guidance of a healthcare professional and therefore will be covered under the pharmacy benefit.”

Source: [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Goals of on-demand treatment: guidelines

> “The goal of acute therapy for HAE is to minimize morbidity and prevent mortality from an ongoing angioedema attack.”

Source: [Busse et al. (2021)](https://www.haea.org/assets/img/TreatmentGuidelines040321.pdf)

> “The aim of treating HAE attacks, also referred to as on-demand therapy, is to minimize the severity and duration of attacks, including potentially fatal upper airway angioedema and associated impairment of quality of life (QoL).”
> “Effective treatment for attacks should not only relieve symptoms but also provide patients with enough time to safely access urgent care if needed.”

Source: [Betschel et al. (2026)](https://link.springer.com/article/10.1186/s13223-025-00999-8)

> “The aim of acute treatment of HAE attacks is to prevent mortality and to minimize morbidity by decreasing the duration and severity of symptoms.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

> “We recommend that the goals of treatment are to achieve total control of the disease and to normalize patients' lives.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.2.7-2"></a>

###### Expected benefit of early treatment: guidelines

> “Compared to delayed treatment, early treatment is associated with better outcomes, including faster symptom resolution, shorter episode duration, and greater efficacy, regardless of the severity of the attack.”
> “ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

> “Studies have shown that treating HAE attacks earlier reduces the total time with swelling symptoms and improves quality of life. People are able to return to their normal activities more rapidly.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

<a id="topic-2.2.2.7-3"></a>

###### Core outcome set for acute treatment trials

> “In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.”

Source: [Petersen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38609017/)

<a id="topic-2.2.2.7-4"></a>

###### Attack duration with and without on-demand treatment: prospective cohorts

> “Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)”

Source: [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/)

> “Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).”
> “Median time from onset of symptoms to drug administration was 1 h with icatibant and 2 h with pd-C1INH and median time from drug administration to complete resolution was 5.5 and 8 h, respectively.”

Source: [Zanichelli et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26304015/)

<a id="topic-2.2.2.7-5"></a>

###### Time to symptom relief and resolution with oral sebetralstat: phase 3 trial

> “The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.”
> “The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.”

Source: [Riedl et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38819658/)

<a id="topic-2.2.2.7-6"></a>

###### Time to symptom relief with oral sebetralstat during long-term prophylaxis: open-label extension

> “Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.”

Source: [Kinaciyan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13355760/)

<a id="topic-2.2.2.7-7"></a>

###### Deucrictibant outcomes in relation to other on-demand agents: RAPIDe-3 discussion

> “Onset of symptom relief was met with a median time of 1·28 h with deucrictibant (compared with >12 h for placebo). In an independent trial of 600 mg oral sebetralstat, onset of symptom relief, measured using the same PGI-C-based endpoint definition, was met with a median time of 1·79 h to 2·0 h (6·72 h to >12 h for placebo).”
> “Variations in trial designs and instruments used across trials for on-demand treatment of hereditary angioedema attacks prevent direct outcome comparisons.”
> “In this trial, complete attack resolution (no symptoms) measured using PGI-S was reached within a median time of 11·95 h with deucrictibant (placebo >48 h).”
> “Treatment with deucrictibant resulted in relatively low use of second capsule (17%) and conventional on-demand therapy as rescue medication (7%) within 12 h, compared with 67% and 36% for placebo, respectively.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.2.7-8"></a>

###### Reduced emergency department use with self-administration and on-demand access

> “Data suggest that self-administration of icatibant reduces and delays the need for Emergency Department visits, which are typically required when attacks affect critical anatomical sites.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “In addition, more patients are receiving their HAE treatment at home and the number of hospitalizations and visits to the emergency room for HAE has decreased.”

Source: [US Hereditary Angioedema Association treatment guidelines](https://haea.org/pages/p/treatment_guidelines)

> “Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.”
> “Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.”

Source: [Christiansen et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25715243/)

<a id="topic-2.2.2.7-9"></a>

###### Outcomes after delayed treatment: patient surveys

> “Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).”

Source: [Christiansen et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39694088/)

> “When asked how long it usually takes to feel in control of their HAE attacks after on-demand treatment, respondents reported a mean time of 2.2 h (SD: 5.1) post-treatment, with those who treat early (less than 1 h) reporting 1.4 h (SD: 1.1) and those who delay on-demand treatment reporting 2.9 h (SD: 6.7) (Fig. 6).”

Source: [Betschel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12093744/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
